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ABSTRACT 
Background: Despite widespread use of therapies such as inhaled corticosteroids (ICS), 
people with chronic obstructive pulmonary disease (COPD) continue to suffer, have reduced 
life expectancy and utilise considerable NHS resources. Laboratory investigations have 
demonstrated that at low plasma concentrations (1-5mg/l) theophylline markedly enhances 
the anti-inflammatory effects of corticosteroids in COPD.  
Objective: To determine the clinical and cost-effectiveness of adding low-dose theophylline 
to a drug regimen containing ICS in people with COPD at high risk of exacerbation. 
Design: A multi-centre pragmatic double-blind randomised placebo controlled clinical trial. 
Setting: 121 UK primary and secondary care sites. 
Participants: People with COPD (FEV1/FVC<0.7) currently on a drug regimen including 
ICS with a history of ≥2 exacerbations treated with antibiotics and/or oral corticosteroids in 
the previous year.  
Interventions: Participants were randomised (1:1) to receive either low-dose theophylline or 
placebo for a year. The dose of theophylline (200mg once or twice a day) was determined by 
ideal body weight and smoking status.  
Primary Outcome: The number of participant reported exacerbations in the one year 
treatment period treated with antibiotics and/or oral corticosteroids.  
Results: 1578 people were randomised, (60% from primary care): 791 theophylline, 787 
placebo. There were 11 post-randomisation exclusions. 1567 participants were prescribed 
study medication: 788 theophylline, 779 placebo. Participants in the trial arms were well 
balanced; mean (SD) age 68.4 (8.4) years, 54% were male, 32% currently smoked, mean 
(SD) FEV1 51.7% (20.0) predicted. 
Primary outcome data were available for 98% of participants: 772 theophylline, 764 placebo, 
there were 1489 person years of follow up data. The mean (SD) number of exacerbations in 
participants allocated to theophylline was 2.24 (1.99) and for participants allocated to placebo 
2.23 (1.97), adjusted incident rate ratio (IRR) (95% CI) 0.99 (0.91, 1.08). 
Low-dose theophylline had no significant effects on lung function (FEV1), incidence of 
pneumonia, mortality, breathlessness, or measures of quality of life or disease impact. 
Hospital admissions because of COPD exacerbation were less frequent with low-dose 
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theophylline, adjusted IRR 0.72 (0.55, 0.94), however, 39 of the excess 51 hospital 
admissions in the placebo group were accounted for by 10 participants having ≥3 
exacerbations.  
There were no differences in the reporting of theophylline side effects between the 
theophylline and placebo arms. 
Limitations: A greater than expected number of participants (26%) ceased study medication, 
this was balanced between theophylline and placebo arms and mitigated by over-recruitment 
(n=154) and high rate of follow up. The limitation of not using documented exacerbations is 
addressed by evidence that patient recall is highly reliable and the results of a small within-
trial validation study. 
Conclusion: For people with COPD at high risk of exacerbation, the addition of low-dose 
oral theophylline to a drug regimen that includes inhaled corticosteroid, confers no overall 
clinical or health economic benefit. This result was evident from the intention to treat and 
per-protocol analyses. 
Future work: To promote consideration of the findings of this trial in National and 
International COPD Guidelines. 
Study registration: ISRCTN27066620 registered 19th September 2013. 
Funding details: National Institute for Health Research Health Technology Assessment (Ref 
11/58/15). 
(Word count n=500) 
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PLAIN ENGLISH SUMMARY 
Chronic obstructive pulmonary disease (COPD) is a long term lung disease that cannot be 
cured. The main symptom is shortness of breath on exertion. In the UK about 1.2 million 
people have COPD. It is a major cause of death and costs the NHS more than £1 billion a 
year. Sudden “flare ups” of symptoms often need emergency treatment, they shorten life 
expectancy and reduce peoples’ ability to get on with their lives.  
 
Theophylline is a drug that has been around for decades. It used to be used in high doses to 
treat COPD by opening up airways. However, its benefits were limited and it often caused 
unpleasant side effects. High-dose theophylline has been replaced by inhalers such as inhaled 
corticosteroids (ICS). Recent work in the laboratory and in animal models suggests that at 
low-dose, theophylline could make ICS work better in COPD with none of the side effects of 
high dose theophylline. 
 
The TWICS trial tested whether adding low-dose theophylline reduces flare ups in people 
with COPD taking ICS. 1578 people with COPD from 121 centres all over the UK took part. 
Participants were randomly divided into two groups: one took low dose theophylline and the 
other took dummy placebo pills. Participants were asked to attend visits at 6 and 12 months.  
 
791 participants were prescribed low-dose theophylline and 787 were prescribed dummy 
placebo pills. Although not everyone took the tablets for a whole year we were able to count 
the number of flare ups in 98% of those taking part. In total there were 3430 flare ups. On 
average the people taking low-dose theophylline had 2.24 flare ups and the people taking 
placebo had 2.23 flare ups.  
 
Overall the trial shows that for people with COPD, taking low-dose theophylline on top of 
steroid inhalers makes no real difference. 
(Word count n=300) 
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SCIENTIFIC SUMMARY 
 
Background 
Chronic obstructive pulmonary disease (COPD) is an incurable lung disease characterised by 
airway inflammation and progressive airflow limitation, typical symptoms include slowly 
worsening shortness of breath on exertion, productive cough and wheeze. The progressive 
airflow limitation of COPD is associated with increasing symptoms, ill health, work absence, 
disability and premature mortality. In the UK there are 1.2 million people with diagnosed 
COPD, it is the fifth leading cause of death, it is also a leading cause of emergency hospital 
admission and costs the NHS in excess of £1billion/year.  
 
Acute deteriorations in symptoms known as exacerbations are an important clinical feature of 
COPD, many require treatment with antibiotics and/or corticosteroids and the severest require 
hospital admission. Exacerbations are associated with increased ill health, a poorer prognosis 
and are the most costly aspect of COPD for the NHS. Recent studies have identified a 
frequent COPD exacerbator phenotype defined as ≥2 exacerbations in a year.  Such patients 
can be reliably identified by patient recall and are highly likely to exacerbate in subsequent 
years. Despite advances in management, there is still an unmet need for improved 
pharmacological treatment of COPD particularly the prevention of exacerbations.  
 
Oral theophylline has been used in the treatment of COPD for over 70 years. Conventionally 
theophylline has been used as a bronchodilator, however in order to achieve modest clinical 
effects relatively high blood concentrations (10-20mg/l) are required that are also associated 
with a wide range of well recognised side effects. The availability of more effective inhaled 
therapies, theophylline’s narrow therapeutic index, its modest clinical effect, and side effect 
profile has resulted in current COPD guidelines relegating high-dose theophylline to third 
line therapy although in low to middle income countries it is often used earlier in clinical 
practice. 
 
In recent years molecular mechanisms contributing to the reduced corticosteroid sensitivity of 
the airway inflammation of COPD have been elucidated. In vitro and animal models have 
demonstrated that at low plasma concentrations (1-5mg/l) there is a marked synergistic effect 
between theophylline and corticosteroids, with theophylline inducing a 100-10,000 fold 
increase in the suppressive effect of corticosteroids on the release of pro-inflammatory 
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mediators. A number of small exploratory studies of short duration have confirmed that at 
low-dose, theophylline increases the anti-inflammatory properties of inhaled corticosteroids 
(ICS) as evidenced by molecular signatures. Two small year-long hospital based placebo 
controlled trials of low-dose theophylline in COPD have reported conflicting results. The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) management strategy 
guideline highlights that the clinical relevance of low-dose theophylline has not been fully 
established and that clinical evidence on low-dose theophylline, particularly on 
exacerbations, is limited and contradictory. 
 
The theophylline with inhaled corticosteroids (TWICS) trial was a pragmatic double blind 
randomised, placebo-controlled clinical trial built on emerging evidence that low-dose 
(plasma concentration 1-5mg/l) theophylline may produce a beneficial synergistic effect in 
COPD by increasing the corticosteroid sensitivity of the airway inflammation underlying 
COPD and as a consequence reduce the rate of COPD exacerbation when used in conjunction 
with ICS.  
 
Objectives 
The primary objective was to determine the clinical and cost-effectiveness of adding low-
dose theophylline to ICS therapy in patients with COPD and a history of two or more 
exacerbations treated with antibiotic and/or oral corticosteroids in the previous year, the 
primary clinical outcome being the number of exacerbations in the one year treatment period 
requiring treatment with antibiotics and/or oral corticosteroids. The primary economic 
outcome was cost-per-QALY gained during the one year treatment period.  
 
The secondary objectives were to compare the following outcomes between participants 
treated with low-dose theophylline and those treated with placebo: 
 Hospital admissions with a primary diagnosis of exacerbation of COPD 
 Total number of episodes of pneumonia 
 Total number of emergency hospital admissions 
 Lung function  
 All-cause and respiratory mortality 
 Drug reactions and serious adverse events 
 Health related quality of life  
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 Disease specific health status 
 Total inhaled corticosteroid dose/usage 
 Health care utilisation  
 Modelled lifetime incremental cost per Quality Adjusted Life Year 
 Time to first exacerbation (an additional secondary objective) 
 
Methods 
TWICS was a pragmatic double-blind randomised, placebo-controlled, UK multicentre 
clinical trial that compared the addition of low-dose theophylline or placebo for 52 weeks to 
current COPD therapy that included ICS, in patients with COPD who had had ≥2 
exacerbations in the previous year treated with oral corticosteroids and/or antibiotics. The 
aim was to recruit 1,424 participants with at least 50% being recruited from primary care.  
 
Inclusion criteria 
Participants were people with COPD likely to exacerbate during the 52 week treatment 
period. The key inclusion criteria were: 
 Aged ≥ 40 years 
 Smoking history of >10 pack years 
 Predominant respiratory diagnosis of COPD (FEV1/FVC<0.7) 
 Current use of ICS therapy 
 Patient report of ≥2 exacerbations treated with antibiotics and/or oral 
corticosteroids in the previous year 
 
Exclusion criteria 
The key exclusion criteria are listed below, they include concomitant treatment with drugs 
with the potential to increase plasma theophylline concentration above the low-dose range of 
1-5mg/l.  
 Severe or unstable ischaemic heart disease  
 A predominant respiratory disease other than COPD including alpha-1-antitrypsin 
deficiency   
 Current use of drugs with the potential to increase plasma theophylline 
 
Participant identification & recruitment 
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Participants were identified and recruited from both primary and secondary care sites across 
the UK. Recruitment strategies differed between centres depending on local geographic and 
NHS organisational factors. 
 
Randomisation/treatment allocation 
Participants were randomised using an internet based computerised randomisation system 
created and administered by the Centre for Healthcare Randomised Trials (CHaRT), 
University of Aberdeen. Participants were stratified by trial centre/area and recruitment 
setting (primary and secondary) and then randomised with equal probability to the 
intervention (low-dose theophylline) and control (placebo) arms.  
 
Intervention 
The treatment period was 52 weeks with either Uniphyllin MR 200 mg tablets or a visually 
identical placebo. Dosing was based upon pharmacokinetic modelling incorporating the 
major determinants of theophylline steady state concentration, designed to achieve a steady 
state plasma theophylline of 1-5 mg/l. The dosing of both active and placebo was determined 
by the participant’s ideal body weight (IBW) and smoking status.  
 Uniphyllin MR 200 mg once daily (or one placebo once daily) for non-smoking 
participants, or participants who smoked but had IBW ≤ 60kg  
 Uniphyllin MR 200 mg twice daily (or one placebo twice daily) for participants 
who smoked with IBW > 60 kg 
 
All supplies of study tablets were delivered to the participants’ homes except for participants 
recruited in secondary care sites who received their initial 4-week supply from their local 
Clinical Trials Pharmacy.  
 
Data collection 
Outcome data were collected by face to face assessments conducted at recruitment/baseline 
(week 0), 6 months (week 26) and 12 months (week 52). Participants unable to attend the 6 
and 12 month assessments were followed up by telephone, home visit, or sent the 
questionnaires to complete at home. The key data collected were: 
 Number of COPD exacerbations requiring antibiotics/oral corticosteroids (i.e. 
moderate/severe exacerbations) 
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 Number of unscheduled hospital admissions 
 Health related quality of life (EQ-5D-3L) 
 Disease related health status (COPD Assessment Test (CAT)) 
 Modified MRC dyspnoea score  
 Post bronchodilator spirometry (FEV1, FVC) 
 Health care utilisation 
 Adverse reactions and serious adverse events 
 Adherence, persistence with study medication 
 
Sample Size 
Sample size was based on the ECLIPSE (Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints) study that indicated for our study population, the mean (SD) 
number of COPD exacerbations within 1 year would be 2.22 (1.86). An estimated 669 
subjects were needed in each trial arm to detect a 15% reduction in COPD exacerbations (i.e., 
from a mean of 2.22 to 1.89) with 90% power at the 5% significance level. Allowing for 6% 
loss to follow-up this was inflated to 712 participants in each study arm, giving 1424 in total.  
 
Statistical analysis 
All analyses were pre-specified in the statistical and health economic analysis plan approved 
in advance of analysis. All analyses were according to the intention to treat (ITT) principle 
with a per-protocol analysis performed as a sensitivity analysis. The per-protocol analysis 
excluded participants who were not compliant, with compliance being defined as taking 
≥70% of their expected doses of study medication.  
 
Results 
Recruitment to the study took place between 6th February 2014 and 31st August 2016, a total 
of 1578 people were randomised: 791 theophylline, 787 placebo. Participants were recruited 
in 121 study sites (88 primary care, 33 secondary care), 941 (60%) of participants were 
identified in primary care. There were 11 post-randomisation exclusions (3 theophylline, 8 
placebo), 1567 participants were prescribed study medication: 788 theophylline, 779 placebo. 
A higher proportion (26%) of participants than the expected 6% ceased their study 
medication, to counteract this, recruitment continued beyond 1424 in the time available with 
the total number recruited being 1578. 
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The baseline characteristics of the participants allocated to theophylline and placebo were 
balanced: mean (SD) age 68.4 (8.4) years, 54% male, mean BMI 27.2 (6.1) kg/m2, 31.7% 
currently smoked, 80% were using inhaled corticosteroids/long-acting-beta2-agonists/long-
acting muscarinic antagonists, mean FEV1 51.7 (20.0)% predicted, 13.6% had very severe 
airflow obstruction (FEV1<30% predicted), 37.7% severe (FEV1 30-50% predicted), 39.6% 
moderate (FEV1 50-80% predicted) and 9.2% mild airflow obstruction (FEV1>80% 
predicted). The mean (SD) number of participant reported exacerbations in previous year was 
3.6 (2.2). CAT scores indicated that COPD had a high impact on participants’ lives, mean 
22.6 (7.7), mean EQ-5D-3L utility score was 0.63 (0.28). 
 
Intention to treat analysis 
Primary outcomes 
For the ITT analysis primary outcome data were available for 98% of participants: 772 
theophylline, 764 placebo, there were 1489 person years of follow up data. In total there were 
3430 exacerbations, 1727 theophylline, 1703 placebo, the mean (SD) number of 
exacerbations in participants allocated to theophylline was 2.24 (1.99) and for participants 
allocated to placebo 2.23 (1.97), unadjusted incident rate ratio (95% CI) 1.00 (0.92, 1.09), 
adjusted IRR 0.99 (0.91, 1.08). 
 
Owing to no statistically significant difference in exacerbation rate between treatment arms, 
the economic analysis was limited to a within trial analysis. There was a significant 
difference in unadjusted mean total costs, higher in the placebo arm compared to theophylline 
arm £452 (95%CI £133, £771).  This was driven by a significant difference in exacerbation 
costs between arms of £447 (95% CI £186, £709). This difference was a result of higher costs 
in the placebo arm for hospitalisations.  After adjusting mean costs for baseline 
characteristics there was no significant difference between arms in either exacerbation or total 
costs; the difference in total costs was £222 (95% CI -£27, £472),  higher in the placebo arm.  
 
Adjusted mean quality adjusted life-years were 0.621 (SE 0.006) in the theophylline arm and 
0.616 (SE 0.007) in the placebo arm, there was no significant difference between arms.  
Overall theophylline dominates placebo, with lower costs and higher QALYs.  However, this 
result is not significant and care should be taken when interpreting it.     
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Secondary outcomes 
There were 319 severe COPD exacerbations treated in hospital: 134 theophylline, 185 
placebo. The mean number of severe COPD exacerbations treated in hospital was: 0.17 (0.49) 
theophylline, 0.24 (0.66) placebo, unadjusted IRR 0.72 (0.55, 0.95), adjusted IRR 0.72 (0.55, 
0.94). However, 39 of the excess 51 hospital admissions in the placebo group were accounted 
for by 10 participants having ≥3 exacerbations. Low-dose theophylline had no significant 
effect on: non-COPD related hospital admissions, adjusted IRR 0.99 (0.71, 1.38); episodes of 
pneumonia, incidence 1.5%, unadjusted IRR 1.55 (0.67, 3.62); FEV1 % predicted, adjusted 
mean difference (95% CI) difference -0.56 (-2.42, 1.30); CAT score, adjusted marginal mean 
difference 0.01 (-0.65, 0.68); mMRC breathlessness score, adjusted OR 1.20 (0.88, 1.63); 
total mortality 2.5% theophylline, 1.8% placebo, p=0.400; COPD/respiratory related 
mortality 0.9% theophylline, 1.1% placebo, p=0.762.  
 
Low-dose theophylline was not associated with a significant increase in adverse reactions 
(ARs) or serious adverse events (SAEs): proportion of participants reporting ARs 48.1% 
theophylline, 43.9% placebo p=0.116, total number of ARs 883 theophylline, 818 placebo, 
proportion of participants reporting SAEs: 13.2% theophylline, 14.0% placebo, p=0.616. 
There were no differences in the profiles of ARs or SAEs events between the theophylline 
and placebo arms.  
 
Per-protocol analysis 
Primary outcome 
Of the 1578 participants randomised, 1567 were prescribed study medication, primary 
outcome data were missing for 31: 16 theophylline, 15 placebo. Adherence/compliance was 
<70% for 356 participants: 181 (23.4%) theophylline, 175 (22.9%) placebo, p=0.802. The 
reasons given by participants for ceasing study medication were equally distributed between 
the theophylline and placebo arms.  
 
For the per-protocol analysis primary outcome data were available for 1180 (75%) of 
participants: 591 theophylline, 589 placebo, there were 1146 person years of follow up data. 
There were 2556 exacerbations: 1298 theophylline, 1258 placebo, the mean number of 
exacerbations in participants allocated to theophylline was 2.20 (1.96) and for participants 
allocated to placebo 2.14 (1.92), unadjusted IRR 1.02 (0.92, 1.13), adjusted IRR 1.00 (0.91, 
1.10).  
13 
 
 
Secondary outcomes 
There were 218 severe COPD exacerbations treated in hospital: 92 theophylline, 126 placebo. 
The mean number of severe COPD exacerbations treated in hospital was: 0.16 (0.45) 
theophylline, 0.21 (0.61), adjusted IRR 0.70 (0.50, 0.97). For the other secondary outcomes 
the per-protocol analysis essentially did not differ from the results of the ITT analysis.  
 
Conclusions 
This is the first pragmatic double blind randomised placebo controlled trial to assess the 
effectiveness of adding low-dose theophylline to a drug regimen containing ICS in people 
with COPD at high risk of exacerbation, the analyses demonstrated that overall, low-dose 
theophylline has no clinical or health economic benefit. 
 
Implications for healthcare 
This study is the largest trial of low-dose theophylline in COPD to date. National and 
International COPD Guidelines will need consider the findings of this study when making 
recommendations on the treatment of COPD and the prevention of COPD exacerbations.  
 
Recommendations for research 
A further study investigating the clinical and cost-effectiveness of low-dose theophylline in 
reducing severe COPD exacerbations requiring admission to hospital needs careful 
consideration. Such a study would necessarily be very large.  
 
Funding 
Funded by the National Institute for Health Research Health Technology Assessment (NIHR 
HTA) programme. 
 
Study registration 
ISRCTN27066620 registered 19th September 2013. 
 
(Word count n=2288)  
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CHAPTER 1 - INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is defined as “a common preventable and 
treatable disease characterised by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lungs to 
noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity 
in individual patients”.1 People with COPD typically present with breathlessness on exertion, 
a productive cough and wheeze. COPD is usually diagnosed from the age of 40 onwards and 
prevalence increases with age.2 In westernised countries COPD is predominantly (80-90%) 
caused by cigarette smoking,3 but outdoor air pollution and occupational exposure to dusts, 
vapours and fumes can be significant contributory factors.4, 5 COPD is closely associated with 
social deprivation, and makes a major contribution to health inequalities in the UK.6 The 
progressive airflow limitation of COPD is associated with increasing disability, work 
absence, long-term morbidity, common physical and psychological co-morbidities, and 
premature mortality. People with COPD are more likely to have associated comorbidities,7 
including ischaemic heart disease,8 hypertension,9 heart failure,10, 11 diabetes,12 
osteoporosis,13 depression14 and lung cancer,15 which increase morbidity and complicate its 
management.7 
 
Acute deteriorations in symptoms known as exacerbations are an important clinical feature of 
COPD. These are usually precipitated by viral/bacterial infection and/or air pollution and are 
characterised by increasing breathlessness, and/or cough, sputum expectoration and malaise. 
Many exacerbations are severe enough for patients to seek medical help, usually in the form 
of antibiotics and/or corticosteroids from their General Practitioner (GP); more severe 
exacerbations frequently require admission to hospital for more intensive treatment. 
Exacerbations are associated with accelerated rate of lung function decline,16 reduced 
physical activity,17 reduced quality of life (QoL),18 increased mortality19 and increased risk of 
comorbidities such as acute myocardial infarction and stroke.20  
 
The observational Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints study (ECLIPSE) of 2138 COPD patients shed light on factors that influence 
COPD exacerbations.21 This study identified a frequent exacerbator phenotype defined as two 
or more exacerbations in a year that affects about 25% of COPD patients. Patients with this 
phenotype have an 84% chance of at least one exacerbation in the subsequent year, moreover 
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this frequent exacerbator phenotype is stable for at least 3 years and can be reliably identified 
by patient recall. This has been supported by further work demonstrating that the strongest 
predictor for exacerbations is the number exacerbations in the preceding year.22 Frequent 
exacerbators incur a disproportionate amount of the annual National Health Service (NHS) 
spend on COPD.  
 
The burden of COPD on individuals and the NHS 
COPD is a major personal and public health burden.23, 24 Data from 591 UK general practice 
(GP) surgeries comprising The Health Improvement Network (THIN) indicate that the 
prevalence of diagnosed COPD in the UK has increased from about 991,000 in 2004 to 1.2 
million in 2012.2 COPD is the fifth leading cause of death in the UK, accounting for about 
5% of all deaths (~30,000 deaths in 2014). More than 80% of COPD patients, irrespective of 
severity, report a reduced quality of life.24-26 Co-morbidities are an important feature of 
COPD, contributing to ill-health and treatment burden. It has been estimated that in the UK 
33% of people with COPD have hypertension, 19% have ischaemic heart disease, 18% have 
depression, 11% have diabetes and 6% have heart failure.23 Over 50% of people currently 
diagnosed with COPD in the UK are under 65 years of age and 24 million working days are 
lost each year from COPD with £3.8 billion/year being lost through reduced productivity.23 
 
COPD costs the NHS more than £1 billion/year; for each COPD patient in 2001, average 
annual NHS direct costs were £819 (>£1,300 in severe COPD), with 60% of this accounted 
for by exacerbations and 19% due to drug costs.27 UK hospital episode statistics show that 
emergency hospital admissions for exacerbations of COPD have steadily increased as a 
percentage of all admissions from 0.5% in 1991 to 1% in 2000 and to 1.5% in 2008/9.28 In 
2008/9, COPD exacerbations resulted in 164,000 hospital admissions in the UK with an 
average length of stay of 7.8 days, accounting for 1.3 million bed days.28 COPD is the second 
leading cause of emergency admission to hospital in the UK and is one of the most costly 
inpatient conditions treated by the NHS.23, 24 At least 10% of emergency admissions to 
hospital are as a consequence of COPD and this proportion is even greater during the winter. 
Approximately 25% of patients who have been diagnosed as having COPD are admitted to 
hospital at some point and about 15% of COPD patients are admitted each year.23, 24 Over 
30% of patients admitted to hospital with an exacerbation of COPD are readmitted within 30 
days and an average of 12% of COPD patients die in the year following admission to 
hospital.19 
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Despite advances in management that have led to the current National Institute for Health and 
Care Excellence (NICE) COPD guidelines, there is still an unmet need for improved 
pharmacological treatment of COPD particularly the prevention of exacerbations.  
 
Standard COPD therapy  
Standard COPD therapy remains suboptimal. At the time the Theophylline With Inhaled 
Corticosteroids study (TWICS) was conceived most international COPD management 
guidelines recommended the use of inhaled corticosteroids (ICS) usually in combination with 
inhaled long acting β2 agonists (LABA) known as ICS-LABA to reduce COPD exacerbation 
rates and to improve lung function and quality of life.1, 24 Although more recent guidelines 
advocate the use of LABA in combination with long acting muscarinic antagonists (LAMA), 
ICS-LABA and ICS/LABA/LAMA combinations remain major therapeutic options and 
continue to be used very widely in the treatment of COPD.29, 30 However, when compared to 
the marked responses observed in asthma, ICS in COPD fail to fully suppress airway 
inflammation and patients continue to have exacerbations despite high ICS doses. 
Furthermore little or no positive impact of ICS on mortality or disease progression is 
evident31, 32 and concerns have been raised about long term sequelae of high dose ICS use in 
COPD.33, 34 A relative insensitivity of COPD airway inflammation to the anti-inflammatory 
effects of high dose ICS has been demonstrated in induced sputum and airway biopsies of 
people with COPD.35-37  
 
In recent years molecular mechanisms contributing to the reduced corticosteroid sensitivity of 
COPD have been elucidated. The chronic airway inflammation of COPD is driven by 
expression of multiple inflammatory genes regulated by acetylation of core histones which 
open up the chromatin structure enabling transcription factors and RNA polymerase II to bind 
to DNA, enabling gene transcription and increased synthesis of inflammatory proteins.38 In 
COPD there is increased acetylation of core histones associated with the promoter regions of 
inflammatory genes, with the degree of acetylation being positively associated with disease 
severity.39 Histone acetylation is reversed by histone deacetylase (HDAC) enzymes. 
Corticosteroids appear to work by reversing histone acetylation through the recruitment of a 
specific histone deacetylase called HDAC2,38, 40, 41 thereby switching off activated 
inflammatory genes. In people with COPD increased histone acetylation appears to be a 
consequence of markedly reduced HDAC2 activity/expression in airways, lung tissue and 
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alveolar macrophages.39 It has been shown that the oxidative stress of COPD activates the 
enzyme phosphoinositide-3-kinase (PI3K)-, which then phosphorylates downstream kinases 
resulting in the phosphorylation and inactivation of HDAC2.41, 42 The critical role played by 
reduced HDAC2 in the corticosteroid resistance of COPD is demonstrated by the finding that 
the corticosteroid resistance of COPD bronchoalveolar macrophages is completely reversed 
by overexpressing HDAC2 (using a plasmid vector) to levels seen in non-COPD controls.40  
 
Low-dose theophylline may have synergistic anti-inflammatory effects with 
corticosteroids 
Oral theophylline has been used in the treatment of COPD for over 70 years but usually at 
doses required to achieve relatively high blood concentrations (10-20mg/l). It has been 
observed that the reduced HDAC2 activity of COPD can be reversed in a dose-dependent 
manner by low-doses of theophylline, moreover low-dose theophylline reduces corticosteroid 
insensitivity in COPD such that there is a marked synergistic interaction between 
theophylline and corticosteroids in suppressing the release of inflammatory mediators from 
alveolar macrophages from COPD patients. This in vitro work has shown that at (low) 
concentrations of 1-5mg/l theophylline increases HDAC2 activity (6 fold) but at (high) 
concentrations over about 10 mg/l theophylline inhibits rather than stimulates HDAC2 
activity.43, 44 These studies show that at concentrations of 1-5mg/l there is a marked 
synergistic effect between theophylline and corticosteroids, with theophylline inducing a 100-
10,000 fold increase in the suppressive effect of corticosteroids on the release of pro-
inflammatory mediators. Such an increase in corticosteroid potency is worthy of clinical 
interest particularly if associated with reduced exacerbation rate. An explanation for the 
ability of low-dose (1-5mg/l) theophylline to increase HDAC activity has been described: it 
specifically inhibits the enzyme PI3K- with consequent restoration of HDAC2 activity to 
normal in COPD macrophages, rendering them steroid responsive. In cigarette smoke 
exposed mice,42 steroid-resistant lung inflammation has also been found to be reduced by 
low-dose theophylline when given together with steroids. Similarly rats exposed to cigarette 
smoke were found to have markedly decreased lung HDAC2 expression and that reduced 
HDAC2 expression was correlated with increased lung destruction index.45 The increased 
lung destruction index was restored to normal with ICS treatment in combination with low, 
(but not high), dose theophylline. It was concluded that low-dose theophylline might provide 
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protection from cigarette smoke damage and improve the anti-inflammatory effects of 
steroids by increasing HDAC2 activity.  
 
In human peripheral blood mononuclear cells corticosteroid insensitivity and reduced 
HDAC2 activity after oxidative stress have been shown to be reversed with low 
concentrations of theophylline.46 In a study of human alveolar macrophages extracted from 
resected lung samples, the addition of hydrogen peroxide reduced HDAC expression and was 
associated with an increase in interleukin-8 (IL-8) and matrix metallo proteinase 9 (MMP-9) 
release.47 The addition of low-dose theophylline restored HDAC expression to levels above 
that observed with LABA, ISC and ICS/LABA.  
 
These basic research studies suggest that low-dose (1-5mg/l) theophylline could increase 
HDAC activity and hence reduce corticosteroid resistance in COPD patients thereby enabling 
ICS to switch off inflammation and potentially more effectively reduce exacerbation rates. 
This is supported by findings from two small randomised controlled trials (RCT) and a 
population based health administration database study. The first RCT in 35 patients with 
acute COPD exacerbations found that low-dose theophylline increased responsiveness to 
corticosteroids as measured by increased HDAC activity and further reduced concentrations 
of pro-inflammatory mediators in induced sputum compared to inhaled corticosteroids 
alone.48 In the second small (n=30) pilot RCT of COPD patients, the combination of low-
dose theophylline with high dose ICS was associated with increased HDAC activity, 
improved lung function and reduced sputum inflammatory cells and mediators, whereas 
either drug alone was ineffective.49 A Canadian health administration database study of 
36,492 COPD patients reported that treatment with theophylline either alone or in 
combination with ICS was more protective against exacerbations than treatment with LABA 
or ICS-LABA (relative risk (RR) 0.89, 95% confidence interval (CI) 0.87-0.92).50  
 
More recent studies however, have not replicated the results of earlier studies. Fexer et al 
used data from a German ambulatory COPD management program and closely matched 1496 
COPD patients commenced on theophylline with 1496 COPD patients not commenced on 
theophylline.51 The use of theophylline was associated with an increased likelihood of 
exacerbation (hazard ratio (HR) 1.41; 95% CI 1.24-1.60), and hospital admission (HR 1.61; 
95% CI 1.29-2.01). Although it was concluded that theophylline is associated with an 
increased incidence of exacerbations and hospitalisations, it should be noted that this study 
19 
 
did not identify those patients on low-dose theophylline.51 The Spanish Low-dose 
Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary 
Disease (ASSET) trial recruited patients with COPD whilst hospitalised for a COPD 
exacerbation and randomised to low-dose theophylline (100mg twice a day) or matched 
placebo in addition to usual ICS/LABA treatment.52 In total 70 patients were randomised (36 
theophylline, 34 placebo) and 46 completed the year of treatment (23 theophylline, 23 
placebo). The addition of theophylline had no effect on COPD exacerbation rate nor 
plasma/sputum concentrations of HDAC and inflammatory mediators. It should be noted that 
the study was small and designed to detect a 50% reduction in exacerbations.  
 
Conventionally oral theophylline has been used as a bronchodilator in COPD, however in 
order to achieve modest clinical effects relatively high blood concentrations (10-20mg/l) are 
required. The bronchodilator effect of high-dose theophylline is the consequence of inhibition 
of phosphodiesterase (PDE) and consequent relaxation of airway smooth muscle. However 
non-specific inhibition of PDE by theophylline is also associated with a wide range of well 
recognised side effects that may occur within the conventional therapeutic range of plasma 
theophylline: namely nausea, gastro-intestinal upset, headaches, insomnia, seizures, cardiac 
arrhythmias and malaise. Theophylline toxicity is dose related and this is an issue with 
conventional theophylline use because the therapeutic ratio of theophylline is small and most 
of the beneficial bronchodilator effect occurs when near toxic doses are given.53 Theophylline 
is metabolised by cytochrome P450 mixed function oxidases and as a consequence 
theophylline use is further complicated by significant drug interactions with drugs commonly 
prescribed to people with COPD, e.g. clarithromycin, ciprofloxacin.54 The narrow therapeutic 
index, modest clinical effect, side effect profile, drug interactions, the need for blood 
concentration monitoring and the availability of more effective inhaled therapies has resulted 
in current COPD guidelines relegating high-dose theophylline to third line therapy.1 
 
The TWICS trial was a pragmatic double blind randomised, placebo-controlled clinical trial 
that was built on emerging evidence that low-dose (1-5mg/l) theophylline may produce a 
beneficial synergistic effect in COPD by increasing the corticosteroid sensitivity of the 
airway inflammation underlying COPD and as a consequence reduce the rate of COPD 
exacerbation when used in conjunction with ICS.  
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Hypothesis 
The hypothesis being tested was that the addition of low-dose theophylline to ICS therapy in 
COPD reduces the risk of COPD exacerbation requiring treatment with antibiotics and/or oral 
corticosteroid (OCS) during the year of treatment, delivers quality of life improvements and 
is cost-effective. 
 
Objectives 
The primary objective of the trial was to determine the clinical and cost-effectiveness of 
adding low-dose theophylline to inhaled corticosteroid therapy in patients with COPD and a 
history of two or more exacerbations treated with antibiotic and/or oral corticosteroids in the 
previous year in relation to the number of exacerbations in the one year treatment period 
requiring therapy with antibiotics and/or oral corticosteroids.  
 
The secondary objectives were to compare the following outcomes between participants 
treated with low-dose theophylline and those treated with placebo: 
 Hospital admissions with a primary diagnosis of exacerbation of COPD 
 Total number of episodes of pneumonia 
 Total number of emergency hospital admissions 
 Lung function 
 All-cause and respiratory mortality 
 Drug reactions and serious adverse events 
 Health related quality of life 
 Disease specific health status 
 Total inhaled corticosteroid dose/usage 
 Health care utilisation 
 Incremental cost-per-exacerbation avoided  
 Lifetime cost-effectiveness based on extrapolation modelling 
 Modelled lifetime incremental cost per Quality Adjusted Life Year (QALY) 
 
An additional secondary objective was:  
 Time to first exacerbation of COPD 
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Outcomes 
Primary Outcomes 
The primary outcome was the total number of exacerbations of COPD necessitating changes 
in management (minimum management change - use of oral corticosteroids and/or 
antibiotics) during the one year treatment period, as reported by the participant. 
 
The primary economic outcome was cost-per-QALY gained during the one year treatment 
period.  
 
Secondary Outcomes 
 Total number of COPD exacerbations requiring hospital admission 
 Total number of episodes of pneumonia 
 Total number of emergency hospital admissions (all causes) 
 Lung function (forced expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC)) post bronchodilator using spirometry performed to American Thoracic 
Society/European Respiratory Society (ATS/ERS) standards 
 All-cause and respiratory mortality 
 Serious adverse events, adverse reactions 
 Total dose of inhaled corticosteroid 
 Utilisation of primary or secondary health care for respiratory events  
 Disease specific health status using the COPD Assessment Test (CAT); modified 
Medical Research Council (mMRC) dyspnoea scale 
 Generic health related quality of life using EuroQoL 5 dimension, 3 level (EQ-5D-3L) 
Index 
 Modelled lifetime incremental cost per Quality Adjusted Life Year. 
 
An additional secondary outcome was:  
 Time to first exacerbation of COPD 
 
Role of the funder 
The study was funded by the National Institute for Health Research Health Technology 
Assessment (NIHR HTA) programme. The NIHR had input into the trial design through peer 
review of the proposal but did not have a role in data collection, data analysis, data 
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interpretation or the writing of the final report. The corresponding author had access to all the 
data and was responsible for the decision to submit. 
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CHAPTER 2 - METHODS/DESIGN 
 
Trial design 
The study protocol has been published in an open access journal.55  
 
TWICS was a pragmatic double blind randomised, placebo-controlled, parallel-arm, UK 
multicentre clinical trial that compared the addition of low-dose theophylline or placebo for 
52 weeks to current COPD therapy that included ICS, in patients with COPD who had had 
two or more exacerbations of COPD in the previous year treated with oral corticosteroids 
and/or antibiotics. The aim was to recruit 1,424 participants with at least 50% being recruited 
in primary care. The trial was approved by Scotland A Research Ethics Committee (REC) 
(ref 13/SS/0081) and the Medicines and Healthcare products Regulatory Agency (MHRA) 
(EudraCT 2013-001490-25, CTA 21583/0218/001). All participants provided written 
informed consent, this included consent to inform the participant’s General Practitioner (GP) 
of involvement and consent to pass on participant’s name and address to a third party 
distributer who delivered the study drug to the participant’s home. Figure 1 provides a 
schematic representation of study design and schedule. Face-to-face study assessments were 
carried out on participants at recruitment/baseline, 6, and 12 months as shown in Figure 2. 
The study was registered on 19 September 2013: ISRCTN27066620. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study design  
6 months 12 months 
Recruitment/ baseline 
visit 
Placebo tablet od/bd 
Patients identified based on 
inclusion/exclusion criteria 
Oral theophylline 200mg od/bd 
Randomisation 
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CAT COPD Assessment Test; mMRC modified Medical Research Council dyspnoea scale;  
EQ-5D-3L EuroQoL 5 dimensions, 3 level 
 
Figure 2: Flow diagram of study schedule 
 
  
Recruitment/baseline visit 
Assessed for eligibility based on inclusion and exclusion criteria 
Informed consent taken 
Assessment: drug history, smoking history, spirometry, CAT, mMRC dyspnoea score, EQ-5D-3L, 
health care utilisation 
Centralised randomisation (n=1424): University of Aberdeen, Centre for Healthcare Randomised 
Trials, web/telephone randomisation service 
2 week follow-up telephone call: tolerating trial medication, adverse reactions, serious adverse 
events 
6 month follow-up: exacerbations, hospital admissions, health care utilisation, drug history, 
spirometry, disease specific health status (CAT, mMRC dyspnoea score), generic health related 
quality of life (EQ-5D-3L), adverse reactions, serious adverse events, weight, smoking status 
12 month follow-up: exacerbations, hospital admissions, health care utilisation, drug history, 
spirometry, disease specific health status (CAT, mMRC dyspnoea score), generic health related 
quality of life (EQ-5D-3L), adverse reactions, serious adverse events  
12 month review of primary and secondary care records for a sample of participants: 
exacerbations, hospital admissions, health care utilisation  
Intervention arm: n=712 
Oral theophylline 200mg once or twice 
daily depending on ideal body weight and 
smoking status 
Control arm: n=712 
Placebo once or twice daily depending on 
ideal body weight and smoking status 
 
  
  
  
  
  
25 
 
Participants 
 
Inclusion criteria 
The participants in TWICS were people with COPD likely to exacerbate during the 52 week 
treatment period as evidenced by two or more exacerbations of COPD in the previous year 
treated with oral corticosteroids or antibiotics. Participants had to meet all the following 
inclusion criteria that are typical of studies in people with COPD with exacerbations as the 
primary endpoint: 
 Aged ≥ 40 years 
 A smoking history of at least 10 pack years 
 An established predominant respiratory diagnosis of COPD (GOLD/NICE Guideline 
definition: post bronchodilator FEV1/FVC<0.7)
1,2 
 Current use of ICS therapy at the baseline/ recruitment visit 
 A history of at least two exacerbations requiring treatment with antibiotics and/or oral 
corticosteroid use in the previous year, based on patient report 
 Clinically stable with no COPD exacerbation for at least 4 weeks 
 Able to swallow study medication 
 Able and willing to give informed consent to participate 
 Able and willing to participate in the study procedures; undergo spirometric 
assessment, complete study questionnaire 
 
Potential participants with COPD who did not fulfil the lung function criterion of 
FEV1/FVC<0.7 at the recruitment/baseline visit were asked to complete a slow vital capacity 
(SVC) manoeuvre and FEV1/SVC<0.7 was accepted as evidence of airflow obstruction. 
Historical evidence of FEV1/FVC<0.7 was deemed acceptable for those participants who did 
not achieve FEV1/FVC<0.7 or FEV1/SVC<0.7 or who were unable to complete spirometry at 
the recruitment/baseline assessment. Eligibility for inclusion was confirmed by a medically 
qualified person. 
 
Exclusion criteria 
The exclusion criteria for TWICS were typical of studies in people with COPD but also 
included criteria specific for theophylline, notably concomitant treatment with drugs that 
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were likely to increase plasma theophylline concentration above the low-dose range of 1-
5mg/l. Potential participants were excluded if they fulfilled any of the following criteria.  
 Severe or unstable ischaemic heart disease 
 A predominant respiratory disease other than COPD 
 Any other significant disease/disorder which, in the investigator’s opinion, either put 
the patient at risk because of study participation or might influence the results of the 
study or the patient's ability to participate in the study 
 Previous allocation of a randomisation code in the study or current participation in 
another interventional study (CTIMP or non-CTIMP) 
 For women, current pregnancy or breast-feeding, or planned pregnancy during the 
study 
 Current medication included theophylline 
 Known or suspected intolerance to theophylline 
 Current use of drugs known to interact with theophylline and/or increase plasma 
theophylline;54  
antimicrobials: aciclovir, clarithromycin, ciprofloxacin, erythromycin, 
fluconazole, ketoconazole, levofloxacin, norfloxacin;  
cardiovascular: diltiazem, mexiletine, pentoxifylline, verapamil;  
neurological: bupropion, disulfiram, fluvoxamine, lithium;  
hormonal: medroxyprogesterone, oestrogens;  
immunological: methotrexate, peginterferon alpha, tacrolimus;  
miscellaneous: cimetidine, deferasirox, febuxostat, roflumilast, thiabendazole. 
 
Patients with COPD as a consequence of alpha-1-antitrypsin deficiency were excluded 
however, short or long term use of azithromycin,56 or use of topical oestrogens or aciclovir 
were not exclusion criteria.  
 
Identification  
Potential participants were recruited from both primary and secondary care sites across the 
UK. To ensure generalisability the intention was that the majority of participants (>50%) 
would be recruited from primary care. Recruitment strategies differed between centres 
depending on local geographic and NHS organisational factors. 
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Primary care and other community based services 
In England recruitment from General Practices was conducted in conjunction with the NIHR 
Clinical Research Network (CRN) at both the national and local level. Practices could 
participate as independent research sites or as participant identification centres (PICs) for 
secondary care or other primary care research sites. 
 
In General Practices the local CRN/collaborating recruitment site/Trial Office liaised directly 
with practice staff who performed database searches (based on search criteria including use 
of inhaled preparations containing corticosteroids and record of one exacerbation treated with 
oral corticosteroids in previous year, interacting medications) to identify potential 
participants. Potentially suitable patients were sent an invitation letter and a patient 
information leaflet (PIL). For General Practices acting as independent research sites, 
interested potential participants were invited to contact the practice-based trial team for more 
information and to arrange a recruitment visit.  For General Practices acting as PICs, 
interested potential participants were invited to contact the local trial team at the associated 
secondary or primary care research site for more information and to arrange a recruitment 
visit. All invitation material, consent forms, trial case report forms and participant completed 
questionnaires are included in Supplementary Material 1 – TWICS paperwork. 
 
In Scotland, the Scottish Primary Care Research Network mirrored the role undertaken by the 
English CRN by identifying potential participants in primary care, with interested potential 
participants being invited to make contact with a local trial team based in secondary care.  
 
Potential participants were also identified from other community COPD services such as 
Pulmonary Rehabilitation, COPD Community Matrons, smoking cessation services and 
Integrated/Intermediate Care services for patients with COPD. Potentially suitable 
participants identified by these services were sent an invitation letter and a PIL, and if 
interested, participants were asked to contact the local trial team (usually in secondary care) 
for more information and to arrange a recruitment visit. 
 
Secondary care 
Potential participants were also identified from patients attending (or who had previously 
attended) Respiratory Out-Patient appointments or who had been in-patients at the hospitals 
of the individual recruiting centres. Potentially suitable patients were sent an invitation letter 
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and a PIL from a member of their hospital care team (usually their consultant). Interested 
potential participants were invited to contact the local hospital based trial team for more 
information and to arrange a recruitment visit. 
 
Recruitment/baseline visit 
At the recruitment visit, the participant’s eligibility was confirmed by a medically qualified 
doctor and fully informed consent was recorded in writing. Baseline data (see later) were also 
collected. 
 
Randomisation/treatment allocation 
Participants were randomised, usually by a research nurse, using a computerised 
randomisation system available as both an Interactive Voice Response telephone system and 
as an internet based application, in reality the internet application was used for all 
randomisations within the study. The randomisation service was created and administered by 
the Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen. Consenting 
participants were stratified by trial centre (for participants recruited in secondary care) or area 
(for participants recruited in primary care), and where the participant had been identified 
(primary or secondary care) and then randomised with equal probability to the intervention 
(low-dose theophylline) and control (placebo) arms.  
 
The random allocation sequence for TWICS was generated using permuted blocks. This 
provided randomly generated blocks of entries of varying sizes permuted for each 
combination of trial centre/area and where the participant had been identified (primary or 
secondary care). Each entry was assigned a treatment according to a randomly generated 
sequence utilising block sizes of two or four. Each treatment option was assigned an equal 
number of times within each block, ensuring that the total entries assigned to each treatment 
remained balanced. The sequence of blocks was also random, so it was not possible for 
anyone to determine the next treatment to be allocated based on previous allocations made 
during the randomisation process. 
 
It was only possible to randomise a participant if the relevant eligibility criteria had been met. 
In addition to trial centre/area, and where the participant had been identified (primary or 
secondary care), gender, height, weight, smoking status (and for smokers, number of 
cigarettes per day) and date of birth was captured during the randomisation process in order 
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to calculate the correct dosage of study medication for that participant and assign an 
appropriate drug pack  
 
With this information captured, the randomisation process would assign a Study Number 
(participant ID), allocate a treatment, and assign a Drug Pack. The user/caller would be 
notified of the Study Number and Drug Pack either on screen or during the randomisation 
telephone call. The allocated treatment remained blinded throughout with neither the 
user/caller nor the participant (or anyone involved in the participant’s care or the assessment 
of outcomes) made aware of the allocation. All the data captured or assigned was saved to a 
secure database. 
 
The random permuted blocks that defined how treatments were allocated to participants was 
created by the CHaRT Programming team during the system development process. The 
system built to utilise these permuted blocks was tested by a run of simulated randomisations 
which allowed the outcomes to be cross-checked and validated. Before the randomisation 
system went ‘live’, enough blocks were created to ensure entries existed for the maximum 
expected number of participants across the maximum expected number of trial centres/areas. 
However, the randomisation system was flexible enough to allow the option to add further 
permuted blocks to the list if more were required during the lifetime of the trial. In such 
circumstances, randomly generated sequences in blocks of two and four continued to be 
utilised. 
 
Intervention 
The active intervention was Uniphyllin MR 200 mg tablets taken once or twice a day for 52 
weeks. The placebo was manufactured to be visually identical, and was taken once or twice a 
day for 52 weeks. The packaging and labelling of active and placebo interventions were 
identical. The intervention was for 52 weeks of therapy. The Uniphyllin MR 200mg tablets 
and placebo were supplied by Napp Pharmaceuticals Limited, Cambridge Science Park, 
Cambridgeshire, CB4 0GW. Napp Pharmaceuticals Limited is the holder of the marketing 
authorisation for Uniphyllin MR 200mg tablets (Marketing Authorisation number: PL 
16950/0066-0068). Uniphyllin continus 200mg, 300mg and 400mg are licensed for the 
treatment and prophylaxis of bronchospasm associated with COPD, asthma, and chronic 
bronchitis, consequently the trial administered theophylline within licensed indication.54 
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Placebo tablets were manufactured by Mundipharma Research Limited, Cambridge Science 
Park, Milton Road, Cambridge, CB4 0AB. 
 
Dosage 
The preclinical studies outlined in chapter 1 demonstrate the critical importance of plasma 
theophylline concentration, with plasma concentrations 1-5 mg/l having the maximal effect 
on reducing corticosteroid insensitivity whereas at concentrations >10mg/l theophylline is 
inhibitory, augmenting corticosteroid insensitivity. Theophylline dosing in TWICS was based 
upon pharmacokinetic modelling57-66 of theophylline incorporating the major determinants of 
theophylline steady state concentration, i.e. weight, smoking status, clearance of theophylline 
(low, normal, high), and was designed to achieve a steady state (Css) plasma theophylline of 
1-5 mg/l and to certainly be <10mg/l, (>10mg is the concentration associated with high dose 
theophylline, possible side effects and augmentation of corticosteroid insensitivity). Full 
details are appended in Appendix 1.  
 
The dosing of both the interventional arm (Uniphyllin MR 200mg tablets) and control arm 
(placebo tablets) was determined by the participant’s ideal body weight (IBW) and self-
reported smoking status.  
 A dose of theophylline MR 200 mg (one tablet) once daily (or one placebo once 
daily) was taken by participants who did not smoke, or participants who smoked but 
had IBW ≤ 60kg.  
 A dose of theophylline MR 200 mg (one tablet) twice daily (or one placebo twice 
daily) was taken by participants who smoked with IBW > 60 kg.  
 
Ideal body weight was used unless the participant’s actual weight was lower than the ideal 
body weight; in such cases, actual body weight was used to determine dose.  
 
Ideal body weight (IBW) was calculated using the following standard equations.67 
IBWfemale =45 + 0.9(height in cms-152) kg 
IBWmale = 50 + 0.9(height in cms-152) kg 
 
For the calculation of dose, to be classed as a “non-smoker” at recruitment a participant must 
have abstained from smoking for ≥ 12 weeks. Participants who had given up smoking 
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recently (less than 12 weeks ago) were classed as a smoker.  
 
Protocol defined changes in dose during treatment period 
Table 1 summarises changes in dose during the treatment period based on changes in 
smoking status or weight.  
 
Table 1: Protocol defined changes in dose during the trial 
Characteristics at 
baseline 
Initial 
dose 
Changes to smoking 
during follow-up 
Changes to weight during 
follow-up 
IBW ABW Smoking 
status 
Change to 
smoking 
Dose 
change 
Change to 
weight 
Dose change 
>60kg >60kg Smoker bd Stop 
Smoking 
Reduce to 
od 
Lose 
ABW<60kg 
Reduce to od 
>60kg <60kg Smoker od Stop 
Smoking 
No change Gain 
ABW>60kg 
Increase to 
bd 
<60kg >60kg Smoker od Stop 
Smoking 
No change Lose 
ABW<60kg 
No change 
      Gain No change 
<60kg <60kg Smoker od Stop 
Smoking 
No change  Gain No change 
>60kg >60kg Non 
smoker 
od Start 
smoking 
Increase to 
bd 
Lose 
ABW<60kg  
No change 
      Gain No change 
>60kg <60kg Non 
smoker 
od Start 
smoking 
No change Gain No change 
<60kg >60kg Non 
smoker 
od Start 
smoking 
No change Lose 
ABW<60kg  
No change 
      Gain No change 
<60kg <60kg Non 
smoker 
od Start 
smoking 
No change Gain No change 
ABW Actual Body Weight, bd twice daily, IBW Ideal Body Weight, kg kilograms, od once daily 
 
Changes in smoking status 
Changes in smoking status are known to influence the pharmacokinetics of theophylline 
(smokers clear the drug more rapidly). Self-reported smoking status was checked at every 
contact and participants provided with written and verbal advice to contact their study team if 
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their smoking status changed during the treatment period. Participants who stopped smoking 
during the treatment period were re-classified as a “non-smoker” if they abstained from 
smoking for ≥12 weeks. Smoking participants whose IBW (and actual body weight) was 
>60kg who stopped smoking had their dose reduced to 200mg od (one tablet once a day) 
[those with IBW<60kg maintained their 200mg od, one tablet once a day dose]. Participants 
who started smoking during the treatment period were re-classified as a “smoker” when they 
had smoked for ≥12 weeks. Non-smoking participants whose IBW (and actual body weight) 
was >60kg who started smoking had their dose increased to 200mg bd (one tablet twice a 
day). 
 
Changes in weight 
Changes in weight are known to influence the pharmacokinetics of theophylline. Smoking 
participants with an IBW>60kg whose actual body weight fell below 60kg had their dose 
reduced to 200mg od (one tablet once a day). Smoking participants with IBW>60kg whose 
actual body weight increased to above 60kg had their dose increased to 200mg bd (one tablet 
twice a day). 
 
Changes in concomitant medication 
When informed of their patient’s participation in the trial, General Practitioners were advised 
to manage their patient for exacerbations as per normal clinical practice but to assume the 
participant was taking low-dose theophylline. GPs were advised to avoid wherever possible 
prescribing drugs that were likely to increase plasma theophylline concentrations; they were 
provided with a list of such drugs. In the event that drugs known to increase theophylline 
concentration had to be prescribed for 3 weeks or less, GPs/participants were asked to 
suspend taking the study medication and recommence their study medication after the course 
of interacting drug had been completed, e.g. prescription of clarithromycin for an 
exacerbation of COPD. If the interacting drug was to be prescribed for more than 3 weeks, 
GPs/participants were asked to discontinue the study medication but remain in the study and 
followed up in accordance with the trial protocol.  
 
Participants were asked to carry a study card and to show this to anyone prescribing 
medication for them. This advised the prescriber to assume that the participant was taking 
low-dose theophylline and included a link to the list of drugs that may increase plasma 
theophylline concentrations.  
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Theophylline in the form of intravenous aminophylline is sometimes used in the treatment of 
severe acute exacerbations of COPD in the hospital setting. It was anticipated that during the 
trial some participants would be hospitalised with life threatening exacerbations of COPD 
and that the treating physician may wish to use intravenous aminophylline. The commonly 
used clinical protocol for intravenous aminophylline was established during the era of high-
dose oral theophylline when patients would be prescribed oral theophylline aiming for plasma 
concentration of 10-20mgl and a loading dose of aminophylline would raise plasma 
theophylline concentrations to toxic concentrations (>20mg/l). For a patient not established 
on oral theophylline the intravenous protocol comprises a bolus of intravenous aminophylline 
(usually 250mg, or 5mg/kg) followed by a maintenance dose (0.5mg/kg/hr), whereas for a 
patient established on oral theophylline the bolus dose is omitted (because of concerns 
regarding toxicity) and a maintenance infusion (0.5mg/kg/hr) commenced. In the era of high-
dose theophylline it was critical to establish if a patient was taking oral theophylline before a 
physician commenced a patient on intravenous aminophylline. 
 
Pharmacokinetic modelling (Appendix 1) of the low-dose theophylline dosing regimen 
demonstrated that a 250mg (or 5mg/kg if <50kg) loading dose of aminophylline could be 
administered to trial participants and their plasma theophylline would remain within the 
therapeutic high-dose bronchodilating concentration of 10-20mg/l (Appendix 1). As per 
Guideline recommendations for plasma theophylline monitoring we advised the measurement 
of plasma theophylline 24 hours after commencing intravenous aminophylline (allocation 
status would not be discernible from such a concentration).24 Study drug was discontinued 
during intravenous aminophylline therapy, but restarted after discontinuation of intravenous 
aminophylline therapy.  
 
The advice regarding use of intravenous aminophylline was summarised on the participant’s 
study card. In reality no treating physicians contacted the study team with concerns about 
intravenous aminophylline. 
 
Supply of study medication 
Each participant received their first bottle of four weeks study medication (or placebo) from a 
participating Clinical Trials Pharmacy. For secondary care sites this was usually the Clinical 
Trials Pharmacy based at that secondary care site. For participants recruited in primary care 
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study sites the first bottle of medication was dispensed from the Clinical Trials Pharmacy in 
NHS Grampian and couriered to the participant’s address.  
 
Each participant also received two further supplies of six bottles (each bottle being a four 
week supply). These supplies were dispatched to participants by a third party (Anderson 
Brecon, Hereford, UK) and delivered to participants addresses via a courier. These shipments 
were made around week 3 and week 27 to enable continuity of supply. Receipt of trial 
medication to the participant’s home address was confirmed by signature on receipt.   
 
Data Collection 
Baseline, outcome and safety data were collected by face to face assessments conducted at 
recruitment/baseline (week 0), 6 months (week 26) and 12 months (week 52). Participants 
were phoned two weeks after starting study medication to ensure that they were tolerating the 
medication. The schedule for data collection within the study is outlined in table 2. If a 
participant was unable to attend a scheduled follow up assessment visit because of an acute 
illness e.g. exacerbation of COPD, or other reasons, the visit was postponed and the 
participant was assessed within four weeks of the scheduled assessment visit. Participants 
unable to attend for face to face assessment at six and twelve months were followed up by 
telephone, home visit, or sent the questionnaires to complete at home.  
 
The following data were collected: 
 
Demographic, clinical data 
Demographic, contact, clinical history and if necessary clinical examination data were 
captured at the recruitment visit. 
 
Drug history 
Regular use of prescription drugs was recorded at recruitment, and the 6 and 12 month 
assessments. ICS use was checked at recruitment, 6 and 12 months. Many participants 
brought they repeat prescription list with them to the assessments. Participants were asked 
how many times a day they used their ICS preparation and the dose. 
 
Smoking history 
Smoking history (age commenced, age ceased, average cigarettes smoked per day) and 
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current smoking status was recorded at recruitment, and pack year consumption computed. At 
the six and twelve month assessments current smoking status was recorded.  
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Table 2: Schedule of study assessments55 
Assessment 
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Assessment of Eligibility Criteria      
Written informed consent      
Demographic data, contact details      
Clinical history      
Drug history      
Smoking status      
Height      
Weight      
Total number COPD exacerbations requiring 
OCS/antibiotics 
     
Hospital admissions      
Health related quality of life      
Disease related health status (CAT, mMRC dyspnoea, 
HARQ) 
     
Post bronchodilator lung function      
Adverse events/drug reactions      
Health care utilisation      
Patient Compliance      
OCS oral corticosteroid, CAT COPD Assessment Test, GP General Practice, mMRC modified Medical 
Research Council dyspnoea scale, HARQ Hull Airways Reflux Questionnaire 
 
Height & weight 
Height was measured using clinic stadeometers at baseline. Weight was assessed using clinic 
scales at recruitment, and the 6 and 12 month assessments. 
 
Number of COPD exacerbations 
The primary outcome measure of the total number of COPD exacerbations requiring 
antibiotics/oral corticosteroids whilst on study medication was ascertained at the 6 and 12 
month assessment. Participants were encouraged to record any exacerbations in a space 
provided on the outer packaging (carton) used to ship medication or on the participant follow-
up card, and to bring this to their follow-up assessments. For those participants where follow-
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up at 12 months could not be completed, GPs were contacted and asked to provide 
information on the number of exacerbations experienced by the participant in the treatment 
period, and whether or not these resulted in hospital admission. 
 
The American Thoracic Society (ATS)/European Respiratory Society (ERS) guideline 
definition of COPD exacerbation was used: a worsening of patient’s dyspnoea, cough or 
sputum beyond day-to-day variability sufficient to warrant a change in management.55, 68 The 
minimum management change was treatment with antibiotics or oral corticosteroids. A 
minimum of two weeks between consecutive hospitalisations/start of new therapy was 
necessary to consider events as separate. A modified American Thoracic Society/European 
Respiratory Society operational classification of exacerbation severity was used for each 
exacerbation:  
Level I, Increased use of their short acting β2 agonist (mild);  
Level II, use of oral corticosteroids or antibiotics (moderate);  
Level III, care by services to prevent hospitalisation (moderate);  
Level IV, admitted to hospital (severe).68 
An exercise to validate patient reported exacerbations was carried out (see Appendix 2). 
 
Hospital admissions  
The number of unscheduled hospital admissions whilst on study medication was ascertained 
at the 6 and 12 month assessments. Emergency admissions consequent upon COPD were also 
identified. Participants were encouraged to record any hospital admissions in the space 
provided on the outer packaging (carton) used to ship medication or on the participant follow-
up card, and to bring this to their follow-up assessments.  For those participants where 
follow-up at 12 months could not be completed, their GP or hospital records were checked to 
ascertain the number of hospital admissions during the treatment period. 
 
Health related quality of life  
Health related quality of life data were captured at recruitment, and at the six and twelve 
month assessments by questionnaire using the EuroQoL 5D (EQ-5D-3L) Index69, 70 that has 
been used widely in studies of COPD. The completed instrument can be translated into 
quality of life utilities suitable for calculation of quality adjusted life years (QALY)s through 
the published United Kingdom tariffs.71 
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Disease related health status  
Disease related health status was ascertained at recruitment and at the 6 and 12 month 
assessments by participant completed questionnaire using the COPD Assessment Test 
(CAT).72-74 The CAT is an 8-item unidimensional measure of the impact of COPD on 
patients’ health. The CAT has a scoring interval of 0-40, with 0-5 being the norm for healthy 
non-smokers and > 30 being indicative of very high impact of COPD on quality of life72. The 
CAT is reliable and responsive, correlates very closely with the St George Respiratory 
Questionnaire and is preferred because it provides a more comprehensive assessment of the 
symptomatic impact of COPD and is shorter and thus more easy to complete,72-74 
 
Participants were also asked to grade their breathlessness using the mMRC dyspnoea scale at 
recruitment, and the six and twelve month assessments.75 The mMRC dyspnoea scale has 
been in use for many years to grade the effect of breathlessness on daily activities. The 
mMRC dyspnoea scale is a single question which assesses breathlessness related to activities, 
the scoring interval is 0-4 with 0 being ‘Not troubled by breathlessness except on strenuous 
exercise’ and 4 being ‘Too breathless to leave the house, or breathless when dressing or 
undressing’. The mMRC score has been validated against walking test performance and other 
metrics of COPD health status eg St George Respiratory Questionnaire.76 
 
In self-selected recruitment centres, the Hull Airway Reflux Questionnaire (HARQ) was 
completed by participants at recruitment, 6 and 12 months. The HARQ was used to assess 
symptoms not elucidated by the CAT or mMRC dyspnoea scale. HARQ is a validated self-
administered questionnaire which is responsive to treatment effects.77  
 
Post bronchodilator lung function 
Lung function was measured at recruitment, and 6 and 12 months using spirometry 
performed to American Thoracic Society/European Respiratory Society standards.78 
Spirometry is a routine part of the clinical assessment of people with COPD. Post 
bronchodilator (LABA within 8 hours, short acting β2 agonist within 2 hours) FEV1 and FVC 
were measured. If necessary lung function was measured 15 minutes after administration of 
the participant’s own short acting β2 agonist (SABA). The European Coal and Steel 
Community (ECSC) predictive equations were used to compute predicted values for FEV1 
and FVC.79 Where spirometry was contraindicated, or participants were not able to complete 
spirometry, this was omitted.  
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Health care utilisation  
Health care utilisation during the previous 6 months was ascertained at recruitment and at the 
6 and 12 month assessments using a modified version of the Client Service Receipt Inventory 
(CSRI).80 The CSRI is a research questionnaire for retrospectively collecting cost related 
information about participant’s use of health and social care services.  
 
Adverse reactions and serious adverse events 
This trial complied with the United Kingdom National Health Service Health Research 
Authority guidelines for reporting adverse events.81 Adverse reactions (AR) and serious 
adverse events (SAE) occurring during the 12 month follow-up period were ascertained at the 
two week telephone call and at the six and twelve month assessments. Participants were 
notified of recognised adverse reactions and encouraged to contact the local study centre if 
they experienced these.  
 
Hospitalisations for treatment planned prior to randomisation and hospitalisations for elective 
treatment of pre-existing conditions were not considered or recorded or reported as an SAE. 
Complications occurring during such hospitalisation were also not considered, recorded or 
reported as an SAE – unless there was a possibility that the complication arose because of the 
study medication (ie a possible adverse reaction). Exacerbations of COPD, pneumonia or 
hospital admissions as a consequence of exacerbations of COPD or pneumonia were not 
considered, recorded or reported as AEs or SAEs because they were primary and secondary 
outcomes for the trial.  
 
Serious adverse events were assessed as to whether the SAE was likely to be related to the 
treatment using the following definitions: 
 Unrelated: where an event is not considered to be related to the study drug 
 Possibly: although a relationship to the study drug cannot be completely ruled out, the 
nature of the event, the underlying disease, concomitant medication or temporal 
relationship make other explanations possible 
 Probably: the temporal relationship and absence of a more likely explanation suggest 
the event could be related to the study drug 
 Definitely: The known effects of the study drug or its therapeutic class, or based on 
challenge testing, suggest that study drug is the most likely cause 
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The reference safety information used to assess whether or not the event was expected was 
section 4.8 of the Summary of Product Characteristics (SmPC) for theophylline.54  
 
Compliance 
Compliance/adherence and persistence with study medication was assessed at the six and 
twelve month assessments. Participants were asked to return empty drug bottles and unused 
medication; compliance was calculated by pill counting.82 Participants were deemed to be 
compliant if they had taken 70% or more of the expected doses. 
 
Participant withdrawal 
Participants who withdrew from treatment (for example because of unacceptable side effects, 
or because they were prescribed a contraindicated medicine for longer than 3 weeks) who 
agreed to remain in the study for follow-up were followed up at 6 and 12 months. Those who 
did not want to attend for clinical follow-up at 6 and 12 months could be followed up by 
telephone or home visit, or opt to receive questionnaires at home. Participants who wished to 
withdraw from study follow-up could continue to contribute follow-up data by agreeing to 
have data extracted from their primary care and secondary care medical records. 
 
Sample Size 
The sample size of 1424 was estimated on the basis of the ECLIPSE (Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints) study reporting the frequency of 
COPD exacerbations in 2138 patients.21 For patients identical to our target population (who 
in a 1-year period have at least two self-reported COPD exacerbations requiring antibiotics or 
oral corticosteroids), the mean (standard deviation) number of COPD exacerbations within 1 
year was 2.22 (1.86).21 Given a similar rate in the placebo arm, 669 subjects were needed in 
each arm of the trial to detect a clinically important reduction in COPD exacerbations of 15% 
(i.e., from a mean of 2.22 to 1.89) with 90% power at the two-sided 5 % significance level. 
Allowing for 6% loss to follow-up83 this was inflated to 712 participants in each study arm, 
giving 1424 in total.  
 
The sample size of 1424 included 6% loss to follow up based upon a Cochrane Review of 
oral theophylline in COPD.83 During the present study, a higher proportion of participants 
than expected ceased their study medication (although most were not lost to follow-up). With 
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the appropriate REC and Regulatory Approvals, recruitment continued beyond 1424 in the 
time available with the total number recruited being 1578 to counteract this loss of person-
years on medication. Recruitment ended in August 2016. 
 
Statistical analysis 
All analyses were pre-specified in the statistical analysis plan which was approved by both 
the Trial Steering Committee (TSC) and the Data Monitoring Committee (DMC) in advance 
of analysis. The statistical analysis plan is included in Supplementary Material 2 – Statistical 
Analysis Plan.  Unless pre-specified, a 5% two-sided significance level was used to denote 
statistical significance throughout and estimates are presented alongside their 95% confidence 
intervals (CI). No adjustments were made for multiple testing. All analyses were according to 
the intention to treat principle with a per-protocol analysis performed as a sensitivity analysis. 
The per-protocol analysis excluded participants who were not compliant, with compliance 
being defined as taking 70% or more of their expected doses of study medication. All 
analyses were undertaken in STATA version 14.84 
 
Categorical variables are described with number and percentage in each category. Continuous 
variables are described with mean and standard deviation (SD) if normally distributed and 
median and inter-quartile range if skewed. The amount of missing data is reported for each 
variable. 
 
Primary outcome 
The primary outcome (number of COPD exacerbations requiring antibiotics and/or oral 
corticosteroids in the 12 month treatment period following randomisation) was compared 
between randomised groups using a generalised linear model with log-link function, over 
dispersion parameter and length of time in study as an offset. The estimated treatment effect 
is presented as unadjusted rate ratio followed by adjusted rate ratio for a set of pre-specified 
baseline variables. The adjustment variables were centre (as a random effect), where the 
participant was identified (primary or secondary care), age (in years) centred on the mean, 
gender (male/female), smoking in pack years, FEV1 % predicted, number of COPD 
exacerbations in the previous year, treatment with LAMA/LABA or a combination and 
treatment with long term antibiotics. Participants that did not provide a full twelve months of 
follow-up information were included to the point at which they were lost to follow-up with 
their time in study utilised in the offset variable. 
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Secondary outcomes 
The total number of COPD exacerbations requiring hospital admission and the total number 
of emergency admissions (all causes) were analysed in the same way as the primary outcome. 
Occurrence of pneumonia during following up was analysed with mixed effects logit model. 
Quality of life measures (CAT, EQ-5D-3L, HARQ) and lung function (FEV1 and FVC) 
measured at baseline, 6 month follow-up and 12 month follow-up were compared between 
groups using a mixed effects model unadjusted and adjusted for the same pre-specified 
covariate set as described for the primary outcome. Fixed effects included visit number, 
treatment with participant and participant-visit interaction fitted as random effects. A 
treatment-visit interaction was included to assess the differential treatment effect on rate of 
change in outcome. An autoregressive (AR(1)) correlation structure was used throughout. All 
participants within the ITT population were included in the analysis and missing outcome 
data assumed to be missing at random. Breathlessness as measured by the mMRC dyspnoea 
scale was analysed using a mixed effects generalized linear model using a logit link function. 
All-cause mortality rate and COPD related mortality and time to first exacerbation were 
compared between randomised groups using Kaplan-Meier survival curves and Cox 
regression for adjustment. Total dose of inhaled corticosteroid at end of follow-up and change 
in total daily dose from baseline were calculated and compared between randomised groups 
using an independent samples t-test and linear regression for adjustment. The proportion of 
participants changing medication during the follow-up period was compared using a chi-
squared test.  
 
Sensitivity analyses 
To assess the impact of death on the treatment effect for the primary outcome, the total 
number of exacerbations and the number of exacerbations requiring hospital admission we 
undertook a sensitivity analysis excluding those participants that died during the study period. 
A sensitivity analyses for QoL and lung function was also undertaken by repeating the mixed 
effects models on only those participants who survived the 12 month follow-up only. 
 
Pre-specified sub group analysis 
The analysis for the primary outcome was repeated for a number of subgroups. The 
subgroups were age (< 60, 60 to 69, ≥70 years), gender (male/female), body mass index 
(<18.5, ≥18.5 to < 25, ≥25 kg/m2), smoking status at recruitment (ex/current), baseline 
treatment for COPD (triple therapy (ICS, LAMA, LABA), double therapy (ICS/LAMA or 
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ICS/LABA), single therapy (ICS only), GOLD stage (I-II, III, IV), exacerbations in 12 
months prior to recruitment (2, 3-4, 5+), oral corticosteroids at recruitment (yes/no), dose of 
inhaled oral corticosteroid at recruitment (1600, ≥1600 µg/day beclomethasone equivalents). 
Sub group analysis was undertaken by the addition of a treatment*covariate interaction term 
and using the ‘lincom’ command in STATA to obtain group specific estimates. We report 
observed mean (SD) exacerbations in each subgroup by treatment group, the treatment effect 
(IRR and 99% CIs) along with the p-value for the interaction term. Due to the exploratory 
nature of the subgroup analysis we used 99% CIs. 
 
Health Economics 
 
Resource Use 
Health care utilisation during the previous 6 months was collected at the 6 and 12 month 
assessments using a modified version of the Client Service Receipt Inventory (CSRI).85  The 
CSRI is a research questionnaire for retrospectively collecting cost related information about 
participant’s use of health and social care services.  The main resource uses collected during 
the follow-up period were:  
 Theophylline intervention 
 Costs of exacerbation treatment, this was broken down into two groups of costs: the 
location of the treatment; ‘home’, ‘care by services to prevent hospitalisation’ and 
‘admitted to hospital’; and the treatment cost of the exacerbations, including 
medication 
 Cost of COPD maintenance medications 
 Other health service use (including inpatient, out-patient and primary care use), none 
of these included exacerbation costs. 
 Non-COPD emergency hospital admissions 
 Regular medication 
 
Baseline resource use was collected for current use of COPD maintenance treatment and 
regular medication.  For calculating baseline resource use and costs we have assumed this 
usage to be for the six months prior to baseline.  The number of exacerbations needing 
treatment in the previous 12 months and the number of exacerbations resulting in 
hospitalisation in the previous 12 months were also collected.  
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Unit costs 
All resource use was valued in GBP (£ sterling) and indexed to 2016, using the Health 
Service Cost Index86 to adjust if necessary. 
 Medication costs were obtained from the British National Formulary (BNF).87  
 For exacerbations, non-COPD emergency admissions, inpatient stays, outpatient 
attendances, and primary care, costs were obtained from; NHS reference costs,88 
Information Services Division (ISD),89 Personal Social Services Research Unit 
(PSSRU),86 BNF87 and papers by Oostenbrink et al90 and Scott et al.91 
 
The total cost per participant was calculated by assigning unit costs to resource use for each 
participant.  Total mean costs were calculated using a generalised linear model (GLM) model 
with a gamma family and clustering for centre number.  After multiple imputation total costs 
were adjusted for baseline characteristics using standard regression methods, to account of 
any differences in cost related variables at baseline.92 
 
Unit costs and their sources are presented in table 3. 
 
Table 3: Unit costs and sources 
Resource Unit Unit cost Source 
Intervention 
Theophylline 200mg od £0.05 BNF87 
 200mg bd £0.11 BNF87 
Exacerbation treatment 
Oxygen Per day £19 Oostenbrink90 
Medication Daily dose Various BNF87 
Inpatient costs  
Ward stay (elective) 
 
Bed day 
 
£362 
 
NHS reference costs 2015/16 (elective 
excess bed day unit cost)88 
Ward stay (non-elective) Bed day £298 NHS reference costs 2015/16 (non-
elective excess bed day unit cost)88 
COPD related ward stay Bed day £262 NHS reference costs 2015/16 (weighted 
average of COPD hospital stays DZ65)88  
Long stay ward 
 
Day 
 
£133 
 
PSSRU 2016 (Not for profit care home 
fee, mean £931 per week)86 
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Table 3 (continued): Unit costs and sources 
Resource Unit Unit cost Source 
Outpatient costs 
Day case 
 
Day 
 
£521 
 
ISD costs book 2015/16 (Day cases all 
specialities)89 
Outpatient appointment 
 
Appointment 
 
£177 
 
NHS reference costs 2015/16 (Total 
outpatient attendances unit cost)88 
Primary care costs 
Emergency GP visit Per contact £86 Based on Scott et al for Out of Hours 
home visit91 
Routine GP visit Per contact £31 PSSRU 16 (inc direct care staff costs, 
without qualifications - 9.22 minutes)86 
Community/district nurse Per contact £38 NHS ref costs 2015/16 (Community 
Health Services - N02AF - District 
nurse)88 
Hospital at home team Per contact £84 NHS ref costs 2015/16 (Community 
Health Services - N08AF - Specialist 
nursing Asthma and respiratory nursing 
liaison)88 
GP telephone Per contact £23.43 PSSRU 2016 (including direct care staff 
costs, without qualification costs 7.1 
minutes)86 
GP home visit Per contact £77.22 PSSRU 2016 (including direct care staff 
costs, without qualification costs 11.4 
minutes visit plus 12 minutes travelling 
time)86 
Blood test Per contact £14.42 ISD costs book 2016 (laboratory 
services, haematology plus practice 
nurse appointment, PSSRU 2016)86 
Dental service Per contact £77 NHS reference costs 2015/16 (general 
dental service attendance)88 
Hearing aid clinic Per contact £53 NHS reference costs 2015/16 
(audiology)88 
Occupational therapist Per contact £79 NHS reference costs 2015/16 
(occupational therapist)88 
  
46 
 
Table 3 (continued): Unit costs and sources 
Resource Unit Unit cost Source 
Diabetic nurse Per contact £71 NHS reference costs 2015/16 (specialist 
nursing, diabetic)88 
Cardiac nurse  Per contact £81 NHS reference costs 2015/16 (specialist 
nursing, cardiac)88 
Long term condition 
nurse/community matron 
Per contact £89 NHS reference costs 2015/16 (Active 
case management)88 
Paramedic Per contact £181 NHS reference costs 2015/16 
(ambulance, see, treat, refer)88 
Chiropodist/community 
clinic/endoscopy 
Per contact £60 NHS reference costs 2015/16 (mean of 
community health services, no separate 
chiropodist or community clinic cost)88 
Physiotherapist Per contact £49 NHS reference costs 2015/16 
(physiotherapist)88 
Podiatrist Per contact £40 NHS reference costs 2015/16 
(podiatrist)88 
Practice nurse Per contact £9.42 PSSRU 2016 (nurse GP practice, 15.5 
minutes per contact)86 
Speech therapist Per contact £88 NHS reference costs 2015/16 (speech 
and language therapist)88 
Nurse telephone call Per contact £6.10 PSSRU 2016 (nurse led triage)86 
Treatment room nurse Per contact £27 NHS reference costs 2015/16 (specialist 
nursing, treatment room)88 
Urine sample/sputum test Per contact £10.28 ISD costs book 2016 (clinical chemistry, 
plus practice nurse appointment, PSSRU 
2016)86 
Dietician Per contact £81 NHS reference costs 2015/16 
(dietician)88 
Flu jab Per contact £14.67 BNF plus practice nurse appointment, 
PSSRU 201686 
Early support discharge Per contact £124 NHS reference costs 2015/16 (crisis 
response and early discharge services)88 
Diagnostic imaging Per contact £37.3 NHS reference costs 2015/16 (total 
outpatient attendances, diagnostic 
imaging)88 
  
47 
 
Table 3 (continued): Unit costs and sources 
Resource Unit Unit cost Source 
Optometry Per contact £79.19 NHS reference costs 2015/16 (total 
outpatient attendances, optometry)88 
Healthcare assistant Per contact £6.20 PSSRU 2016 (band 3 nurse, 15.5 
minutes)86 
Talking matters Per contact £24.06 PSSRU 2009/10 (counselling services in 
primary care, telephone consultation 
29.7 minutes)86 
Community psychiatric 
nurse/stroke nurse 
Per contact £77 NHS reference costs 2015/16 (other 
specialist nursing)88 
Counselling  Per contact £78.27 PSSRU 2009/10 (counselling services in 
primary care, consultation 96.6 
minutes)86 
Breast care nurse Per contact £59 NHS reference costs 2015/16 (beast care 
nursing)88 
Community mental health 
team 
Per contact £121 NHS reference costs 2015/16 (other 
mental health specialist team)88 
Pulmonary rehabilitation Per contact £78 NHS reference costs 2015/16 (other 
single condition community 
rehabilitation teams)88 
Emergency costs 
Ambulance Per 
attendance 
£236 NHS reference costs 2015/16 (See, treat 
convey)88 
Accident and Emergency 
attendance 
Per 
attendance 
£138 NHS reference costs 2015/16 
(Emergency medicine average unit 
cost)88 
bd twice daily, BNF British National Formulary, ISD Information Services Division, NHS National Health 
Service, od once daily, PPSRU Personal Social Services Research Unit 
 
Health Outcomes 
The economic outcome used was the quality adjusted life-year (QALY); a combination of 
quality and quantity of life.  The quality of life measure was generated using completed EQ-
5D-3L questionnaires.  Participants completed the questionnaire at baseline, 6 months and 12 
months.  
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Patient-reported health-related quality of life obtained from EQ-5D-3L questionnaires were 
valued in terms of utilities (from a scale of -0.59 to 1, where 1 is full health) using a standard 
UK value set,71 which were converted into QALYs using standard area-under-the-curve 
methods; patient utility measurements from each follow-up point were weighted by the time 
interval between follow-up points.  Discrete changes in utility values between follow-up time 
points were assumed to be linear. After multiple imputation QALYs were adjusted for 
baseline characteristics using standard regression methods.   
 
Analysis 
The total cost per participant in each intervention was summed and divided by the number of 
participants in each arm to calculate the total mean cost per participant in each arm, along 
with the difference in means and a 95% confidence interval (CI). 
 
The mean QALY per participant for each intervention was calculated by summing all 
participant’s QALYs and dividing by the number of participants in that intervention arm.  
The difference in the means were also calculated along with a 95% CI.   
 
The incremental cost-effectiveness ratio (ICER) was calculated by dividing the difference in 
mean costs by the difference in mean QALYs.  The National Institute for Health and Clinical 
Excellence (NICE) threshold of £20,000 to £30,000 was used when judging whether the 
intervention was cost-effective.93   
 
Withdrawn participants were included in the analysis and the total time they spent in the trial 
was used to adjust total costs and QALYs using regression methods.  
 
To explore the uncertainty around the cost and QALY differences and the resulting ICER, a 
non-parametric bootstrapping technique was employed with 1,000 iterations, results are 
presented using a cost-effectiveness plane, showing all 1,000 incremental cost-effectiveness 
pairs, and a cost-effectiveness acceptability curve. 
 
The analysis was carried out using STATA 14.0.84   
 
Missing data 
There was a small amount of multivariate missingness in collected resource data.   
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Resource use data were not available for some exacerbations, either because this was not 
reported by participants, or only limited data were available from GP or hospital records.  
Missing resource use data on exacerbations were dealt with as detailed below: 
 For exacerbations with missing length of exacerbation data, the length was assumed to 
be the mean, treatment arm specific, length of exacerbation. 
 For exacerbations missing a marker to indicate the location of treatment this was 
assumed to be at home, as the majority of location of treatments were at home (over 
80%). 
 For exacerbations treated in hospital, missing lengths of stay were assumed to be the 
length of exacerbation. 
 For exacerbations missing treatment costs a treatment arm specific mean cost of 
treatment was assumed. 
 
At a resource use level there were small amounts of missing data which were dealt with as 
described below: 
 Where the length of stay data was missing for emergency hospital admissions, this was 
imputed using the treatment arm specific mean length of stay. 
 Where participants had no observations completed to indicate the duration of a 
maintenance COPD treatment, it was assumed that the treatment duration was for the 6 
months prior to the date that information about the COPD maintenance treatment was 
collected. 
 Where a participant had indicated that they received a maintenance COPD treatment 
but no medication details were available, a treatment arm specific mean cost was 
imputed for that specific maintenance medication. 
 Where resource use was missing for inpatient, outpatient and primary care service 
use, the participant was assumed not to have used the resource in question.   
 
Complete cases were analysed initially and multiple imputation was used to explore the effect 
of missing data on the analysis. 
 
The multiple imputation technique used was multiple imputation using chained links (MICE).  
Multiple imputation assumes that data is missing at random; missing data may depend on 
observed data.    
50 
 
Assumptions 
The following assumptions were made in the health economics analysis: 
 Complete case is defined as having data covering resource use for the 12 month 
follow-up period.  For a small number of participants there was no 6 month data 
collection, however the 12 month data collection covered resource use for the whole 
of the 12 month follow-up period. 
 
Public and patient involvement (PPI) 
A patient with COPD was an independent voting member of the TSC. Initially this was a 
patient from the Aberdeen Chest Clinic who was nominated by Chest Heart and Stroke 
Scotland as part of their Voices Scotland initiative. In 2015 this patient had to resign from the 
TSC because of ill-health and was replaced by another patient from the Aberdeen Chest 
Clinic who is a patient living with COPD.  
 
Early versions of the trial protocol and PILs were reviewed by a representative from the 
British Lung Foundation-North Region, and a patient who lives with COPD and attends the 
Chest Clinic at the Freeman Hospital, Newcastle. They both attended the Trial Initiation 
Meeting, purposively held in Newcastle in February 2013 and contributed suggestions and 
changes to the final study design that were reflected in the protocol and PIL.  
 
The TWICS trial was publicised in 2014 by a press release that included supportive quotes 
from the British Lung Foundation and Chest Heart and Stroke Scotland, this publicity 
resulted in members of the public with COPD volunteering to participate, with their 
permission their details were passed on to their local TWICS study site.  
 
We anticipate that the PPI member of the Trial Steering Committee will comment on results 
letter to be sent to trial participants. It is also anticipated that the publication of the trial 
results will be co-ordinated with press releases from the participating academic/NHS 
institutions, British Lung Foundation and Chest Heart and Stroke Scotland. Members of the 
study team will be participating in local Public Engagement with Research activities.  
 
Protocol amendments 
There were seven protocol amendments and these are summarised in table 4. 
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Table 4: Summary of protocol amendments. 
Version number, date Summary of amendments 
Version 2, 20 June 2013 Version initially approved by REC. 
Version 3, 5 August 2013 To incorporate clarification of the definition of smoker and non-
smoker as required by MHRA.  
Version 4, 5 February 2014 To add episodes of pneumonia as a secondary outcome and to 
confirm that pneumonia will not be classified as an AE or SAE 
within the trial;  
To clarify that, in addition to the study intervention, participants 
will receive "usual NHS care" in the treatment of COPD rather 
than guideline compliant care;  
To clarify that patients with Alpha-1-Antitrypsin Deficiency and 
COPD should be excluded. 
Version 5, 2 July 2014 To clarify when spirometry may be contraindicated; 
To update the version of the SmPC appended to the protocol; 
To include the definition of the source data 
Version 6, 4 August 2014 To list additional potential avenues for identification of eligible 
patients (including smoking cessation clinics, community 
spirometry clinics and other services for patients with COPD); 
To confirm that participants with limited mobility or who live 
some distance from the study site can be recruited during a home 
visit. 
Version 7, 11 August 2015 To update the telephone number for the switchboard at Aberdeen 
Royal Infirmary (for emergency unblinding); 
To describe how cases where medications that potentially interact 
with theophylline are prescribed to trial participants are 
documented within the trial. 
Version 8, 19 May 2016 To amend the protocol to allow for over-recruitment. 
Version 9, 14 April 2017 To describe how requests for unblinding made by participants (or 
their GPs) at the end of their 12 month follow-up should be 
handled; 
To revise the planned validation exercise in relation to participant 
reported exacerbations. 
AE Adverse Event, COPD Chronic Obstructive Pulmonary Disease, GP General Practitioner, MHRA Medicines 
and Healthcare products Regulatory Agency, NHS National Health Service, REC Research Ethics Committee, 
SAE Serious Adverse Event, SmPC Summary of Product Characteristics 
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Trial oversight 
A Trial Steering Committee, with independent members, including PPI, oversaw the conduct 
and progress of the trial. An independent Data Monitoring Committee oversaw the safety of 
subjects within the trial. 
 
Breaches  
Breaches of trial protocol or GCP were recorded and reported to the sponsor. A summary of 
breaches is included in Appendix 3. Participants who were the subject of a breach remain in 
the intention to treat population, the safety population and the per protocol population (if 
compliance criteria were met).  
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CHAPTER 3 – BASELINE CHARACTERISTICS 
 
Recruitment 
Participants were recruited to the trial between February 2014 and August 2016.  During this 
31 month period, 141 UK sites were opened to recruitment.  Once opened, some sites (n=20) 
failed to recruit any patients to the study.  Reasons for this included staff changeover, lack of 
eligible patients, competing priorities, practice closure and eligible patients who did not agree 
to take part. 
 
In total, 1578 participants were recruited from 121 sites (see table 5).  A detailed summary of 
recruitment, by site, is given in Appendix 4.  In summary, across 33 secondary care sites, 
1101 participants were recruited, and across 88 primary care sites, 477 participants were 
recruited. Of those recruited in secondary care, 464 participants were identified in primary 
care. Overall, 59.6% of participants were identified in primary care. 
 
Table 5: Summary of recruitment 
Recruitment site based in Participants identified in Number of participants 
Secondary care Secondary care 637 
Secondary care Primary care 464 
Primary care Primary care 477 
 
The initial funding included a 24 month recruitment period. There were delays in 
manufacturing and packaging the study medication, and the projected recruitment was re-
profiled across 21 months. After around six months of recruitment, it became clear that we 
were unlikely to meet the recruitment target within 21 months.  To address this, several 
measures were successfully implemented: ‘second’ and ‘third’ wave sites were opened up 
earlier than planned; additional primary and secondary care sites were identified and a rolling 
programme of opening these sites up was established; a six month extension to recruitment 
was granted by the funder; and we were able to accommodate additional recruitment time 
within the existing funding. Within the 31 month recruitment period, we were granted 
approval to over-recruit beyond the original target of 1424 participants. The justification for 
this was the higher than anticipated numbers of participants who ceased taking the study 
medication (see chapter 5, section on treatment adherence/compliance for more information).  
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Figure 3 shows the original recruitment targets, the re-profiled recruitment targets (to 
accommodate the delay in manufacturing/packaging), our revised recruitment targets (after 
the extension to recruitment was granted) and the actual recruitment.  
 
 
 
Figure 3: Recruitment 
 
Post randomisation exclusions 
Eleven participants were recruited in error and were then excluded. None of these participants 
took any dose of study medication and are excluded from all study analyses. Reasons for 
these post-randomisation exclusions are given in table 6. 
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Table 6: Reasons for post-randomisation exclusion 
Overarching reason for post-
randomisation exclusion 
Specific reason for post-randomisation exclusion 
Concomitant medications Already taking a form of theophylline (n=1) 
 Concomitant prescription of diltiazem (n=2) 
 Concomitant prescription of methotrexate (n=1) 
 Not currently prescribed inhaled corticosteroid (n=1) 
COPD diagnosis Diagnosed with right middle lobe collapse not COPD (n=1) 
 COPD diagnosis disputed by consultant (n=1) 
 Less than two exacerbations in the previous year (n=3) 
Spirometry Did not fulfil spirometric criteria for the study (n=1) 
COPD Chronic Obstructive Pulmonary Disease 
 
Sixteen participants who were recruited into TWICS were subsequently noted to be ineligible 
for the study at the point of recruitment. All sixteen participants had taken at least one dose of 
study medication and were retained in follow-up and included in the study analyses. Seven of 
these were taking a form of diltiazem at recruitment, and were identified during a review of 
all baseline medication recorded for participants. Diltiazem can cause a slight increase in 
serum theophylline concentration, however any effect is usually clinically insignificant.94 
One of these participants took study medication for approximately 10 days but stopped 
because they experienced symptoms considered likely to be related to theophylline. A further 
participant experienced some symptoms that may have been side effects related to the study 
medication and stopped after approximately four months. One further participant experienced 
some symptoms that may have been side effects related to study medication but did not cease 
taking study medication.  
 
In this same review, a further five participants were noted to have been taking a 
contraindicated medication at baseline.  Three participants were noted to be taking a form of 
oestrogen. Serum theophylline concentration is slightly increased by concomitant oestrogen 
but no toxicity has been reported.94 Two participants co-prescribed oestrogen continued to 
take study medication through their 12 month follow-up with no adverse reactions. The other 
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participant experienced symptoms (thought to be related to theophylline) and stopped taking 
the study medication after 14 days. One participant was noted to have been taking febuxostat 
at recruitment. They had taken study medication through their 12 month follow-up and 
experienced symptoms that may have been side effects related to study medication. High-
dose febuxostat has been reported to possibly increase serum theophylline.94 One participant 
was noted to have been taking roflumilast at recruitment. Although roflumilast has no 
reported effect on serum theophylline concentrations the two drugs act through 
phosphodiesterase enzymes94 albeit theophylline at conventional ‘high dose’ levels with 
serum concentrations of 10-20mg/l. This participant had taken study medication throughout 
their 12 month follow-up without any adverse reactions.  
 
Three participants were taking a form of theophylline at recruitment. In two of these, this was 
only noted after the participant had completed their 12 month follow-up (and the participants 
had taken study medication through their 12 month follow-up).  In the other participant, this 
was noted after the participant had taken study medication for 8 days and the study 
medication was then stopped. In all three cases, no adverse reactions relating to the study 
medication were noted.  
 
One participant was recruited into TWICS when they were already participating in another 
CTIMP for an unrelated condition. The participant did not disclose this at the time of 
recruitment and it was not clearly documented in their hospital notes. No interaction between 
the TWICS study medication and the medication used within the other study is likely. The 
participant continued to take study medication for approximately eleven months, when a non-
related throat problem caused problems in taking the study medication.  
 
Baseline characteristics 
Baseline characteristics are presented for the 1567 included participants (after exclusion of 
the 11 post randomisation exclusions). The theophylline and placebo groups were well 
balanced in terms of demographic and disease characteristics at baseline.  
 
The mean age of participants was 68.4 years (SD 8.4) (see table 7). Just over half of the 
participants (53.8%) were male. Approximately one third (31.7%) were current smokers; the 
remainder were ex-smokers. The median pack years smoked was 42 (IQR 27.7, 56.0) pack 
years. Mean BMI was 27.2 kg/m2 (SD 6.1).  
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The median number of participant reported exacerbations in the 12 months prior to 
recruitment was 3 (IQR 2, 4), the mean number of exacerbations was 3.6 (SD 2.2) (see table 
8). The majority of participants (79.9%) were prescribed the ‘triple therapy’ combination of 
ICS, LABA and LAMA at baseline. Almost one fifth (16.7%) were prescribed ICS and 
LABA. The remainder were prescribed ICS only (2.0%) or ICS and LAMA (1.5%).   
 
Co morbidities, as reported by participants, were relatively common. Almost one fifth 
(18.3%) had a concurrent diagnosis of asthma. Four percent of participants reported a 
diagnosis of bronchiectasis. Just over one third of participants (38.2%) reported a diagnosis 
of hypertension. Thirteen percent reported ischaemic heart disease and 6.7% reported a 
previous cerebrovascular event. Almost one third (28.0%) reported anxiety or depression in 
the last five years. Eleven percent had a diagnosis of diabetes mellitus and 12.8% had a 
diagnosis of osteoporosis.  
 
Measurement of lung function at baseline revealed that the mean FEV1 was 51.7 (SD 20.0) 
percent predicted. Using the GOLD classification,1 13.6% were classified as very severe 
COPD, 37.7% as severe, 39.6% as moderate and 9.2% as mild. 
 
The mean score on the COPD assessment test (CAT) was 22.6 (SD 7.7) indicating that 
overall, COPD was having a high impact on the lives of participants (see table 9). 
Considering the cut-offs used to interpret scores derived from the CAT, COPD was having a 
low impact on the lives of 5.3% of participants, in 29.9% COPD was having a medium 
impact, in 44.4% COPD was having a high impact and in 20.4% COPD was having a very 
high impact on their lives. 
 
The mean EQ-5D-3L utility score was 0.63 (SD 0.28). The mMRC dyspnoea score revealed 
that 7.1% of participants were too breathless to leave the house; 27.6% had to stop for breath 
after walking about 100 metres, 31.5% walked slower than contemporaries on level ground 
because of breathlessness, 28.3% became short of breath when hurrying or walking up a 
slight hill, only 5.5% of participants were not troubled by breathlessness except on strenuous 
exercise.  
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A comparison of the participants recruited in primary and secondary care indicated that those 
identified in secondary care were slightly younger, more likely to be ex-smokers, greater 
number of exacerbations in previous 12 months, higher proportion with more severe COPD, 
more on triple (ICS/LAMA/LABA) therapy and on long term antibiotic use, there was also a 
significantly greater prevalence of co-morbidities: bronchiectasis, IHD, osteoporosis 
(Appendix 5; Table 34). Participants recruited in secondary care had a higher CAT score, and 
slightly lower QoL. 
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Table 7: Baseline sociodemographic characteristics  
 Theophylline Placebo Overall 
Sex          
  Male (N, n, %) 788 425 53.9 779 418 53.7 1567 843 53.8 
  Female (N, n, %) 788 363 46.1 779 361 46.3 1567 724 46.2 
Age (N, Mean, SD) 788 68.3 8.2 779 68.5 8.6 1567 68.4 8.4 
Smoking status          
  Current smoker (N, n, %) 788 247 31.3 779 249 32.0 1567 496 31.7 
  Ex-smoker (N, n, %) 788 541 68.7 779 530 68.0 1567 1071 68.3 
Pack years (N, Mean, SD) 785 47.0 26.3 775 47.1 30.6 1560 47.1 28.5 
Pack years (N, Median, IQR) 785 43.0 28.5, 57.0 775 41.0 27.0, 55.0 1560 42.0 27.7, 56.0 
BMI (N, Mean, SD) 788 27.1 6.2 779 27.3 6.0 1567 27.2 6.1 
BMI group          
  Underweight (N, n, %) 788 37 4.7 779 38 4.9 1567 75 4.8 
  Normal (N, n, %) 788 285 36.2 779 246 31.6 1567 531 33.9 
  Overweight (N, n, %) 788 252 32.0 779 266 34.1 1567 518 33.1 
  Obese (N, n, %) 788 214 27.2 779 229 29.4 1567 443 28.3 
BMI Body Mass Index, SD Standard Deviation, IQR Interquartile range 
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Table 8: Baseline clinical characteristics  
 Theophylline Placebo Overall 
Exacerbations in the last 12 months (N, mean, SD) 785 3.6 2.2 773 3.5 2.1 1558 3.6 2.2 
Exacerbations in the last 12 months (N, median, IQR) 785 3 2, 4 773 3 2, 4 1558 3 2, 4 
Exacerbations requiring hospitalisation in the last 12 months 
(N, mean, SD) 784 0.4 0.8 773 0.4 1.0 1557 0.4 0.9 
Exacerbations requiring hospitalisation in the last 12 months 
(N, median, IQR) 784 0 0, 1 773 0 0, 0 1557 0 0, 0 
GOLD 2011 category           
  C- ≥2 exacerbations in last year, mMRC 0-1 and CAT<10  
(N, n, %) 779 37 4.7 768 45 5.9 1547 82 5.3 
  D ≥2 exacerbations in last year, mMRC ≥2and CAT≥10  
(N, n, %) 779 742 95.3 768 723 94.1 1547 1465 94.7 
FEV1 % predicted (N, mean, SD)  785 51.3 20.1 771 52.2 19.8 1556 51.7 20.0 
FEV1 % predicted category           
  80+% [GOLD mild] (N, n, %) 785 70 8.9 771 73 9.5 1556 143 9.2 
  50-79.9% [GOLD moderate] (N, n, %) 785 308 39.2 771 308 39.9 1556 616 39.6 
  30-49.9% [GOLD severe] (N, n, %) 785 291 37.1 771 295 38.3 1556 586 37.7 
  0-29.9% [GOLD very severe] (N, n, %) 785 116 14.8 771 95 12.3 1556 211 13.6 
FVC % predicted (N, mean, SD)  783 84.3 22.3 770 86.2 23.4 1553 85.2 22.8 
FEV1/FVC ratio (N, mean, SD) 783 49.0 19.7 770 48.5 14.1 1553 48.8 17.1 
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Table 8 (continued): Baseline clinical characteristics  
 Theophylline Placebo Overall 
Current treatment for COPD          
Inhaled Corticosteroid           
  ICS only (N, n, %) 788 14 1.8 779 17 2.2 1567 31 2.0 
  ICS LABA (N, n, %) 788 136 17.3 779 125 16.0 1567 261 16.7 
  ICS LAMA (N, n, %) 788 13 1.6 779 10 1.3 1567 23 1.5 
  ICS LABA/LAMA (N, n, %) 788 625 79.3 779 627 80.5 1567 1252 79.9 
Oral mucolytic use (N, n, %) 784 201 25.6 771 197 25.6 1555 398 25.6 
Long-term antibiotic use (N, n, %) 784 51 6.5 771 48 6.2 1555 99 6.4 
Co-morbidities          
  Asthma (N, n, %) 782 138 17.6 772 147 19.0 1554 285 18.3 
  Bronchiectasis (N, n, %) 782 41 5.2 770 27 3.5 1552 68 4.4 
  Ischaemic Heart Disease (N, n, %) 781 111 14.2 771 96 12.5 1552 207 13.3 
  Hypertension (N, n, %) 782 317 40.5 772 277 35.9 1554 594 38.2 
  Diabetes Mellitus (N, n, %) 782 83 10.6 772 93 12.0 1554 176 11.3 
  Osteoporosis (N, n, %) 783 109 13.9 771 90 11.7 1554 199 12.8 
  Anxiety/depression treated in last 5 years (N, n, %) 782 222 28.4 772 213 27.6 1554 435 28.0 
  Cerebrovascular event (N, n, %) 783 46 5.9 772 58 7.5 1555 104 6.7 
FEV1 Forced expiratory volume in 1 second; FVC Forced vital capacity; GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS Inhaled 
corticosteroid, SD Standard deviation, IQR interquartile range, LABA Long acting β2 agonist; LAMA Long-acting muscarinic antagonists, SD standard 
deviation 
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Table 9: Baseline patient reported symptoms and quality of life 
 Theophylline Placebo Overall 
Degree of breathlessness (mMRC dyspnoea) 75          
Not troubled by breathlessness except on strenuous exercise (N, n, %) 783 35 4.5 772 50 6.5 1555 85 5.5 
Short of breath when hurrying or walking up a slight hill (N, n, %) 783 216 27.6 772 224 29.0 1555 440 28.3 
Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own pace (N, n, 
%) 
783 251 32.1 772 239 31.0 1555 490 31.5 
Stops for breath after walking about 100 metres or after a few minutes on 
level ground (N, n, %) 
783 225 28.7 772 204 26.4 1555 429 27.6 
Too breathless to leave the house, or breathless when dressing or undressing 
(N, n, %) 
783 56 7.2 772 55 7.1 1555 111 7.1 
COPD assessment test (N, mean, SD) 780 22.8 7.5 771 22.3 7.9 1551 22.6 7.7 
COPD assessment test group  
  
      
Low (score 0-9) (N, n, %) 780 37 4.7 771 45 5.8 1551 82 5.3 
Medium (score 10-19) (N, n, %) 780 219 28.1 771 244 31.6 1551 463 29.9 
High (score 20-29) (N, n, %) 780 361 46.3 771 328 42.5 1551 689 44.4 
Very high (score 30-40) (N, n, %) 780 163 20.9 771 154 20.0 1551 317 20.4 
EQ-5D-3L utility (N, mean, SD) 785 0.62 0.28 772 0.63 0.28 1557 0.63 0.28 
EQ-5D-3L VAS (N, mean, SD) 785 59.6 19.0 770 60.8 19.1 1555 60.2 19.1 
COPD Chronic Obstructive Pulmonary Disease, EQ-5D-3L EuroQoL 5 dimension 3 level, mMRC modified Medical Research Council, SD standard 
deviation, VAS visual analogue scale, SD Standard deviation
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CHAPTER 4 – CLINICAL EFFECTIVENESS 
 
Clinical effectiveness of low-dose theophylline compared to placebo  
In this chapter we report the results of people with COPD being treated for one year with 
low-dose theophylline compared with placebo. There were 1578 participants randomised to 
theophylline or placebo, with 11 post-randomisation exclusions resulting in 1567 participants 
eligible to initiate study medication and for whom baseline characteristics have been reported 
(Chapter 3). Follow-up data were unavailable for 31 (2%) participants (16 theophylline, 15 
placebo), and the results presented for the intention to treat analysis are based on 1536 
participants (772 theophylline, 764 placebo), see figure 4. In total there were 1489 person 
years of follow-up data, with 747 person years in the theophylline group and 742 person 
years in placebo (see table 10). 
 
Intention to treat (ITT) analysis 
 
Primary outcome: total number of exacerbations of COPD requiring a change in 
management 
In total 633/772 (82.0%) of participants allocated to theophylline had at least one 
exacerbation, with 1727 exacerbations in the group overall. For participants allocated to 
placebo 609/764 (79.7%) had at least one exacerbation and there were 1703 exacerbations in 
the group overall.  The mean (SD) number of exacerbations per participant was 2.24 (1.99) in 
those allocated to low-dose theophylline and 2.23 (1.97) in those allocated to placebo. The 
adjusted incidence rate ratio (IRR) and 95% CI for exacerbation was 0.99 (0.91, 1.08), 
indicating no difference in the exacerbation rate during the 12 month follow-up period for 
those on low-dose theophylline compared with placebo (see table 10).   
 
The primary outcome was exacerbation treated with antibiotics and/or oral corticosteroids, 
but we also conducted analyses relating treatment with low-dose theophylline to differing 
levels of treatment for COPD exacerbations, i.e. antibiotics only, oral corticosteroids only or 
antibiotics and oral corticosteroids (see Appendix 5, table36). In the adjusted model, for 
exacerbations treated with antibiotics only, IRR (95% CI) was 0.94 (0.78, 1.14), for 
exacerbations treated with oral corticosteroids only 0.88 (0.62, 1.25), and for exacerbations 
treated with antibiotics and oral corticosteroids 1.02 (0.92, 1.14).   
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a Reasons for ineligibility were as follows:  16 did not meet inclusion criteria for established COPD 
diagnosis or had predominant respiratory disease other than COPD, 10 had not had 2 exacerbations in 
previous year, 7 did not meet the smoking history criteria, 7 contraindicated medication, drug 
interaction 3 were not currently using ICS, 1 was not clinically stable, 2 were participating in another 
clinical trial, 1 was currently taking theophylline, 1 had known or suspected hypersensitivity to 
theophylline, 1 pregnancy, 2 with severe heart disease, 11 did not meet two or more of the inclusion 
criteria. 
  
Figure 4: Consort (intention to treat analysis) 
 
Randomised (n=1578) 
Screened (n=1648) 
Allocated 
theophylline (n=791) 
Allocated placebo 
(n=787) 
Post randomisation 
exclusions (n=8) 
Number included 
(n=788) 
Number included 
(n=779) 
Post randomisation 
exclusions (n=3) 
Missing primary 
outcome data (n=15) 
Missing primary 
outcome data (n=16) 
Included in intention 
to treat analysis of 
primary outcome 
(n=772) 
Included in intention 
to treat analysis of 
primary outcome 
(n=764) 
Not eligiblea (n=62) 
Eligible, but did not 
consent (n=8) 
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Table 10: Exacerbation outcomes (Intention to treat analysis) 
 
Theophylline Placebo 
 
Estimate Lower CI Upper CI p-value 
Primary outcome: Exacerbations        
Total number included in analysis 772 764 
     
Person years follow-up 747.5 742.1      
Number with at least one exacerbation 633 609 
     
Total number of exacerbations 1727 1703 
     
Mean number of exacerbations 2.24 2.23 unadjusted IRR 1.00 0.92 1.09 0.965 
SD (number of exacerbations) 1.99 1.97 adjusted IRRa 0.99 0.91 1.08 0.840 
Exacerbations requiring hospital treatment        
Total number included in analysis 772 764 
     
Person years follow-up 747.5 742.1      
Number with at least one exacerbation  106 130 
     
Total number of exacerbations 134 185 
     
Mean number of exacerbations 0.17 0.24 unadjusted IRR 0.72 0.55 0.95 0.021 
SD (number of exacerbations) 0.49 0.66 adjusted IRRa 0.72 0.55 0.94 0.017 
Time to first exacerbation (from randomisation)        
Total number included in analysisb 756 753 
     
Number with at least one exacerbation 617 598 
     
% with at least one exacerbation 81.6 79.4 
     
Median time to first exacerbation (days) 219 227 unadjusted HR 1.03 0.92 1.14 0.652 
25th percentile (time to first exacerbation (days)) 132 116 adjusted HRa 1.01 0.90 1.13 0.895 
75th percentile (time to first exacerbation (days)) 334 337 
     
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics. 
b number in analysis differs to primary outcome as exacerbation onset date was unavailable for 27 participants 
CI confidence interval, HR hazard ratio, IRR incident rate ratio, SD standard deviation
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Secondary outcome: total number of exacerbations of COPD resulting in hospital 
admission 
In those allocated to low-dose theophylline, 106 (13.7%) participants had at least one 
exacerbation requiring hospital admission, with 134 hospital admissions in total for the 
group. For those allocated to placebo, there were 130 (17.0%) participants with at least one 
exacerbation requiring hospital admission, and 185 admissions in total. A comparison of the 
proportion with at least one exacerbation requiring hospital admission was not significant at 
the 5% level (13.7% theophylline vs. 17.0% placebo, p = 0.074). In the adjusted model, the 
IRR for exacerbations of COPD requiring hospital treatment was 0.72 (0.55, 0.94), 
suggesting that low-dose theophylline resulted in a reduction in the number of exacerbations 
requiring hospital admission when compared with placebo (table 10). However, further 
exploration of the data showed that in the theophylline group only 3 participants had more 
than 3 exacerbations requiring treatment in hospital (12 exacerbations in total), compared to 
13 participants in placebo group having more 3 or more exacerbations requiring hospital 
treatment. (51 exacerbations in total).  Therefore a small excess of participants (10) allocated 
to placebo who had ≥3 exacerbations requiring treatment in hospital accounted for 39 of the 
excess 51 admissions in the placebo group (see table 11).    
 
Table 11: Number of exacerbations requiring hospital admission 
Number of exacerbations  Theophylline Placebo 
requiring hospital admission N % N % 
0 666 86 634 83 
1 84 11 100 13 
2 19 2 17 2 
3 0 - 5 1 
4 3 <1 5 1 
5 0 - 2 <1 
6 0 - 1 <1 
 772  784  
 
Secondary outcome:  time to first exacerbation 
The date of onset of the first exacerbation after commencing study medication was not 
available for 27 of the 1242 participants who had at least one exacerbation, therefore this 
analysis was based on 1509 in the ITT population (294 no exacerbation, 1215 (80.5%) with 
exacerbation). In those allocated to theophylline, 617/756 (81.6%) had at least one 
exacerbation, with median time to first exacerbation of 219 days (7.2 months) after 
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randomisation. For placebo, there were 598/753 (79.4%) participants with at least one 
exacerbation, with median time to first exacerbation of 227 days (7.5 months). In a Cox 
regression analysis, the adjusted HR for time to first exacerbation was 1.01 (0.90, 1.13), 
suggesting no significant difference between the treatment groups in terms of time to first 
exacerbation (from point of randomisation) during the 12 month follow-up period (see table 
10). 
 
Secondary outcome:  total number of emergency hospital admissions (non COPD) 
Hospital admission data were available for 1517 of the 1536 participants in the ITT 
population (762 theophylline, 755 placebo). A similar proportion of participants had at least 
one hospital admission for non-COPD related causes. In the participants allocated to low-
dose theophylline this was 10.4% (79/762) compared with placebo 12.2% (92/755). In total, 
there were 116 hospital admissions for participants allocated to theophylline and 119 for 
those allocated to placebo. The adjusted IRR (95% CI) was 0.99 (0.71, 1.38), suggesting no 
significant difference in rate of emergency (unscheduled) hospital admissions between the 
groups (see table 12). 
 
Secondary outcome:  mortality (all cause and respiratory related) 
There were 33 deaths (from all causes) during the 12 month follow-up period, 19 (2.5%) in 
participants allocated to low-dose theophylline and 14 (1.8%) in participants allocated to 
placebo. These deaths were respiratory related for 7 theophylline cases and 8 placebo cases. 
For theophylline relative to placebo the adjusted hazard ratio (95% CI) for deaths from all 
causes was 1.38 (0.69, 2.76), and for respiratory related causes 0.85 (0.30, 2.40). Therefore 
there was no evidence of a significant difference between treatment groups for mortality 
outcomes (see table 12). 
 
Secondary outcome:  total number of episodes of pneumonia 
In total there were 23 episodes of pneumonia reported during the follow-up, 14 in participants 
allocated to theophylline and 9 in participants allocated to placebo (1.8% theophylline vs 1.2 
% placebo). The proportion of admissions for pneumonia was not found to significant differ 
between treatment groups (p = 0.307). The unadjusted OR was 1.55 (0.67, 3.62), however in 
light of the small event counts no adjustments were made (see table 12).   
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Table 12: Secondary clinical outcomes (Intention to treat analysis)   
 
Theophylline Placebo 
 
Estimate Lower CI Upper CI p-value 
Emergency hospital admissions (non-COPD)        
Total number included in analysis 762 755 
     
Number with ≥1emergency hospital admission 79 92 
     
Total admissions 116 119 
     
Mean admission rate 0.15 0.16 unadjusted IRR 0.96 0.69 1.35 0.830 
SD admission rate 0.56 0.47 adjusted IRRa 0.99 0.71 1.38 0.952 
All-cause mortality        
Total number included in analysis 772 764 
     
Number deceased within 12 months 19 14 unadjusted HR 1.35 0.68 2.69 0.398 
% deceased within 12 months 2.5 1.8 adjusted HRa 1.38 0.69 2.76 0.369 
COPD/Respiratory related mortality        
Total number included in analysis 772 764 
     
Number deceased within 12 months 7 8 unadjusted HR 0.87 0.31 2.39 0.785 
% deceased within 12 months 0.9 1.0 adjusted HRa 0.85 0.30 2.40 0.762 
Pneumonia        
Total number included in analysis 772 764 
     
Number with pneumonia  14 9 unadjusted OR 1.55 0.67 3.62 0.307 
% with pneumonia 1.8 1.2 
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Table 12 (continued): Secondary outcomes (Intention to treat analysis)   
 
Theophylline Placebo 
 
Estimate Lower CI Upper CI p-value 
Total daily dose ICS        
Total number included in analysis 770 762 
     
N changed medication from baseline 104 111 
     
Mean ICS daily dose at end of follow up 1606 1622 
unadjusted mean 
difference -16.3 -86.8 54.2 0.650 
SD ICS daily dose at end of follow up 694 714 
adjusted mean 
differencea -12.4 -81.5 56.6 0.724 
Change in daily ICS dose from baseline        
Total number included in analysis 770 762      
Mean change in daily ICS dose from baseline -57 -58 
unadjusted mean 
difference 1.4 -36.5 39.2 0.943 
SD change in daily ICS dose from baseline 346 408 
adjusted mean 
differencea 3.6 -34.1 41.3 0.852 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics. 
OR Odd ratio, HR Hazard ratio, CI confidence interval, ICS inhaled corticosteroid, SD standard deviation 
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Secondary outcome:  Total dose of inhaled corticosteroids (ICS) 
The total daily dose of ICS at baseline was available for 1532 of the 1536 members of the 
ITT population (two missing from each treatment group). Mean (SD) total daily 
beclomethasone equivalent ICS dose at baseline was 1662µg (677) in those allocated to 
theophylline and 1680 µg (691) in those allocated to placebo. During the 12 month follow-up 
215 participants changed their medication, 104 (13.5%) theophylline participants and 111 
(14.6%) placebo participants (p = 0.550). Mean (SD) total daily beclomethasone equivalent 
dose at the end of follow-up was 1606µg (694) in those allocated to theophylline and 1622µg 
(714) in those allocated to placebo, resulting in an adjusted difference of -12.4µg/day (-81.4, 
56.6) for theophylline compared to placebo (see table 12). This lower dose at end of follow-
up in those taking theophylline was not significantly different from placebo. Both groups 
showed a slight reduction in total daily dose from baseline to end of follow-up but a 
comparison of the adjusted mean dose change between treatment groups was not significant 
(p = 0.852).  
 
Secondary outcome:  lung function (% predicted FEV1 and FVC) 
In the ITT analysis lung function was found to be similar between the treatment groups with 
mean (SD) percent predicted FEV1 at the end of the 12 month follow-up of 51.5% (20.4) for 
participants allocated to low-dose theophylline (n = 533) and 52.1% (21.7) for participants 
allocated to placebo (n = 489). The overall difference in FEV1 percent predicted (across the 
12 month period) was -0.56% (-2.42, 1.30) between the groups. A similar pattern was 
observed for percent predicted FVC with the overall significant difference of -0.28% (-2.33, 
1.76) (see table 13). 
 
Secondary outcome:  mMRC breathlessness scale 
Table 14 details the responses to the mMRC breathlessness scale at baseline, 6m and 12m for 
each treatment group. The proportion of participants in each category is relatively similar 
across the groups at each time point. The overall adjusted OR from the mixed effects ordinal 
logistic regression for theophylline relative to placebo is 1.20 (0.88, 1.63) indicating a slight 
increase in odds of higher mMRC score in theophylline participants than placebo, but the 
increase is not significant.  
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Table 13: Lung function (Intention to treat analysis) 
Outcome Time point 
 
Theophylline Placebo 
 
Overall 
mean 
difference 
Lower CI Upper CI p-value 
% Predicted FEV1 Baseline Total N 769 757 
 
    
  
Mean 51.2 52.3 
 
    
  
SD 20.1 19.8 
 
    
 
6 months Total N 553 539 
 
    
  
Mean 52.2 53.2 
 
    
  
SD 20.5 20.9 
 
    
 
12 months Total N 533 489 
 
    
  
Mean 51.5 52.1 unadjusted -0.57 -2.51 1.36 0.561 
  
SD 20.4 21.7 Adjusteda -0.56 -2.42 1.30 0.555 
% Predicted FVC Baseline Total N 767 756 
 
    
  
Mean 84.3 86.3 
 
    
  
SD 22.3 23.4 
 
    
 
6 months Total N 548 535 
 
    
  
Mean 83.8 84.5 
 
    
  
SD 22.8 24.7 
 
    
 
12 months Total N 525 486 
 
    
  
Mean 83.1 82.3 unadjusted -0.37 -2.50 1.75 0.732 
  
SD 23.8 25.3 Adjusteda -0.28 -2.33 1.76 0.788 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics.  
CI confidence interval, SD standard deviation, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity 
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Secondary outcome:  COPD assessment test (CAT) 
The CAT score was very similar between groups at baseline (see table 15) and remained 
similar throughout the 12 month treatment period, with mean (SD) 21.4 (8.2) for participants 
allocated to low-dose theophylline (n = 633) and 21.4 (8.6) for placebo (n = 615). A 
comparison of the profile of the CAT scores across the three time points (0, 6 and 12 
months), showed an adjusted difference of 0.01 (-0.65, 0.68), suggesting no significant 
difference between the groups on the impact of COPD on the participants’ lives. 
 
Secondary outcome:  Hull Airways Reflux Questionnaire (HARQ) 
The HARQ assesses respiratory symptoms associated with airway reflux, and was completed 
by a subset of participants. Participants for whom HARQ data were available were more 
likely to be female and younger in age than those that had no HARQ data (Appendix 5; Table 
35). Data were available on 199 (26.0%) participants allocated to theophylline and 203 
(26.9%) allocated to placebo at baseline. The HARQ scores were very similar between 
treatment groups throughout the study and at 12 months follow-up; for participants allocated 
to low-dose theophylline the mean (SD) HARQ score was 24.1 (15.7) based on 184 
participants, and for those allocated to placebo 24.2 (15.9) on 172 participants. A comparison 
of the profiles of HARQ scores across the three time points (0, 6 and 12 months), revealed an 
adjusted difference of -1.10 (-3.46, 1.26), suggesting no significant difference between the 
groups in reflux associated respiratory symptoms measured by the HARQ (see table 15). 
 
Safety outcomes (safety population) 
The safety population comprised all participants who were randomised and included in the 
study (n = 1567) and initiated their study medication. There were 5/788 (0.6%) theophylline 
allocated participants who did not initiate medication, and 9/779 (1.2%) in the placebo group. 
The safety population consisted of 1553 (99.1%) participants (783 theophylline, 770 
placebo). 
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Table 14: mMRC Breathlessness (Intention to treat analysis) 
Time-point mMRC category Theophylline Placebo 
Baseline Not troubled by breathlessness 
except on strenuous exercise (N, n, 
%) 
767 35 4.6 757 50 6.6 
 
Short of breath when hurrying or 
walking up a slight hill (N, n, %) 
767 211 27.5 757 218 28.8 
 
Walks slower than contemporaries on 
level ground or has to stop for breath 
when walking at own pace (N, n, %) 
767 248 32.3 757 235 31.0 
 
Stops for breath after walking about 
100metres or after a few minutes on 
level ground (N, n, %) 
767 219 28.6 757 201 26.6 
 
Too breathless to leave house, or 
breathless when dressing/undressing 
(N, n, %) 
767 54 7.0 757 53 7.0 
6 months Not troubled by breathlessness 
except on strenuous exercise (N, n, 
%) 
676 42 6.2 655 51 7.8 
 
Short of breath when hurrying or 
walking up a slight hill (N, n, %) 
676 209 30.9 655 189 28.9 
 
Walks slower than contemporaries on 
level ground or has to stop for breath 
when walking at own pace (N, n, %) 
676 197 29.1 655 179 27.3 
 
Stops for breath after walking about 
100metres or after a few minutes on 
level ground (N, n, %) 
676 178 26.3 655 186 28.4 
 
Too breathless to leave house, or 
breathless when dressing/undressing 
(N, n, %) 
676 50 7.4 655 50 7.6 
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Table 14 (continued): mMRC Breathlessness (Intention to treat analysis) 
Time-point mMRC category Theophylline Placebo 
12 months Not troubled by breathlessness 
except on strenuous exercise (N, n, 
%) 
631 38 6.0 615 52 8.5 
 
Short of breath when hurrying or 
walking up a slight hill (N, n, %) 
631 186 29.5 615 158 25.7 
 
Walks slower than contemporaries on 
level ground or has to stop for breath 
when walking at own pace (N, n, %) 
631 174 27.6 615 182 29.6 
 
Stops for breath after walking about 
100 metres or after a few minutes on 
level ground (N, n, %) 
631 178 28.2 615 167 27.2 
 
Too breathless to leave house, or 
breathless when dressing/undressing 
(N, n, %) 
631 55 8.7 615 56 9.1 
  Estimate Lower 
CI 
Upper 
CI 
 p-
value 
 
unadjusted OR 1.27 0.91 1.76  0.157 
 
adjusted ORa 1.20 0.88 1.63  0.244 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the 
mean, gender (male/female), smoking in pack years, FEV1 % predicted, number of COPD exacerbations in 
the previous year, baseline COPD treatment, treatment with long term antibiotics. 
CI confidence interval, OR odds ratio, mMRC modified Medical Research Council 
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Table 15: Patient reported outcomes (Intention to treat analysis) 
Outcome, time point 
 
Theophylline Placebo 
 
Overall mean 
difference 
Lower CI Upper CI p-value 
COPD Assessment Test score         
Baseline Total N 764 756 
 
    
 
Mean 22.7 22.3 
 
    
 
SD 7.5 7.9 
 
    
6 months Total N 675 657 
 
    
 
Mean 21.3 21.1 
 
    
 
SD 8.1 8.3 
 
    
12 months Total N 633 615 
 
    
 
Mean 21.4 21.4 unadjusted 0.13 -0.59 0.85 0.715 
 
SD 8.2 8.6 Adjusteda 0.01 -0.65 0.68 0.975 
Hull Airways Reflux Questionnaire Score         
Baseline Total N 199 203 
 
    
 
Mean 24.9 25.8 
 
    
 
SD 16.0 14.8 
 
    
6 months Total N 191 188 
 
    
 
Mean 21.9 22.9 
 
    
 
SD 15.1 15.7 
 
    
12 months Total N 184 172 
 
    
 
Mean 24.1 24.2 unadjusted -0.85 -3.34 1.64 0.504 
 
SD 15.7 15.9 Adjusteda -1.10 -3.46 1.26 0.359 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics. 
CI confidence interval, COPD Chronic Obstructive Pulmonary Disease, SD standard deviation 
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Serious adverse events 
There were 211 (13.6%) participants who had at least one SAE, with 103/783 (13.2%) in 
participants allocated to low-dose theophylline and 108/770 (14.0%) in participants allocated 
to placebo. In total there were 276 SAEs reported in individuals within the safety population, 
these were balanced between the treatment groups, with 141 in theophylline allocated 
participants and 135 in placebo participants. SAEs were classified using the system organ 
classification (SOC) code95.  Table 16 details for each SOC code and for each treatment 
group the number of participants with at least one SAE of that code, and the total number of 
SAEs of that SOC code. No significant differences were observed in the SAE profile of the 
two treatment groups. The most common SAE SOC code was for ‘cardiac disorders’, 2.8% 
(2.3% theophylline, 3.4% placebo). SAEs with a coding of ‘respiratory, thoracic and 
mediastinal’ occurred in 2.5% of participants (2.3% theophylline, 2.7% placebo). A 
borderline significant higher proportion of participants in the theophylline group (2.7%) 
reported a gastrointestinal SAE compared to 1.3% in placebo (p = 0.051). No pregnancies 
were reported. Line listings are provided in Appendix 6. 
 
Adverse reactions 
Information on adverse reactions was available for 1408 of the participants (709 theophylline, 
699 placebo), with 648 (46%) suffering at least one adverse reaction (341 theophylline, 307 
placebo). There were 1701 adverse reactions in total with 883 in those allocated to low-dose 
theophylline and 818 in those allocated placebo. Table 17 presents these adverse reactions in 
more detail, with total number available for analysis for each adverse reaction, number of 
participants with at least one adverse reaction of that type and the percentage in each group. 
The five most common adverse reactions were nausea (10.9% theophylline, 8.0% placebo, p 
= 0.059), insomnia (9.3% theophylline, 8.9% placebo, p = 0.790), dizziness (8.1% 
theophylline, 9.6% placebo, p = 0.290), gastro-oesophageal reflux (9.4% theophylline, 7.5% 
placebo, p = 0.217) and headache (9.0% theophylline, 7.7% placebo, p = 0.383).  In addition, 
a slightly higher proportion of placebo participants reported tachycardia (3.5%) compared to 
1.9% for those allocated theophylline (p = 0.058). There were no other observed significant 
differences in adverse reactions between treatment groups.  
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Table 16: Serious Adverse Events (Intention to treat analysis) 
 
Theophylline Placebo p-value 
Total number included in analysis 783 770  
All SAEs    
Number of participants with at least one SAE 103 108 
 
% of participants with at least one SAE 13.2 14.0 0.616 
Total number of SAEs 141 135 
 
Infection & infestations    
N of participants with at least one SAE of this type 13 9 
 
% of participants with at least one SAE of this type 1.7 1.2 0.413 
Total number of SAEs of this type 13 9 
 
Neoplasms benign, malignant and unspecified    
N of participants with at least one SAE of this type 17 11 
 
% of participants with at least one SAE of this type 2.2 1.4 0.272 
Total number of SAEs of this type 18 11 
 
Blood and lymphatic system disorders    
N of participants with at least one SAE of this type 0 2 
 
% of participants with at least one SAE of this type 0 0.3 
 
Total number of SAEs of this type 0 2 
 
Immune system disorders    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Endocrine disorders    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Metabolism & nutrition disorders    
N of participants with at least one SAE of this type 1 0 
 
% of participants with at least one SAE of this type 0.1 0 
 
Total number of SAEs of this type 2 0 
 
Nervous system disorders    
N of participants with at least one SAE of this type 11 7 
 
% of participants with at least one SAE of this type 1.4 0.9 0.361 
Total number of SAEs of this type 13 7 
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Table 16 (continued): Serious Adverse Events (Intention to treat analysis) 
 
Theophylline Placebo p-value 
Psychiatric disorders    
N of participants with at least one SAE of this type 1 2 
 
% of participants with at least one SAE of this type 0.1 0.3 
 
Total number of SAEs of this type 1 3 
 
Eye disorders    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Ear & labyrinth disorders     
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Cardiac disorders    
N of participants with at least one SAE of this type 18 26 
 
% of participants with at least one SAE of this type 2.3 3.4 0.201 
Total number of SAEs of this type 21 29 
 
Vascular disorders    
N of participants with at least one SAE of this type 5 6 
 
% of participants with at least one SAE of this type 0.6 0.8 
 
Total number of SAEs of this type 6 6 
 
Respiratory, thoracic and mediastinal disorders    
N of participants with at least one SAE of this type 18 21 
 
% of participants with at least one SAE of this type 2.3 2.7 0.590 
Total number of SAEs of this type 19 22 
 
Hepatobiliary disorders    
N of participants with at least one SAE of this type 2 4 
 
% of participants with at least one SAE of this type 0.3 0.5 
 
Total number of SAEs of this type 2 4 
 
Gastrointestinal disorders    
N of participants with at least one SAE of this type 21 10 
 
% of participants with at least one SAE of this type 2.7 1.3 0.051 
Total number of SAEs of this type 22 12 
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Table 16 (continued): Serious Adverse Events (Intention to treat analysis) 
 
Theophylline Placebo p-value 
Skin & subcutaneous tissue disorders    
N of participants with at least one SAE of this type 1 0 
 
% of participants with at least one SAE of this type 0.1 0 
 
Total number of SAEs of this type 1 0 
 
Musculoskeletal and connective tissue disorders    
N of participants with at least one SAE of this type 5 9 
 
% of participants with at least one SAE of this type 0.6 1.2 
 
Total number of SAEs of this type 5 11 
 
Renal and urinary disorders    
N of participants with at least one SAE of this type 6 4 
 
% of participants with at least one SAE of this type 0.8 0.5 
 
Total number of SAEs of this type 6 4 
 
Pregnancy, puerperium and perinatal conditions    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Reproductive system & breast disorders    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Congenital, familial and genetic disorders    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
General disorders and administration site 
disorders    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
Investigations    
N of participants with at least one SAE of this type 0 2 
 
% of participants with at least one SAE of this type 0 0.3 
 
Total number of SAEs of this type 0 2 
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Table 16 (continued): Serious Adverse Events (Intention to treat analysis) 
 
Theophylline Placebo p-value 
Injury, poisoning & procedural complications    
N of participants with at least one SAE of this type 9 13 
 
% of participants with at least one SAE of this type 1.1 1.7 0.369 
Total number of SAEs of this type 11 13 
 
Surgical and medical procedures    
N of participants with at least one SAE of this type 1 0 
 
% of participants with at least one SAE of this type 0.1 0 
 
Total number of SAEs of this type 1 0 
 
Social circumstances    
N of participants with at least one SAE of this type 0 0 
 
% of participants with at least one SAE of this type 0 0 
 
Total number of SAEs of this type 0 0 
 
SAE serious adverse event 
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Table 17: Adverse reactions (intention to treat analysis)  
Adverse Reaction Theophylline Placebo p-value 
Any adverse reaction    
N included in analysis 709 699 
 
N with at least one adverse reaction 341 307 
 
% with at least one adverse reaction 48.1 43.9 0.116 
Total AR 883 818 
 
Anaphylactic/anaphylactoid reaction    
N included in analysis 692 679 
 
N with at least one adverse reaction of this type 0 1 
 
% with at least one adverse reaction of this type 0.0 0.1 
 
Hypersensitivity    
N included in analysis 692 679 
 
N with at least one adverse reaction of this type 5 5 
 
% with at least one adverse reaction of this type 0.7 0.7 >0.999 
Nausea    
N included in analysis 695 679 
 
N with at least one adverse reaction of this type 76 54 
 
% with at least one adverse reaction of this type 10.9 8.0 0.059 
Reflux    
N included in analysis 693 678 
 
N with at least one adverse reaction of this type 65 51 
 
% with at least one adverse reaction of this type 9.4 7.5 0.217 
Diarrhoea    
N included in analysis 693 680 
 
N with at least one adverse reaction of this type 53 46 
 
% with at least one adverse reaction of this type 7.6 6.8 0.527 
Abdominal pain    
N included in analysis 692 679 
 
N with at least one adverse reaction of this type 42 34 
 
% with at least one adverse reaction of this type 6.1 5.0 0.390 
Gastric irritation    
N included in analysis 691 679 
 
N with at least one adverse reaction of this type 38 28 
 
% with at least one adverse reaction of this type 5.5 4.1 0.235 
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Table 17 (continued): Adverse reactions (intention to treat analysis) 
Adverse Reaction Theophylline Placebo p-value 
Vomiting    
N included in analysis 693 678 
 
N with at least one adverse reaction of this type 28 22 
 
% with at least one adverse reaction of this type 4.0 3.2 0.432 
Palpitations    
N included in analysis 690 678 
 
N with at least one adverse reaction of this type 29 26 
 
% with at least one adverse reaction of this type 4.2 3.8 0.729 
Tachycardia    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 13 24 
 
% with at least one adverse reaction of this type 1.9 3.5 0.058 
Insomnia    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 64 60 
 
% with at least one adverse reaction of this type 9.3 8.9 0.790 
Anxiety    
N included in analysis 691 679 
 
N with at least one adverse reaction of this type 52 42 
 
% with at least one adverse reaction of this type 7.5 6.2 0.327 
Rash    
N included in analysis 691 679 
 
N with at least one adverse reaction of this type 35 27 
 
% with at least one adverse reaction of this type 5.1 4.0 0.332 
Pruritus    
N included in analysis 692 679 
 
N with at least one adverse reaction of this type 51 63 
 
% with at least one adverse reaction of this type 7.4 9.3 0.201 
Tremor    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 34 38 
 
% with at least one adverse reaction of this type 4.9 5.6 0.571 
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Table 17 (continued): Adverse reactions (intention to treat analysis) 
Adverse Reaction Theophylline Placebo p-value 
Headache    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 62 52 
 
% with at least one adverse reaction of this type 9.0 7.7 0.383 
Dizziness    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 56 66 
 
% with at least one adverse reaction of this type 8.1 9.7 0.290 
Agitation    
N included in analysis 691 679 
 
N with at least one adverse reaction of this type 22 18 
 
% with at least one adverse reaction of this type 3.2 2.6 0.558 
Convulsions    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 2 4 
 
% with at least one adverse reaction of this type 0.3 0.6 0.448 
Hyperuricemia    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 9 7 
 
% with at least one adverse reaction of this type 1.3 1.0 0.803 
Diuresis    
N included in analysis 691 678 
 
N with at least one adverse reaction of this type 49 48 
 
% with at least one adverse reaction of this type 7.1 7.1 0.993 
Urinary retention    
N included in analysis 691 677 
 
N with at least one adverse reaction of this type 16 15 
 
% with at least one adverse reaction of this type 2.3 2.2 0.901 
Other    
N included in analysis 691 677 
 
N with at least one adverse reaction of this type 82 86 
 
% with at least one adverse reaction of this type 11.9 12.7 0.638 
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Subgroup analysis (intention to treat) 
Table 37(Appendix 5) details the results of the subgroup analysis for the pre-specified 
subgroups. Given the exploratory nature of the analyses, we present 99% confidence 
intervals. Figure 5 displays this information, alongside the p-value for the interaction in the 
adjusted model. There was no evidence at the 1% level of statistical significance that any 
effect of low-dose theophylline differed between subgroups of age, gender, smoking status, 
BMI, COPD treatments, exacerbation history, COPD severity, baseline ICS dose or use of 
maintenance oral corticosteroids.  
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a Vertical dotted line represents the line of no effect (IRR = 1), vertical solid line indicates the overall 
treatment effect for exacerbation (IRR = 0.992).  
*Upper limit of CI truncated to 1.5, actual value is 4.09 
** Upper limit of CI truncated to 1.5, actual limit is 2.20 
 
Figure 5: Forest plot of estimates from the subgroupsa 
 
Treatment adherence/compliance 
Adherence/compliance was defined as participants having taken ≥ 70% of expected doses of 
study tablets. Within the ITT population (n = 1536), there were 1180 (76.8%) participants 
who fulfilled the definition of adherent/compliant (and make up the per-protocol population). 
Within the theophylline allocated group 181/772 (23.4%) were classed as non-adherent/non-
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compliant, with 3 of these never initiating treatment, 171 were non-persistent (i.e. ceased) 
with study medication and 7 who persisted with study medication, but from returned 
medication it was evident that they were non-adherent/non-compliant (see table 18). In 
addition, 32/591 of low-dose theophylline participants fulfilled the adherent/compliant 
definition despite not persisting with study medication, usually very late in the treatment 
period (see table 19). Within the placebo group, 175/764 (22.9%) were classed as non-
adherent/non-compliant, with 6 never initiating medication, 159 were non-persistent with 
study medication and 10 who persisted with  study medication but medication returns 
demonstrated poor implementation (see table 18). A further 34 were non-persistent with 
medication but fulfilled the definition of adherent/compliant because they ceased study 
medication late into the treatment period (see table 19). In summary, the per-protocol 
population consists of 1180 participants, 591 theophylline and 589 placebo, there were 1146 
person years of follow up data (see table 18). A comparison of the proportion non-
adherent/compliant (23.4% theophylline vs 22.9% placebo) was not significant (p = 0.802). 
In total 203 of 772 participants in the theophylline arm were non-persistent with medication 
compared to 193 of 764 in the placebo arm (unadjusted IRR= 1.05 (0.84-1.32)). 
 
Table 18: Compliance information 
 
Theophylline Placebo 
Total N 772 764 
Not adherent/ compliant (<70%)a 181 175 
Did not start medication (non-initiation) 3 6 
Actively ceased medication (non-persistence) 171 159 
Did not cease (persistent), but adherence/compliance < 70% 7 10 
Compliant (>70%) 591 589 
a unadjusted incident rate ratio 1.03, 95% confidence interval 0.81-1.31, p=0.802 
 
Reasons for stopping medication 
Table 19 presents the reasons for stopping medication amongst the ITT population by System 
Organ Class (SOC) code. The most common reason for stopping medication was for 
gastrointestinal disorders (46 theophylline, 32 placebo), with surgical and medical procedures 
second (19 theophylline, 21 placebo), although this included some participants who had 
discontinued ICS containing inhalers, the majority of this group comprised participants 
advised to discontinue the study drug by a clinician after presenting with a wide range of 
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illnesses. In total 46 participants discontinued study medication because they felt no benefit 
(25 theophylline, 21 placebo) and in 64 cases no reason was given (28 theophylline, 36 
placebo), with a further 29 ceasing for social circumstances. There were no obvious 
differences between the two treatment groups in the reasons why study medication was 
discontinued, but no formal statistical testing was undertaken. 
 
Table 19: Reasons for stopping medication (of those that started) 
 
Theophylline Placebo 
Total N 772 764 
Did not start medication (non-initiation) 3 6 
Actively ceased medication (non-persistent) 171 159 
Adherent/compliant but ceased medication (non-persistent) 32 34 
Total ceasing medication (that started) (non-persistent)a 203 193 
Reason for stopping medication   
Infections and infestations 2 1 
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 7 2 
Psychiatric disorders 2 4 
Nervous system disorders 19 15 
Ear and labyrinth disorders 3 3 
Cardiac disorders 7 6 
Vascular disorders 1 1 
Respiratory, thoracic and mediastinal disorders 10 19 
Gastrointestinal disorders 46 32 
Hepatobiliary disorders 0 1 
Skin and subcutaneous tissue disorders 9 7 
Musculoskeletal and connective tissue disorders 4 8 
Renal and urinary disorders 5 1 
Injury, poisoning and procedural complications 1 1 
Surgical and medical procedures 19 21 
Social circumstances 15 14 
Participant felt no benefit 25 21 
No reason given 28 36 
a unadjusted incident rate ratio 1.05, 95% confidence interval 0.84-1.32, p=0.676 
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Per protocol analysis 
The per-protocol population comprised the 1180 participants of the ITT population that met 
the study definition of adherent with their study medication. The per-protocol analysis 
comprised 591 participants allocated to low-dose theophylline and 589 allocated to placebo 
(figure 6). 
 
Primary outcome: total number of exacerbations of COPD requiring a change in 
management 
In the per-protocol population, 591 theophylline allocated participants had mean (SD) 
exacerbations of 2.20 (1.96) compared with 2.14 (1.92) for the 589 placebo participants. In 
total there were 1298 exacerbations in the theophylline group and 1258 in placebo. The 
adjusted incidence rate ratio (IRR) and 95% CI for COPD exacerbation was 1.00 (0.91, 1.10),  
indicating no difference in the exacerbation rate during the 12 month follow-up period for 
those on low-dose theophylline compared with placebo who were adherent/compliant with 
study medication (see table 20).   
 
Secondary outcome:  total number of exacerbations of COPD resulting in hospital 
admission 
In the PP population, 76/591 (13%) participants allocated to theophylline had at least one 
COPD exacerbation enquiring hospital admission and there were 92 admissions in the group 
overall. In those allocated to placebo 88/589 (15%) had at least one admission, with 126 
admission overall. The mean (SD) number of COPD exacerbations requiring hospital 
admission was 0.16 (0.45) for the 591 theophylline compliant participants and 0.21 (0.61) for 
the 589 placebo participants. In the adjusted model, the IRR for COPD exacerbations 
requiring hospital admission was 0.70 (0.50, 0.97) suggesting a significant reduction in the 
number of exacerbations requiring hospital admission for the low-dose theophylline 
compliant group compared to placebo (see table 20).  
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Figure 6: Consort (per-protocol analysis)  
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Secondary outcome: time to first exacerbation 
Time to first exacerbation information was missing for 19 of the 1180 per-protocol 
participants therefore this analysis was based on 1161 of the PP population. In those allocated 
to theophylline, 468/578 (81.0%) had at least one exacerbation, with median time to first 
exacerbation of 221 days (7.3 months) after randomisation. For placebo, there were 459/583 
(78.7%) participants with at least one exacerbation, with median time to first exacerbation of 
232 days (7.7 months). In a Cox regression analysis, the adjusted HR for time to first 
exacerbation was 1.02 (0.90, 1.16), suggesting no difference between the treatment groups in 
terms of time to first exacerbation (from point of randomisation) during the 12 month follow-
up period (see table 20). 
 
Secondary outcome:  total number of emergency hospital admissions (non COPD) 
Hospital admission data were available for 1176 /1180 of the per-protocol population. 
Overall 111 participants had at least one admission (45 theophylline, 66 placebo), with 66 
and 85 admissions respectively. The adjusted IRR for admission was 0.82 (0.54, 1.24), 
suggesting no significant difference in the rate of non-COPD emergency hospital admissions 
for participants compliant with low-dose theophylline compared to placebo (see table 21). 
 
Secondary outcome:  mortality (all cause and respiratory related) 
There were 22 deaths (from all causes) during the 12 month follow-up period in the per-
protocol population, 13 (2.2%) in participants taking theophylline and 9 (1.5%) in 
participants taking placebo. These deaths were respiratory related for 5 cases in each of the 
theophylline and placebo groups. The unadjusted hazard ratio (95% CI) for deaths from all 
causes was 1.45 (0.62, 3.38), and for respiratory related causes 1.00 (0.29, 3.46) for 
theophylline relative to placebo (see table 21). Therefore there was no evidence of a 
significant difference between treatment groups for mortality outcomes in the per-protocol 
population. No adjustments were made due to small event counts. 
 
Secondary outcome:  total number of episodes of pneumonia 
There were 14 episodes of pneumonia with 1.5% (9/591) for low-dose theophylline 
adherent/compliant participants and 0.9% (5/589) for placebo. The unadjusted IRR was 1.81 
(0.60, 5.44) and no adjustments were made due to small event counts (see table 21).  
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Table 20: Exacerbation outcomes (per-protocol analysis) 
 Theophylline Placebo  Estimate Lower CI Upper CI p-value 
Primary outcome: Exacerbations        
Total number included in analysis 591 589 
     
Person years follow-up 572.8 573.8      
Number with at least one exacerbation 481 465 
     
Total number of exacerbations 1298 1258 
     
Mean number of exacerbations 2.20 2.14 unadjusted IRR 1.02 0.92 1.13 0.664 
SD (number of exacerbations) 1.96 1.92 adjusted IRRa 1.00 0.91 1.10 0.934 
Exacerbations requiring hospital admission        
Total number included in analysis 591 589 
     
Number with at least one exacerbation 76 88 
     
Total number of exacerbations 92 126 
     
Mean number of exacerbations 0.16 0.21 unadjusted IRR 0.74 0.53 1.03 0.072 
SD (number of exacerbations) 0.45 0.61 adjusted IRRa 0.70 0.50 0.97 0.031 
Time to 1st exacerbation (from randomisation)        
Total number included in analysisb 578 583 
     
Number with at least one exacerbation 468 459 
     
% with at least one exacerbation 81.0 78.7 
     
Median time to first exacerbation (days) 221 232 unadjusted HR 1.04 0.91 1.18 0.576 
25th percentile (time to first exacerbation (days)) 132 126 adjusted HRa 1.02 0.90 1.16 0.733 
75th percentile (time to first exacerbation (days)) 341 339 
     
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, FEV1 % predicted, number of 
COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics. 
b Number included is reduced due to date of onset of first exacerbation being missing for 19 participants. CI confidence interval, IRR incident rate ratio, HR hazard ratio, SD standard deviation 
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Table 21: Secondary clinical outcomes (per-protocol analysis)  
 
Theophylline Placebo 
 
Estimate Lower CI Upper CI p-value 
Emergency hospital admissions (non-COPD)        
Total number included in analysis 587 589 
     
N with at least one emergency hospital admission 45 66 
     
Total admissions 66 85 
     
Mean admission rate 0.11 0.14 unadjusted IRR 0.77 0.51 1.17 0.220 
SD admission rate 0.49 0.45 adjusted IRRa 0.82 0.54 1.24 0.351 
All-cause mortality        
Total number included in analysis 591 589 
     
N deceased within 12 months 13 9 unadjusted HR 1.45 0.62 3.38 0.394 
% deceased within 12 months 2.2 1.5 
     
Respiratory related mortality        
Total number included in analysis 591 589 
     
N deceased within 12 months 5 5 unadjusted HR 1.00 0.29 3.46 0.998 
% deceased within 12 months 0.9 0.9 
     
Pneumonia        
Total number included in analysis 591 589 
     
Number with pneumonia  9 5 unadjusted OR 1.81 0.60 5.44 0.291 
% with pneumonia  1.5 0.9 
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Table 21 (continued): Secondary clinical outcomes (per-protocol analysis)  
 
Theophylline Placebo 
 
Estimate Lower CI Upper CI p-value 
Total daily dose ICS        
Total number included in analysis 589 588 
     
N changed medication from baseline 78 93 
     
Mean ICS daily dose at end of follow up 1617 1605 unadjusted mean 
difference 
12.2 -67.6 92.1 0.764 
SD (ICS daily dose at end of follow up) 693 704 adjusted mean 
differencea 
12.5 -65.9 90.9 0.754 
Change in daily ICS dose from baseline        
Total number included in analysis 589 588 
     
Mean change in daily ICS dose from baseline -62 -60 unadjusted mean 
difference 
-1.60 -45.4 42.3 0.943 
SD (change in daily ICS dose from baseline) 347 417 adjusted mean 
differencea 
-0.58 -44.3 43.1 0.979 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics. 
HR hazard ratio, ICS inhaled corticosteroid, IRR incident rate ratio, OR odds ratio, SD standard deviation 
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Secondary outcome:  total dose of ICS 
The total daily dose of ICS at baseline was available for 1176 of the 1180 members of the 
per-protocol population. During the 12 month follow-up 171 participants changed their 
medication, 78 (13.2%) theophylline participants and 93 (15.8%) placebo participants (p = 
0.210). Mean (SD) total daily beclomethasone equivalent dose at the end of follow-up was 
1617µg (693) in those allocated to theophylline and 1605µg (704) in those allocated to 
placebo, resulting in an adjusted daily beclomethasone equivalent difference of 12.5µg (-
65.9, 90.9) higher for theophylline compared to placebo (see table 21). This higher dose at 
end of follow-up in those taking theophylline was not significantly different from placebo. 
Both groups showed a slight reduction in total daily dose from baseline to end of follow-up 
but a comparison of the adjusted mean dose change between treatment groups was not 
significant (p = 0.979).  
 
Secondary outcome:  lung function (% predicted FEV1 and FVC) 
In the per-protocol analysis of lung function the profile was found to be similar between the 
treatment groups with mean (SD) percent predicted FEV1 at the end of the 12 month follow-
up of 51.3% (20.3) for the theophylline compliant participants (n=455) and 52.6% (21.8) for 
placebo (n=432). The overall difference (across the 12 month period) was -1.33% (-3.47, 
0.80), between the groups, with theophylline adherence/compliance showing a slight (non-
significant) reduction compared to placebo (see table 22). A similar pattern was observed for 
percent predicted FVC with an overall difference of -0.65% (-2.96, 1.67). This was a larger 
reduction than that observed in the ITT analysis, but remained non-significant. 
 
Secondary outcome:  mMRC breathlessness scale 
Table 23 details the responses to the mMRC breathlessness scale at baseline, 6m and 12m for 
each treatment group in the per-protocol population. In the unadjusted model the OR for 
higher mMRC in theophylline participants compared to placebo is 1.54 (1.05, 2.26), and 
adjusted 1.39 (0.97, 1.98). 
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Table 22: Lung function (per-protocol analysis) 
Outcome Time point 
 
Theophylline Placebo 
 
Overall mean 
difference 
Lower CI Upper CI p-value 
% Predicted FEV1 Baseline Total N 588 583 
 
    
  
Mean 50.7 52.8 
 
    
  
SD 20.5 20.0 
 
    
 
6 months Total N 471 471 
 
    
  
Mean 52.0 53.7 
 
    
  
SD 20.8 20.8 
 
    
 
12 months Total N 455 432 
 
    
  
Mean 51.3 52.6 unadjusted -1.41 -3.65 0.82 0.215 
  
SD 20.3 21.8 Adjusteda -1.33 -3.47 0.80 0.221 
% Predicted FVC Baseline Total N 586 582 
 
    
  
Mean 84.2 86.6 
 
    
  
SD 22.9 23.5 
 
    
 
6 months Total N 467 467 
 
    
  
Mean 84.3 84.6 
 
    
  
SD 23.0 24.3 
 
    
 
12 months Total N 449 431 
 
    
  
Mean 83.3 82.6 unadjusted -0.84 -3.25 1.56 0.492 
  
SD 23.2 25.3 Adjusteda -0.65 -2.96 1.67 0.584 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics.SD standard 
deviation, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, CI confidence interval
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Table 23: mMRC Breathlessness (per-protocol analysis) 
Time-point mMRC category 75 Theophylline Placebo 
Baseline Not troubled by breathlessness except 
on strenuous exercise (N, n, %) 
586 26 4.4 584 44 7.5 
 
Short of breath when hurrying or 
walking up a slight hill (N, n, %) 
586 160 27.3 584 176 30.1 
 
Walks slower than contemporaries on 
level ground or has to stop for breath 
when walking at own pace  
(N, n, %) 
586 198 33.8 584 181 31.0 
 
Stops for breath after walking about 
100metres or after a few minutes on 
level ground (N, n, %) 
586 157 26.8 584 149 25.5 
 
Too breathless to leave house, or 
breathless when dressing/undressing 
(N, n, %) 
586 45 7.7 584 34 5.8 
6 months Not troubled by breathlessness except 
on strenuous exercise (N, n, %) 
560 34 6.1 552 46 8.3 
 
Short of breath when hurrying or 
walking up a slight hill (N, n, %) 
560 182 32.5 552 160 29.0 
 
Walks slower than contemporaries on 
level ground or has to stop for breath 
when walking at own pace 
 (N, n, %) 
560 161 28.8 552 155 28.1 
 
Stops for breath after walking about 
100metres or after a few minutes on 
level ground (N, n, %) 
560 142 25.4 552 153 27.7 
 
Too breathless to leave house, or 
breathless when dressing/undressing 
(N, n, %) 
560 41 7.3 552 38 6.9 
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Table 23 (continued): mMRC Breathlessness (per-protocol analysis) 
Time-point mMRC category Theophylline Placebo 
12 months Not troubled by breathlessness except 
on strenuous exercise  
(N, n, %) 
535 32 6.0 527 47 8.9 
 
Short of breath when hurrying or 
walking up a slight hill (N, n, %) 
535 167 31.2 527 149 28.3 
 
Walks slower than contemporaries on 
level ground or has to stop for breath 
when walking at own pace  
(N, n, %) 
535 146 27.3 527 153 29.0 
 
Stops for breath after walking about 
100metres or after a few minutes on 
level ground (N, n, %) 
535 147 27.5 527 135 25.6 
  Too breathless to leave house, or 
breathless when dressing/undressing 
(N, n, %) 
535 43 8.0 527 43 8.2 
  
Estimate 
Lower 
CI 
Upper 
CI 
 
p-
value 
 
unadjusted OR 1.54 1.05 2.26 
 
0.028 
  adjusted ORa 1.39 0.97 1.98 
 
0.074 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the 
mean, gender (male/female), smoking in pack years, FEV1 % predicted, number of COPD exacerbations in 
the previous year, baseline COPD treatment, treatment with long term antibiotics. 
CI confidence interval, OR odds ratio 
 
 
Secondary outcome:  COPD assessment test (CAT) 
CAT scores were very similar between treatment groups at baseline (see table 24) and remained 
similar through to 12 months, with a mean (SD) score of 21.0 (8.2) for theophylline 
adherent/compliant participants (n = 534) and 20.9 (8.7) for placebo (n = 527) in the per-protocol 
population. A comparison of the profile of the CAT score across the three time points (0, 6 and 12 
months), showed an adjusted difference of 0.29 (-0.45, 1.04), suggesting no significant difference 
between the groups of the per-protocol population on the impact of COPD on the participants’ 
lives. 
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Secondary outcome:  HARQ 
At 12 months, the mean (SD) HARQ score was 23.0 (15.6) in 153 theophylline 
adherent/compliant participants and 24.4 (15.8) in 141 placebo adherent/compliant participants. A 
comparison of the profile of the HARQ scores across the three time points (0, 6 and 12 months), 
showed an adjusted difference of -1.62 (-4.25, 1.01), suggesting no significant difference between 
the per-protocol treatment groups in reflux associated respiratory symptoms measured by the 
HARQ (see table 24). 
 
Sensitivity analysis 
We undertook a sensitivity analysis for the primary outcome and a number of secondary 
outcomes that excluded the 33 participants who died during the 12 month follow up period. This 
left 1503 participants of the ITT population, 753 theophylline and 750 placebo. Supplementary 
tables 38 and 39 (Appendix 5) give the detail for these analyses. 
 
Primary outcome 
After excluding participants who died the adjusted IRR for COPD exacerbations was 0.99 (0.91, 
1.07), (Appendix 5, table 38) indicating that restricting the result to only those who were alive for 
the full 12 month follow-up did not change the result of the original ITT analysis (0.99 (0.91, 
1.08)). 
 
Secondary outcomes – hospital admissions 
Excluding the 33 deaths from the analysis for COPD exacerbations requiring hospital admission, 
the adjusted IRR was 0.73 (0.55, 0.97) in the remaining 1503 members of the ITT population, 
which is very similar to the treatment estimate observed for all 1536 members of the ITT 
population (0.72 (0.55, 0.94)).  For admission to hospital for non-COPD reasons, data were 
available for 1485 people after excluding the deaths. The adjusted IRR for admission for 
theophylline relative to placebo was 1.03 (0.73, 1.43) compared to 0.99 (0.71, 1.38) in the full 
ITT population. 
 
Secondary outcomes - other 
Excluding the 33 deaths made very little difference to the estimates of treatment effect for lung 
function (FEV1 or FVC) or the patient reported outcomes of CAT and HARQ (Appendix 5, table 
39). For FEV1 the adjusted difference was -0.58% (-2.46, 1.29) compared with -0.56% (-2.42, 
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1.30) and for FVC -0.37% (-2.43, 1.69) compared with -0.28% (-2.33, 1.76) for the ITT 
population. For the CAT score, the treatment difference was 0.02 (-0.65, 0.69) compared with 
0.01 (-0.65, 0.69) in the original ITT population. The HARQ analysis gave -0.88 (-3.27, 1.51) 
compared with -1.10 (-3.46, 1.26) of the original ITT population. In summary excluding the 33 
deaths made little or no difference to the estimates of treatment effect within the ITT population. 
 
Summary 
In summary, there was no evidence that overall low-dose theophylline significantly reduced the 
number of COPD exacerbations requiring treatment compared to placebo. There was some 
evidence that low-dose theophylline reduced exacerbations that required hospital admission with 
most benefit being evident in a small 1% (13/1556) sub-group of patients frequently hospitalised 
with COPD. Total number of emergency hospital admissions (non COPD) did not significantly 
differ between groups, and neither did total episodes of pneumonia or mortality. Lung function 
was similar across the 12 month follow-up in the two groups. Impact of disease on patients 
measured by CAT, mMRC breathlessness scale and HARQ showed no significant differences. 
The safety profile of low-dose theophylline was similar to placebo. There was no evidence that 
the treatment effect differed in any of the pre-specified sub groups. 
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Table 24: Patient reported outcomes (per-protocol analysis) 
Time point 
 
Theophylline Placebo 
 
Overall mean 
difference 
Lower CI Upper CI p-value 
COPD Assessment Test Score         
Baseline Total N 584 583 
 
    
 
Mean 22.7 21.8 
 
    
 
SD 7.5 7.9 
 
    
6 months Total N 560 555 
 
    
 
Mean 21.0 20.5 
 
    
 
SD 8.2 8.2 
 
    
12 months Total N 534 527 
 
    
 
Mean 21.0 20.9 unadjusted 0.52 -0.29 1.33 0.212 
 
SD 8.2 8.7 Adjusteda 0.29 -0.45 1.04 0.444 
Hull Airways Reflux Questionnaire Score         
Baseline Total N 153 152 
 
    
 
Mean 25.2 26.8 
 
    
 
SD 15.9 14.7 
 
    
6 months Total N 160 151 
 
    
 
Mean 21.2 22.5 
 
    
 
SD 14.8 15.6 
 
    
12 months Total N 153 141 
 
    
 
Mean 22.9 24.4 unadjusted -1.39 -4.17 1.40 0.329 
 
SD 15.6 15.8 Adjusteda -1.62 -4.25 1.01 0.227 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, FEV1 % predicted, number of 
COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics.  
CI confidence interval, COPD Chronic Obstructive Pulmonary Disease, SD standard deviation 
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CHAPTER 5 – COST EFFECTIVENESS 
 
This chapter reports the health economics results from the trial.  The objectives of the health 
economics section was to determine the cost-effectiveness of adding low dose theophylline to 
ICS therapy over a 12-month period.  Mean resource use per participant is presented, along 
with levels of missing data and mean unadjusted and adjusted costs.    
 
Baseline resource use and costs 
Baseline resource use and costs are presented in table 25. 
 
Table 25: Baseline resource use and costs (per participant) 
 Theophylline  
Mean (SD)    
Placebo  
Mean (SD)    
RESOURCE USE 
Exacerbations 
Number of exacerbations requiring treatment in 
previous 12 months 
3.63 (2.22)  
n=772 
3.52 (2.08)  
n=764 
Exacerbations resulting in hospitalisation in previous 
12 months 
0.404 (0.840)  
n=768 
0.358 (0.918)  
n=758 
Non-exacerbation resource use  
(Mean number of uses per participant in 6 months prior to randomisation) 
COPD maintenance treatment at baseline n=769 n=758 
Inhaled short acting beta 2 agonist 0.967 (0.177) 0.972 (0.164) 
Inhaled combined ICS LABA 0.966 (0.181) 0.960 (0.195) 
Inhaled short acting muscarinic antagonist 0.068 (0.251) 0.065 (0.246) 
Inhaled ICS 0.043 (0.203) 0.040 (0.195) 
Inhaled non-combination LABA 0.018 (0.134) 0.029 (0.168) 
Inhaled LAMA 0.805 (0.397) 0.817 (0.387) 
Nebulised ipratropium 0.051 (0.291) 0.041 (0.246) 
Nebulised short acting beta 2 agonist 0.204 (0.536) 0.185 (0.491) 
Oral mucolytics 0.247 (0.432) 0.248 (0.432) 
Oral leukotriene antagonists 0.042 (0.200) 0.041 (0.198) 
Long-term antibiotics 0.066 (0.249) 0.059 (0.236) 
Regular medication 
Counta  4.65 (3.64) n=772 4.41 (3.54) n=764 
102 
Table 25 (continued): Baseline resource use and costs (per participant) 
 Theophylline  
Mean (SD)    
Placebo  
Mean (SD)    
COSTSb 
Baseline COPD maintenance treatment costsc n=769 n=758 
Inhaled short acting beta 2 agonist £17.5 (£3.2) £17.60 (£3.0) 
Inhaled combined ICS LABA £325.00 (£1,897) £247.00 (£486) 
Inhaled short acting muscarinic antagonist £2.77 (£10.3) £2.64 (£10.1) 
Inhaled ICS £7.28 (£50.8) £8.27 (£71.2) 
Inhaled non-combination LABA £3.89 (£28.6) £6.20 (£35.9) 
Inhaled LAMA £164.00 (£80.9) £167.00 (£79.0) 
Nebulised ipratropium £4.78 (£26.3) £4.19 (£24.0) 
Nebulised short acting beta 2 agonist £8.55 (£21.3) £8.14 (£20.4) 
Oral mucolytics £34.70 (£60.7) £34.90 (£60.8) 
Oral leukotriene antagonists £0.44 (£2.10) £0.43 (£2.08) 
Long-term antibiotics £21.00 (£88.0) £25.70 (£275) 
Total baseline COPD maintenance treatment costs £590.00 (£1,904) £522.00 (£571) 
a Count (medication); mean number of non-COPD medications taken by each participant. 
b Baseline resource use was collected for current use of COPD maintenance treatment and regular 
medication.  For calculating baseline resource use and costs we have assumed this usage to be for the 
six months prior to baseline. 
c Baseline costs are calculated for the previous 6 months based on the medications used at baseline. 
COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroid, LABA long-acting beta-
agonist, LAMA long-acting muscarinic antagonists, n number of participants, SD standard deviation 
 
There is no significant difference between arms for any of these baseline resources. 
 
Resource use 
Table 26 reports the mean resource use per participant for complete cases, during the 12 
month follow-up period.   
 
As discussed in the previous chapter the treatment of exacerbations at hospital was 
significantly different between groups; there were more exacerbations treated in hospital in 
the placebo group than the theophylline group (p=0.02).  
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Table 26: 12 month resource use for complete cases (per participant) 
 Theophylline  
Mean (SD) 
Placebo 
Mean (SD) 
 n=743 n=727 
Intervention 
Theophylline 1 0 
Exacerbation resource usea 
(Mean number of uses per participant in 12 month follow-up period) 
Increased use of short acting beta 2 agonist 1.01 (1.51) 1.04 (1.60) 
Increased/started nebulised bronchodilator 0.288 (0.836) 0.318 (0.910) 
Oral corticosteroid 1.72 (1.87) 1.68 (1.79) 
Antibiotics 2.01 (1.83) 2.01 (1.84) 
Oxygen 0.129 (0.511) 0.142 (0.541) 
Other 0.075 (0.320) 0.076 (0.354) 
Treated at home 2.08 (1.92) 2.10 (1.90) 
Care by services to prevent hospitalisation 0.086 (0.379) 0.100 (0.416) 
Admitted to hospital 0.179 (0.497) 0.253 (0.676) 
Non-exacerbation resource use 
COPD maintenance treatment 
(Mean number of uses per participant in 12 month follow-up period) 
Inhaled short acting beta 2 agonist 0.926 (0.262) 0.934 (0.248) 
Inhaled combined ICS LABA 0.918 (0.275) 0.922 (0.269) 
Inhaled short acting muscarinic antagonists 0.069 (0.253) 0.062 (0.241) 
Inhaled ICS 0.039 (0.194) 0.044 (0.205) 
Inhaled non-combination LABA 0.032 (0.177) 0.047 (0.211) 
Inhaled LAMA 0.817 (0.387) 0.824 (0.381) 
Nebulised ipratropium 0.046 (0.209) 0.037 (0.189) 
Nebulised short acting beta 2 agonist 0.157 (0.364) 0.176 (0.381) 
Oral mucolytics 0.285 (0.452) 0.294 (0.456) 
Oral leukotriene antagonists 0.046 (0.209) 0.044 (0.205) 
Long-term antibiotics 0.092 (0.289) 0.085 (0.279) 
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Table 26 (continued): 12 month resource use for complete cases (per participant) 
 Theophylline  
Mean (SD) 
Placebo 
Mean (SD) 
Non-exacerbation health services use 
Inpatient services 
General medical ward stays (number of stays) 0.059 (0.263) 0.084 (0.406) 
Long stay ward stays  (number of stays) 0.004 (0.063) 0 (0) 
Other inpatient services (number of contacts) 0.027 (0.192) 0.022 (0.173) 
Out-patient 
Hospital day-case admissions (number of 
admissions) 
0.187 (0.900) 0.169 (0.530) 
Hospital out-patient appointments (number of 
appointments) 
1.68 (2.63) 1.58 (2.66) 
Accident & Emergency (no overnight admission; 
number of visits) 
0.137 (0.490) 0.128 (0.513) 
Other inpatient services (number of admissions)  0.514 (2.87) 0.476 (2.23) 
Primary care services 
Emergency GP visit  1.03 (1.97) 1.01 (2.10) 
Routine GP visit 3.18 (4.33) 2.84 (3.83) 
Community district nurse (number of appointments) 0.801 (9.64) 0.631 (3.50) 
Hospital at home team (number of contacts) 0.101 (1.01) 0.158 (2.92) 
Other primary care services (number of contacts) 2.16 (5.37) 1.77 (3.68) 
Non-COPD emergency hospital admissions 
Emergency hospital admissions 0.150 (0.555) 0.158 (0.468) 
Regular medication count 
Regular medication count b 4.34 (3.55) 4.32 (3.51) 
 a mean number of times each treatment was used for exacerbations per participant 
b Count (medication); mean number of non-COPD medications taken by each participant 
COPD chronic obstructive pulmonary disease, GP general practitioner, ICS inhaled corticosteroid, 
LABA long-acting beta-agonist, LAMA long-acting muscarinic antagonists, n number of participants, 
SD standard deviation 
 
Missing data  
The disaggregated level of missing data affecting resource use is reported below, these are 
broken down into exacerbations, maintenance COPD treatment and non-COPD emergency 
hospital admissions.   
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Exacerbations (length of exacerbation, treatment costs and location of treatment), 3,430 
exacerbations were recorded in total 
 329 participants had missing length of exacerbation data (5.9% missing data points).  
 210 recorded exacerbations were missing location of treatment marker (3.4% missing 
data points).  
 46 participants with exacerbations treated in hospital had missing lengths of stay. 
 171 recorded exacerbations were missing a treatment cost (1% missing data points).  
 
Maintenance COPD treatment  
 82 participants had missing total COPD maintenance costs (5.6% missing data 
points), this missing data were replaced with a treatment specific mean. 
 
Non-COPD emergency hospital admissions, 235 non-COPD emergency hospital admissions 
were recorded 
 9 participants had missing length of stays for emergency hospital admissions (2.8% 
missing data points).   
 
All missing resource data were replaced using pragmatic, naïve methods suitable for use 
when missing data is less than 10%.   
 
Table 27 presents the missing economic data for resource use and EQ-5D-3L completion.  
 
Resource use was available for 743 participants in the theophylline arm and 727 in the 
placebo arm; 29 (3.8%) participants did not have resource use data captured during the 
follow-up period in the theophylline arm, 37 (4.8%) participants did not have 12 months 
resource use in the placebo arm. Overall, there were 66 (4.3%) participants missing resource 
use data for the whole 12 month follow-up period. 
 
The number of participants with missing EQ-5D-3L data was 137 (17.7%) in the theophylline 
arm and 156 (20.4%) in the placebo arm.  Overall there were 293 (19.1%) missing EQ-5D-3L 
questionnaires. 
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Table 27: Missing resource use and EQ-5D-3L data 
 Theophylline 
n (%) 
Placebo 
n (%) 
Total 
Cost data 
Intention to treat population 772 (100%) 764 (100%) 1,536 (100%) 
No resource use captured during follow-
up 
29 (3.8%) 37 (4.8%) 66 (4.3%) 
Complete cases 743 (96.2%) 727 (95.2%) 1,470 (95.7%) 
EQ-5D-3L data  
Intention to treat population 772 (100%) 764 (100%) 1,536 (100%) 
Missing EQ-5D-3L at baseline/6 months 
or 12 months 
137 (17.7%) 156 (20.4%) 293 (19.1%) 
Complete cases 635 (82.3%) 608 (79.6%) 1,243 (80.9%) 
EQ-5D-3L EuroQoL 5 dimension, 3 level 
 
Costs 
Table 28 reports complete case costs (unadjusted).  Differences between arms are calculated 
using a GLM model with identity link, gamma family and a cluster for centre number. 
Regular medication was not included in these costs due to there being no significant 
difference between arms in regular medication count.  
 
There is a significant difference of £452 (95% CI £133 to £771) in the mean total costs 
between arms; placebo being more costly than theophylline.  This difference is driven by the 
difference in exacerbation mean costs between arms; £447 (95% CI £186 to £709) higher in 
the placebo arm.  The difference in exacerbation costs is driven by the location of treatment 
of exacerbation.  The mean difference in location of exacerbation treatment costs is £422 
(95% CI £171 to £673) higher in the placebo arm than the theophylline arm.  As presented in 
chapter 4, this is driven by a higher number of exacerbations treated in hospital in the placebo 
arm than in the theophylline arm.  This is reflected in the health economics analysis when 
location of treatment costs are broken down further into: ‘treatment at home’, ‘care by 
services to prevent hospitalisation’ and ‘admitted to hospital’.  In ‘treatment at home’ and 
‘care by services to prevent hospitalisation’ resource use costs there are no significant 
differences between arms, however, ‘admitted to hospital’ is £416 (95% CI £177 to £655) 
higher in the placebo arm compared to the theophylline arm, a statistically significant result.  
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Table 28: Complete case costs (unadjusted) 
 Theophylline 
mean (SD) 
Placebo  
mean (SD) 
Difference 95% CI 
Intervention costs  £22 (£0.24) £0 £22 £22 to £22 
Exacerbation costs 
Total exacerbation costs £585 (£1,682) £1,033 (£3,383) -£447 -£709 to -£186 
   Total location costs £535 (£1,594)  £958 (£3,185) -£422 -£673 to -£171 
   Location - home £67 (£61) £68 (£60) -£1 -£6 to £4 
   Location - services £33 (£145) £38 (£159) -£5 -£23 to £12 
   Location - hospital £436 (£1,538) £852 (£3,142) -£416 -£655 to -£177 
   Treatment £50 (£167) £75 (£296) -£25 -£41 to -£8 
Non-exacerbation costs  
Maintenance COPD treatment £974 (£379) £978 (£416) -£4 -£45 to £38 
Health services resource use 
(not exacerbation related) 
£819 (£1,224) £862 (£1,812) -£43 -£175 to £89 
Non-COPD related emergency 
hospital admissions 
£282 (£1,529) £262 (£1,136) £20 -£102 to £143 
Total costs  £2,684 (£2,882) £3,136 (£4,851) -£452 -£771 to -£133 
Non-intervention, non-
exacerbation costs 
£2,075 (£2,079) £2,101 (£2,528) -£26 -£234 to £181 
CI confidence interval, COPD Chronic Obstructive Pulmonary Disease, SD standard deviation  
 
At a per exacerbation level this difference can be explored further.  The mean cost per 
exacerbation treated in hospital is £3,613 (SE £342) in the placebo arm and £2,671 (SE £220) 
in the theophylline arm, a significant difference of £941 (SE £386) (95% CI £140 to £1,743).  
The ten most costly observations (over £10,000) were all in the placebo arm, and were the 
result of hospital stays of greater than 40 days.  Due to the lack of treatment effect we believe 
this difference to be a chance finding and not a real result of the trial. The distribution for 
length of hospital stay is similar for both arms apart from a small excess of participants in the 
placebo arm with longer stays.    It is important to note that the proxy for hospital length of 
stay is length of exacerbation and that this is likely to over-estimate length of stay in hospital. 
In total, 319 exacerbations were treated in hospital, 185 in the placebo arm and 134 in the 
theophylline arm. 
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The treatment of exacerbations had a significant difference between arms of £25 mean cost 
per participant, less expensive in the theophylline arm.  At a per exacerbation level this is 
driven by treatment with oxygen. The difference in oxygen use per exacerbation using 
oxygen is £141 (SE £52) (95% CI £40 to £243); less expensive in the theophylline arm than 
placebo arm.  The difference in oxygen treatment is driven by a small number of participants 
with duration of oxygen treatment greater than 51 days.  Seven participants have oxygen 
treatment duration greater than 51 days, resulting in costs per exacerbation of greater than 
£1,000 and six of these participants are in the placebo arm.   
 
The wide standard deviations for hospitalised exacerbations, treatment of exacerbations, non-
COPD emergency hospital admissions and other health services use indicate a wide range of 
individual participant’s costs within these resource groups. 
 
No other resource use costs are significantly different between arms, which is reflected in no 
difference between arms for the non-intervention, non-exacerbation costs presented in table 
28. 
 
Economic outcome  
Complete case EQ-5D-3L data and QALYs are reported in table 29.  
 
Table 29: Complete case EQ-5D-3L utilities and QALYs for 12 month trial period 
 Theophylline 
Mean (SD) 
Placebo 
Mean (SD) 
Difference (95% CI) 
Baseline 0.629 (0.280) 0.643 (0.279) -0.014 (-0.045 to 0.017) 
6 months 0.630 (0.296) 0.642 (0.295) -0.012 (-0.045 to 0.021) 
12 months 0.622 (0.292) 0.623 (0.308) -0.001 (-0.034 to 0.032) 
QALYs over 12 monthsa 0.626 (0.259) 0.637 (0.263) -0.011 (-0.040 to 0.018) 
a There were 33 deaths in the ITT population, these participants had QALYs allocated to them for the 
period they were alive, on a monthly basis. 
CI confidence interval, EQ-5D-3L EuroQoL 5 dimension, 3 level, QALY quality adjusted life year, 
SD standard deviation 
 
Utilities from the EQ-5D-3L at baseline, 6 and 12 month follow-up and QALYs are higher in 
the placebo arm than the theophylline arm, however, this difference is not significant. 
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Multiple imputation 
Multiple imputation results are presented in table 30 for costs and QALYs. 
 
Table 30: Multiple imputation results (unadjusted) 
 Theophylline  
Mean (SE) 
Placebo  
Mean (SE) 
Difference (95% CI) 
Total costs  £2,702 (£110) £3,141 (£148) -£439 (-£846 to -£32) 
Total QALYs 0.617 (0.010) 0.621 (0.010) -0.004 (-0.031 to 0.024) 
CI confidence interval, QALY quality adjusted life year, SE standard error 
 
Multiple imputation results mirror the complete case results, with costs significantly higher in 
the placebo arm, a difference of £439.  Total QALYs are higher in the placebo arm, however 
this is not a statistically significant result, a difference of 0.004. 
 
Bootstrapping 
To explore the robustness of these results, 1,000 non-parametric bootstrapped samples were 
taken from the observed data.  The results were plotted using a cost-effectiveness plane to 
illustrate the mean differences between the arms in incremental costs and QALYs.  
 
Non-adjusted bootstrapped results are presented in figure 7.  This cost-effectiveness plane 
clearly illustrates that the majority of total mean costs are less in the theophylline than the 
placebo arm, with the majority of incremental samples falling in the south-east and south-
west quadrants of the cost-effectiveness plane (below the horizontal axis of £0).  The 
majority of total mean QALYs are less in the theophylline arm than the placebo arm, 
represented by the majority of bootstrapping samples falling in the south-west quadrant 
where the placebo arm has higher mean QALYs than the theophylline arm.  The cost-
effective plane includes an ellipse to illustrate the 95% confidence level. 
 
This uncertainty is explored further using cost-effectiveness acceptability curves. 
 
The unadjusted bootstrapped results are presented in figure 8.  At a willingness to pay of 
£20,000 there is a 75% chance of theophylline being cost-effective.  At £30,000 there is a 
64% of theophylline being cost-effective. However, this should be viewed with caution as 
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there is no significant difference in QALYs or clinical effect, and the difference in costs is 
driven by a very small number of participants with prolonged hospital admissions and the 
likelihood that the finding of a difference between arms for exacerbations treated in hospital 
is a chance finding. Moreover as discussed below the cost benefits of theophylline are not 
evident in multivariate models. 
 
 
Figure 7: Cost-effectiveness plane (unadjusted) 
 
 
Figure 8: Cost-effectiveness acceptability curve (unadjusted) 
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Adjusted analysis 
Multiple imputation total mean costs were adjusted for baseline variables that were 
significant predictors of cost.  These were: medication count at baseline, EQ-5D-3L at 
baseline, offset time (time spent in the trial), age, number of hospitalisations for 
exacerbations in the 12 months prior to randomisation, and number of exacerbations in the 12 
months prior to randomisation.  A cluster command was used for centre number.  
 
Multiple imputation total mean QALYS were adjusted for baseline variables that were 
significant predictors of QALYs.  These were: baseline EQ-5D-3L, medication count at 
baseline, offset time, age, gender, hospitalisation for exacerbations in the 12 months prior to 
randomisation and exacerbations in the 12 months prior to randomisation. A cluster 
command was used for centre number.  These results are presented in table 31. 
 
Table 31: Multiple imputation results (adjusted) 
 Theophylline 
Mean (SE) 
Placebo  
Mean (SE) 
Difference Cost-effectiveness 
Total costs  £2,784 (£125) £3,006 (£167) -£222 (-£472 to £27) Theophylline 
dominates, less 
costs and higher 
QALYs 
Total QALYs 0.621 (0.006) 0.616 (0.007) 0.005 (-0.015 to 0.025) 
 
When multiple imputation total costs are adjusted, there is a trend towards higher costs in the 
placebo arm, however this difference is not significant. 
 
Adjusting QALYs for baseline characteristics results in theophylline having higher QALYs 
than placebo, however, this difference is not significant. 
 
Figure 9 illustrates that when the results are adjusted for baseline characteristics, the results 
are more uncertain: the majority of total mean costs in the theophylline arm are still less than 
the placebo arm, although this is now not a significant result.  In addition, the QALYs are 
marginally higher in the theophylline arm, again not a significant result.  The ellipse 
represents the 95% confidence levels. 
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Figure 9: Cost-effectiveness plane (adjusted) 
 
The adjusted bootstrapped results are presented in a cost-effectiveness acceptability curve in 
figure 10.  At a willingness to pay of £20,000 there is a 90% chance of theophylline being 
cost-effective, and at £30,000 there is an 85% chance of theophylline being cost-effective. 
Again, these results should be viewed with caution as there was no significant difference 
between arms for QALYs or treatment effect. 
 
 
Figure 10: Cost-effectiveness acceptability curve (adjusted) 
0
0.2
0.4
0.6
0.8
1
£0 £20,000 £40,000 £60,000 £80,000 £100,000£120,000
P
ro
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
 (
%
)
Willingness to pay
113 
 
Exacerbation costs were also adjusted separately to explore the adjustment on the significant 
difference in exacerbation costs between arms. Strong predictors of exacerbation costs were 
offset time, hospitalisation for exacerbations in the 12 months prior to randomisation and 
exacerbations in the 12 months prior to randomisation.  A cluster command was used for 
centre number. These results are presented below in table 32 and show that for adjusted 
exacerbation costs, whilst there is a trend for higher costs in the placebo arm, this difference 
is not significant.  The mean costs difference has decreased from £447 to £67. 
 
Table 32: Complete case adjusted exacerbation costs 
 Theophylline 
mean (SE) 
Placebo  
mean (SE) 
Difference 95% CI 
Total exacerbation cost  £732 (£96) £799 (£71) -£67 -£196 to £61  
   Location costs £675 (£98) £735 (£72) -£60 -£190 to £68 
   Treatment costs £58 (£11) £64 (£8) -£6 -£19 to £7 
CI confidence interval, SE standard error 
 
Cost-effectiveness 
For cost per QALY, unadjusted results suggest that whilst theophylline is cheaper than 
placebo (significant result), the QALYs gained in the placebo arm are higher than in the 
theophylline arm (non-significant result).  The adjusted results suggest that theophylline 
dominates, it is cheaper with higher QALYs than placebo. However this result should be 
interpreted with caution; the difference in QALYs is not significant.  This is mirrored by the 
trial primary outcome; theophylline is not clinically effective in terms of reducing 
exacerbations. 
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CHAPTER 6 - DISCUSSION 
 
Main results 
The results of this trial show that, for people with COPD at high risk of exacerbation, the 
addition of low-dose oral theophylline to a drug regimen that includes an inhaled 
corticosteroid, confers no overall clinical or health economic benefit. This result was evident 
from both the intention to treat and the per-protocol analyses. The primary outcome measure 
for this trial was the total number of exacerbations of COPD requiring changes in 
management (minimum management change - use of oral corticosteroids and/or antibiotics) 
during the one year treatment period, as reported by the participant. For the 11 pre-specified 
secondary outcome measures, the addition of low-dose theophylline had no clinical or health 
economic benefit in 10. The addition of low-dose theophylline did reduce the number of 
COPD exacerbations requiring hospital admission (often classified as ‘severe’)68 (adjusted 
incidence rate ratio 0.72 (95% CI 0.55,0.94)), however further inspection of the data 
indicated that this difference was the consequence of a small excess of participants allocated 
to placebo (n=10) having ≥3 hospital treated exacerbations who accounted for 39 of the extra 
51 hospital treated exacerbations in the placebo arm. This effect on hospital admissions was 
also evident on the per-protocol analysis. Given that adjustments for multiple comparisons 
were not performed, it is possible that this finding could be due to type I error. However, in 
light of a recent report that another phosphodiesterase inhibitor (roflumilast) is most 
beneficial in people with prior COPD hospitalization for exacerbation and greater 
exacerbation frequency,96 this finding warrants further investigation. The safety data 
demonstrated that the addition of low-dose theophylline was not associated with an increase 
in serious adverse events or adverse reactions.  
 
Relevance to existing literature 
Oral theophylline has been used in the treatment of COPD and asthma for over 70 years. 
Conventionally oral theophylline has been used as a bronchodilator in COPD, this effect 
being mediated by inhibition of phosphodiesterase (PDE), however in order to achieve 
modest clinical effects relatively high blood concentrations (10-20mg/l) are required but at 
these concentrations non-specific inhibition of PDE is also associated with a wide range of 
well recognised side effects, e.g. nausea, palpitations, headaches. A Cochrane Review 
published in 2010 identified 20 randomised placebo controlled trials of theophylline in 
COPD, all of crossover design, using dosing schedules to obtain conventional plasma 
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theophylline levels in the therapeutic range (10-20 mg/l) i.e. conventional high-dose 
theophylline.83 The number of participants in these trials ranged from 8 to 60, the total 
number of participants in the 20 trials was 488. The duration of the studies was 9-90 days, the 
mean age of participants ranged from 58 to 69 years, four of the studies were graded as high 
quality. The systematic review demonstrated that use of high-dose conventional theophylline 
resulted in a small but significant increase in FEV1 of 100ml (95% CI; 40, 160), this was 
derived from 13 studies with 244 participants. Two studies with a total of 45 participants 
reported on the incidence of exacerbations, concluding that high-dose conventional 
theophylline had no effect on the incidence of exacerbations. Three studies with a total of 64 
participants reported data on nausea, with the risk of experiencing nausea when on 
theophylline treatment being significantly increased (RR 7.67; 95%CI 1.47, 39.94). When 
compared with previous trials of conventional high-dose theophylline in COPD the current 
trial of low-dose theophylline that recruited 1578 participants is clearly somewhat larger and 
the treatment period longer in duration. Moreover in contrast to conventional high-dose 
theophylline trials with their focus on lung function, the primary outcome of the current study 
was exacerbations of COPD and the study population comprised participants at high risk of 
exacerbating. When compared with these trials of high-dose conventional theophylline the 
current trial, as expected, showed no effect of low-dose theophylline on lung function (FEV1) 
and reassuringly no increase in side effects. One of the findings from the Cochrane Review 
was that very few participants withdrew from intervention trials of high-dose conventional 
theophylline for any reason. In the Review, nine studies reported no ‘dropouts’ and in the 
remaining studies the dropout out rate was generally very low, the only exception to this low 
‘dropout’ rate was the study of Guyatt who reported eight withdrawals from 27 recruited 
(30%).97 The sample size of the current trial included an estimate of 6% of participants 
ceasing taking their study medication based on the four high quality studies reported in the 
Cochrane Review,83 in which three of 51 (6%) participants ‘dropped out’. The 26% of 
participants ceasing study medication in the current study is greater than anticipated 
(although balanced across the arms) and more in keeping with the study of Guyatt,97 probably 
reflecting the pragmatic nature of the current trial, the older age of participants and the much 
longer duration of the current trial when compared with those in the Cochrane Review.  
 
The use of high-dose conventional theophylline has declined over the years because of its 
narrow therapeutic index, modest clinical effect, side effect profile, drug interactions, the 
need for blood concentration monitoring and the availability of more effective inhaled 
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therapies.98 High-dose conventional theophylline is now included in current COPD guidelines 
as a third line therapy.1  
 
The concept of using low-dose theophylline to augment the anti-inflammatory effects of 
corticosteroids on the airway inflammatory processes in COPD originated from in vitro and 
animal studies investigating the molecular mechanisms contributing to the reduced 
corticosteroid sensitivity of COPD.32, 38-40, 43, 46 The key observation was that the reduced 
HDAC2 activity of COPD can be reversed by low concentrations (1-5mg/l) of theophylline, 
moreover theophylline reduces corticosteroid insensitivity in COPD such that there is a 
marked synergistic interaction between theophylline and corticosteroids in suppressing the 
release of inflammatory mediators from alveolar macrophages obtained from COPD 
patients.43, 44 These basic research studies suggest that low-dose (1-5mg/l) theophylline could 
increase HDAC activity and hence reduce corticosteroid resistance in COPD patients thereby 
enabling ICS to switch off inflammation and potentially more effectively reduce exacerbation 
rates. 
 
Prior to commencing the current study, the concept of using low-dose theophylline in 
conjunction with corticosteroids in COPD had been explored in two small RCTs. The first 
RCT was in 35 patients admitted to a Spanish hospital with an acute exacerbation of COPD 
who were treated with a regime that included systemic corticosteroids.48 Participants were 
randomised to receive additional low-dose theophylline or nothing in a single blind design, 
participants not on ICS at admission were commenced on ICS. After three months of 
treatment low-dose theophylline increased sputum macrophage HDAC activity and reduced 
sputum concentrations of the pro-inflammatory mediators IL-8 and TNF-α. There were no 
clinically significant effects in this small study, although fewer participants in the 
theophylline group had a subsequent exacerbation than in the control group (12.5% vs 26%). 
This study differed from the current study: small sample size, single blinded, no placebo 
control, three month follow up, participants were only recruited during hospitalisation with 
exacerbations of COPD, all were male, and only 14% had had ≥2 exacerbations in the 
previous year. Notably 26% of participants were not followed up at three months.  
 
The second small (n=30) RCT of COPD patients was of double dummy (low-dose 
theophylline vs placebo, standardised dose of ICS vs placebo), randomised double blind, 
parallel study based in the UK.49 After four weeks of low-dose theophylline there was no 
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effect on the primary outcome of absolute number of sputum neutrophils. The combination of 
low-dose theophylline/ICS significantly reduced a number of secondary endpoints (e.g. 
sputum percentage neutrophils, sputum total eosinophil count). In an open label extension of 
the trial the combination of low-dose theophylline/ICS increased peripheral blood 
mononuclear cell HDAC activity by nine-fold. The study concluded that the combination of 
ICS and low-dose theophylline may attenuate airway inflammation in patients with COPD. 
One of the limitations of this study was that the significant findings were for low-dose 
theophylline/ICS vs theophylline rather than low-dose theophylline/ICS vs ICS suggesting 
perhaps that the observed effects were a consequence of the ICS and not the low-dose 
theophylline. This study differs from the current study: four week duration, small numbers, 
83% male, younger age (61 years) although lung function (mean FEV1 54%) was similar. 
 
Whilst the current trial was being conducted two trials investigating the therapeutic 
consequences of low-dose theophylline were published.52, 99 The first study from India was a 
hospital based single blinded, prospective, randomized, placebo controlled study that 
investigated the effects of adding low-dose theophylline to the combination of formoterol 
plus budesonide.99 A total of 58 patients with moderate/severe COPD were commenced on a 
standardised ICS/LABA therapy (budesonide and formoterol) and were randomised to 
receive either low-dose theophylline or placebo for 60 days. Fifty participants completed the 
trial and their data presented. The addition of low-dose theophylline resulted in a greater 
improvement in total symptom scores, a greater increase in FEV1 and a greater increase in 6 
minute walking distance when compared with placebo. Of note, however, the method of 
randomisation was not described, the actual number of participants randomised to each 
treatment group was not presented, the nature of the ‘single blind’ was not explained and 
there was no ‘intention to treat’ analysis. The randomisation appeared not to have eliminated 
potential sources of bias, the participants allocated to low-dose theophylline were clearly 
more severely affected by COPD: their respiratory rate was greater (20.7 vs 18.7, p=0.003); 
their FEV1 was lower (49% vs 57% predicted, p=0.05); their symptom scores were greater 
(10.17 vs 8.37, p=0.003); their 6 minute walking distance shorter (373 vs 409m, p=0.07); and 
more were classified as severe (54% vs 27%, p=0.09), moreover the placebo tablets were 
described as similar rather than identical. These differences could reflect a bias for the more 
severely affected participants to be preferentially allocated to the low-dose theophylline arm 
of the trial. This study differs from the current study: sample size was much smaller, hospital 
based; 92% of participants were male; younger age ~55 years; BMI was lower ~17 kg/m2; 60 
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day treatment period and single blinded. In addition to the issues regarding blinding and 
randomisation the results of the trial also raise the possibility that whilst the intention was to 
investigate low-dose theophylline, in reality conventional high-dose theophylline was being 
tested: an improvement in FEV1 was described with theophylline treatment, the dosing 
regimen for this study was 400mg theophylline for a weight >50kg, 300mg for a weight of 
40-50kg and 200mg for <40kg, however a significant proportion of participants appeared to 
be underweight with a mean BMI of ~17 kg/m2, and theophylline treatment resulted in higher 
incidences of typical high-dose theophylline toxicity symptoms such as nausea, vomiting, 
headache, palpitation and insomnia. In the current study this was avoided by basing 
theophylline dose on ideal body weight and smoking status.     
 
The second study, the Spanish Low-dose Theophylline as Anti-inflammatory Enhancer in 
Severe Chronic Obstructive Pulmonary Disease (ASSET) trial was a multicentre, 
randomised, double-blind, placebo-controlled trial that recruited patients with COPD whilst 
hospitalised for a COPD exacerbation.52 Participants were randomised to low-dose 
theophylline (100mg twice a day) or matched placebo in addition to ICS/LABA treatment, 
participants not routine taking ICS/LABA were established on ICS/LABA. In total 70 
patients were randomised (36 theophylline, 34 placebo) and 46 completed the year of 
treatment (23 theophylline, 23 placebo). The co-primary outcomes were change in HDAC 
and exacerbation frequency during the one year treatment period. The addition of low-dose 
theophylline had no effect on plasma/sputum HDAC concentrations and no effect on COPD 
exacerbation rate (theophylline vs placebo, 0.97 (SD 0.94) vs 0.88 (SD 0.89)). This trial has 
some similarities with the current trial: primary outcome of exacerbation; same definition of 
exacerbation; one year treatment period; similar participant age CAT score and levels of 
cardiovascular comorbidity at baseline; no significant difference in adverse reactions between 
groups. However, there are some important differences between this trial (ASSET) and the 
current study (TWICS). The current study is much larger (n=1578) than ASSET (n=70), 
being designed to detect a 15% reduction in exacerbations with 90% power, whereas ASSET 
was designed to detect an arguably implausibly large 50% reduction in exacerbations with 
80% power. The exacerbation rate in ASSET was about half that observed for TWICS (0.92 
vs 2.23/yr). Perhaps the most plausible explanation for this is that all participants in the 
ASSET trial were recruited whilst hospitalised with an exacerbation of COPD irrespective of 
exacerbation history, whereas participants in TWICS were clinically stable, 60% were 
identified from primary care and all had a history of ≥2 exacerbations in the previous year 
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requiring treatment with antibiotics and/or corticosteroids. The proportion of participants 
ceasing study medication was possibly higher in ASSET than in TWICS (34% vs 26%), 
however it should be noted that 14% of participants in ASSET ceased study medication 
because their FEV1 improved to >50% predicted during the one year treatment period. This is 
most likely to be a consequence of ASSET recruiting in the peri-exacerbation period and 
TWICS recruiting when participants were clinically stable. When compared with TWICS, 
participants in ASSET were more likely to be male, had more severe COPD (lower FEV1), 
more likely to be hospitalised during the treatment period but less likely to be diabetic 
(probably reflecting the higher mean BMI of TWICS participants, 27 vs 22 kg/m2).   
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) management strategy 
guideline highlights that the clinical relevance of low-dose theophylline has not been fully 
established and that clinical evidence on low-dose theophylline, particularly on 
exacerbations, is limited and contradictory.1 TWICS is the first large pragmatic community 
based trial to investigate the effect of adding low-dose theophylline to the treatment regimen 
of people with COPD who are at high risk of exacerbating despite a treatment regime that 
includes maintenance inhaled corticosteroids in COPD.  
 
Pre-clinical work convincingly demonstrates that the combination of low-dose theophylline 
and corticosteroid has a strong biological effect, increasing HDAC and inhibiting the release 
of pro-inflammatory mediators.38, 39, 41-44 The trials conducted to date have been small (n=30-
70), hospital based, and have tended to focus on biological outcomes with short treatment 
periods.48, 49, 52, 99 The largest trial to date in this field has reported that low-dose theophylline 
had no effect on HDAC or exacerbations, however as the authors of ASSET acknowledge, 
‘we might have overestimated the potential clinical benefit when we calculated the sample 
size, which may have precluded us from identifying a clear-cut clinical effect.’.52  The 
TWICS trial avoids many of the limitations of previous studies and clearly demonstrates that 
in an NHS setting that for people with COPD, the addition of low-dose oral theophylline to a 
drug regimen that includes an inhaled corticosteroid, confers no overall clinical benefit. The 
participants in TWICS were a group of people with COPD at high risk of exacerbating based 
on their history of exacerbating in the previous year, this group was deliberately chosen 
because of their impact on the NHS and it enabled us to design a trial of realistic (but 
ambitious) sample size. Although TWICS did not investigate whether people with COPD at 
low risk of exacerbation would benefit from low-dose theophylline, the combination of the 
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findings of TWICS and the absence of a biological effect (HDAC concentrations) in the 
ASSET trial despite a sample size ‘more than enough to demonstrate a biological effect of 
the intervention’52 make it highly unlikely that low-dose theophylline would be beneficial in 
low exacerbation risk COPD patients. A possible explanation for the disparity between the 
biological effects observed in previous studies, with short treatment periods, and the absence 
of beneficial effects in TWICS, with a year long treatment period, is that any biologically 
beneficial effect of low-dose theophylline is not sustained in the long term. 
 
Cost-effectiveness 
The health economics results indicate that after adjustment for baseline characteristics there 
was no significant difference in the total health economic costs associated with treatment 
with low-dose theophylline compared with placebo: adjusted mean difference -£222 (95% CI 
-£27 to £472). With unadjusted complete case data the total costs are higher in the placebo 
arm compared to the theophylline arm, a significant difference of £452 (95% CI £132 to 
£771).  This difference was driven by a greater number of participants in the placebo arm 
receiving treatment for exacerbations in hospital, compared the theophylline arm.  The ten 
most costly observations (over £10,000) were all in the placebo arm, and were the result of 
hospital stays of greater than 40 days. The multiple imputation results mirror the complete 
case results with a significant difference in unadjusted costs of £439 (95% CI £32 to £846), 
higher in the placebo arm.  
 
The difference between arms in total costs is driven solely by the hospital treated 
exacerbations and exacerbations treated with oxygen, no other resource group has a 
significant difference between arms.  The difference in the number of exacerbations receiving 
hospital treatment is likely to be the result of a small number of participants in the placebo 
arm having very frequent hospital admissions.  Therefore these results should be interpreted 
with caution. 
 
Exacerbation costs are 22%-33% of the total costs (theophylline and placebo respectively) 
which is somewhat less than the 60% reported by Britton et al27 in 2003 perhaps reflecting 
differences in management between 2003 and 2015/6 particularly increased use of 
preventative drugs, pulmonary rehabilitation and more structured chronic disease 
management in primary care.  
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The economic outcome of QALYs was higher in the placebo arm in the unadjusted complete 
case results than in the theophylline arm, however this difference is not significant 0.011 
(95% CI -0.018 to 0.040).  Multiple imputation results mirrored the complete case results; 
there were no significant differences, with unadjusted results favouring the placebo arm, and 
adjusted results favouring the theophylline arm.  
 
These results reflect the primary outcome of number of exacerbations needing treatment in 
the 12 month follow-up period; there was no significant difference between arms. 
 
Hettle et al100 reported 4 year UK costs in their paper on tiotropium versus usual care in the 
UK and Belgium.  Exacerbation costs ranged from £2,295 to £2,744, (£574 to £686 per year) 
and maintenance costs ranged from £2,935 to £3,937 (£737 to £984 per year).  This compares 
to one year costs from this research of; exacerbations £585 to £1,033, and maintenance costs 
of £2,074 to £2,101.  Whilst the annual exacerbation costs of the current study are similar to 
that of Hettle et al, the maintenance costs are somewhat higher reflecting the older age of the 
participants of the current study (68.4 years vs 64 years), that 80% of the current participants 
were prescribed LAMAs (none for usual care in Hettle study), people with COPD using long 
term oxygen were included in the current study and in the current study participants were 
more likely to be in the severest GOLD category (14% vs 8%). Hettle et al also reported a 33 
times higher cost for hospitalised exacerbations compared to non-hospitalised exacerbations 
in Belgium, reflecting the increased cost between hospitalised and non-hospitalised 
exacerbations in this research. 
 
The strengths of this research include; few participants with no outcome or resource use (low 
number of missing cases; 4.3%); uncertainty was explored using non-parametric 
bootstrapping; and where there was a significant difference in exacerbation costs this was 
explored further to identify what was driving this difference. 
 
The two main limitations to the cost-effectiveness analysis include; the number of missing 
EQ-5D-3L questionnaires (19.1%) and that small amounts of missing data were imputed 
using naïve methods at disaggregated level. 
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Strengths and limitations 
The main strength of TWICS is that it was a large pragmatic, predominantly community 
based, suitably powered, double blind randomised, placebo-controlled, UK multicentre 
clinical trial with a high follow-up rate for the primary clinical outcome. A total of 1578 
individuals were recruited in 121 UK sites, 60% of participants were identified in primary 
care making it highly likely that TWICS participants reflected normal clinical practice across 
both primary and secondary care in the UK. The one year treatment period allowed capture of 
the seasonality of exacerbations.101 
 
Originally TWICS aimed to recruit 1424 participants, the sample size being primarily based 
on the findings of the observational ECLIPSE (Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints) cohort study of 2138 COPD patients recruited in 46 
centres from 12 countries.21 ECLIPSE demonstrated that the best predictor of an exacerbation 
in a year, was a treated exacerbation in the previous year. In addition, ECLIPSE identified a 
frequent exacerbator phenotype defined as ≥2 exacerbations in the previous year, moreover 
this frequent exacerbator phenotype was relatively stable for three years and could be reliably 
identified by patient report. For the frequent exacerbating patients recruited into TWICS, data 
from ECLIPSE predicted a mean 2.22 (SD 1.86) exacerbations in the year of treatment and 
the sample size for TWICS was based on this. This prediction proved to be remarkably close 
to what we observed, increasing confidence in the findings, with a mean number of 
exacerbations in the theophylline arm of 2.24 (SD 1.99) and in the placebo arm 2.23 (SD 
1.97). A notable finding of TWICS was an apparent disparity between the number of 
exacerbations reported by participants in the year prior to the study (mean 3.59, SD 2.15) 
whereas in the treatment year the number of self-reported exacerbations was somewhat less 
(mean 2.23, SD 1.99). The most likely explanation for this disparity is that we did not ask for 
dates for the reported exacerbations in the year prior to the study, whereas during the study 
we asked for dates and the conventional minimum of two weeks between consecutive 
exacerbation episodes was necessary to consider exacerbations as separate,68 this resulted in 
exacerbations separated by less than two weeks being merged. Although further factors 
contributing to the disparity in exacerbations before, and during the study may include an 
over-reporting bias by participants and regression to the mean, the exacerbation frequency 
during the treatment period was remarkably consistent with that predicted by ECLIPSE. 
Although the exacerbation rate observed in the current trial is somewhat higher than recent 
explanatory trials102, 103, it is entirely consistent with the recent pragmatic UK Salford Lung 
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Study.104 The Salford Lung Study with an inclusion criterion of ≥1 exacerbation in the 
previous year reported exacerbation rates of 1.74-1.90/year, the slightly higher exacerbation 
rate in the current trial most likely reflects the participants’ increased propensity to 
exacerbate (≥2 exacerbations in the previous year) as well as the lack of requirement to 
withhold therapy other than theophylline meaning investigators were happier to recruit higher 
risk patients. . Although the diagnosis of COPD was confirmed by post-bronchodilator 
FEV1/FVC <0.7, 18.3% of participants reported a concurrent/previous diagnosis of asthma. 
Whilst this may, in part reflect a diagnostic bias towards the more socially acceptable 
diagnosis of asthma in the past, it is possible that the current trial included up to 18% of 
participants with asthma COPD overlap syndrome. Whilst it may be possible that these 
patients may respond differently to the theophylline this was not one of the study objectives. 
 
By recruiting 1578 individuals, 60% of whom were identified in primary care, TWICS 
exceeded its original recruitment target of 1424 with at least 50% being recruited in primary 
care. It was initially envisaged that TWICS would recruit from a limited number (seven) 
secondary care sites with primary care sites acting as PIC sites for these secondary care 
centres. Recruitment to TWICS was delayed by five months because of a worldwide shortage 
of bottle tops for the drug bottles. Initially recruitment in 16 primary and six secondary care 
sites was on target and TWICS achieved its recruitment targets for the feasibility phase by 
recruiting 100 participants in months 7, 8 & 9 with 55% identified in primary care. Within 
four months it became apparent that it would not be possible to sustain recruitment with 
recruitment falling below the required 59/month to a nadir of 26 in month 15 (October 2014). 
To address this, a change in recruitment strategy was implemented in month 12 (July 2014) 
with rapid increases in the number and rate of opening up primary and secondary care sites. 
Ultimately 121 recruiting sites were opened up comprising: 88 primary care sites and 33 
secondary care sites.  Other primary care practices acted as PICs for primary and secondary 
care sites.  In total 477 participants were recruited and followed up entirely in primary care, 
464 participants were identified in primary care but recruited and followed up in secondary 
care (this was particularly the case in Scotland) and 637 participants were identified, recruited 
and followed up in secondary care. This change in recruitment strategy was successful with 
monthly recruitment remaining above 50/month from month 19 and reaching a peak of 81 in 
month 35.  
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Primary outcome data (number of COPD exacerbations) were collected on 98% of the 1567 
participants who commenced the one year treatment period (1578 recruited less 11 post-
randomisation exclusions). Several factors contributed to the high follow-up rate. TWICS 
was designed to be as inclusive as possible by facilitating participation by people with COPD 
who would normally find it too difficult to participate in a trial because of their ill health. The 
trial was designed to be relatively ‘light touch’ with three study visits to a local study centre, 
if participants were unable to attend for assessment, they were visited at home, contacted by 
telephone, or sent the questionnaires to complete at home. Participation and remote follow-up 
was further facilitated by delivering the study drug to the participants’ homes using a third 
party distributor. All participants who ceased taking the study drug were invited to remain in 
the study for follow-up, either by face to face assessment, telephone assessment or postal 
questionnaire. For participants who could not be followed-up directly e.g. failed to attend 
follow-up, various methods of follow-up, independent of participant involvement were used. 
In the first instance the participant’s GP was sent a questionnaire enquiring about 
exacerbations (number, dates, how and where treated), the minimum data requested were the 
number of exacerbations in the treatment period. Failing this, GP surgeries were contacted by 
telephone or a request was made for a redacted copy of patient encounter summaries from 
which the Co-CI extracted exacerbation data.  The combination of follow-up methods 
enabled the intention to treat analysis to include 1489 years of participant follow-up data. 
Inevitably there were some participants who did not provide a full 12 months of follow-up 
data e.g. deaths, or for whom 12 months of follow-up data were not available even using 
remote follow-up method. A strength of TWICS was that the statistical analytical methods 
used enabled inclusion of these participants up to the point at which they were lost to follow-
up with their time in study utilised in the offset variable during analysis.  
 
Previous studies investigating the potential anti-inflammatory effects of low-dose 
theophylline in COPD and asthma (not in conjunction with ICS) have used a ‘one size fits all’ 
dosing approach e.g. all participants received 100 mg bd or 200 mg bd.43, 44, 48, 99, 105-107 In 
contrast, one of the strengths of TWICS was that theophylline dosing was somewhat 
personalised, being determined by ideal body weight (IBW) and smoking status. As noted in 
our protocol paper,55 population studies have demonstrated that theophylline 
pharmacokinetics are influenced by weight, COPD disease status (reduced clearance) and 
smoking (increased clearance).57-66, 108 Smoking induces theophylline clearance by 
approximately 60% that gradually returns to normal levels upon smoking cessation.  This was 
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incorporated into the definition of a non-smoker in TWICS and procedures were 
implemented to modify, where necessary, the dose of study drug in a timely manner if 
participants changed their smoking status during the treatment period. The use of IBW in 
preference to actual weight avoided the potential for giving an inappropriately high dose of 
theophylline to obese participants. In TWICS theophylline dosing was based upon 
pharmacokinetic modelling incorporating the major determinants of theophylline steady state 
concentration, i.e. weight, smoking status, clearance of theophylline (low, normal, high), and 
was designed to achieve a steady state plasma theophylline concentration of 1-5 mg/l and 
certainly to be <10 mg/l55. Theophylline is metabolised in the liver by the enzyme CYP1A2 
which is induced by smoking and inhibited by a number of medications with a consequent 
increase in plasma theophylline concentration. For this reason, the exclusion criteria included 
long-term use of drugs with the potential to increase plasma theophylline concentration,94 
conversely concomitant use of drugs with the potential to lower plasma theophylline 
concentration were permitted in the trial. Reassuringly the dosing regimen used for TWICS 
appeared to be effective in establishing low-dose plasma theophylline concentrations of 1-
5mg/l because there was no evidence of the typical sequelae of conventional high-dose 
theophylline such as an improvement in FEV1. In addition, when compared with the placebo 
group, there was no evidence that participants allocated to low-dose theophylline experienced 
more serious adverse events or adverse reactions, nor did the low-dose theophylline report 
more serious adverse events or adverse reactions typical of theophylline toxicity, namely 
gastro-intestinal, cardiac, psychological or neurological symptoms. Furthermore when the 
reasons for ceasing study medication were analysed there were no significant differences 
between the arms, notably for gastro-intestinal, cardiac, psychological or neurological 
symptoms typical of theophylline toxicity.  A consequence of the personalised dosing of 
study drug to achieve a low-dose plasma theophylline concentration well below that 
associated with typical side effects was that there was no need for blood sampling to monitor 
plasma theophylline, a necessity that would have greatly increased the complexity of the trial 
and increased the likelihood of unblinding the participant and/or investigator. The absence of 
blood testing reduced costs and was extremely popular with primary care sites and 
contributed to the willingness of many primary care sites to participate in TWICS. The 
potential limitation of relying on participant reported smoking status is perhaps less important 
in this study, as a smoker declaring themselves to be a non-smoker would have resulted in the 
lower dose of theophylline being prescribed, perhaps ensuring plasma theophylline to be in 
the low-dose range of 1-5mg/l. 
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As with all studies, there are limitations associated with TWICS. The primary outcome for 
the study was the number of participant reported exacerbations during the one year treatment 
period, to facilitate recall participants were given a diary card to make notes on 
exacerbations, treatment, and healthcare usage. The definition of an exacerbation was the 
widely used ATS/ERS guideline recommendation of a worsening of patient’s dyspnoea, 
cough or sputum beyond day-to-day variability sufficient to warrant a change in 
management.68 The minimum management change was treatment with antibiotics or oral 
corticosteroids, and consequently, the TWICS study only quantified moderate and severe 
exacerbations.  However, these exacerbations are the ones which are the most burdensome to 
patients and health care services. A limitation of TWICS is that the relatively conservative 
definition of exacerbation probably underestimates the frequency of symptom-defined mild 
exacerbations that are short lived and treated by the patient with a temporary increase in 
bronchodilator therapy,109 the identification of such mild exacerbations would have required 
participants to complete daily symptom diary cards adding to the intrusiveness of the study 
and considerably adding to the data entry burden of research staff. Although TWICS did not 
quantify mild exacerbations there were no significant differences between treatment and 
placebo in quality of life/impact on health status as quantified by EQ-5D-3L/CAT suggesting 
either that low-dose theophylline had no effect on mild exacerbations or if there was an effect 
it did not impact on health status/healthcare usage.  
 
A possible limitation of participant reported exacerbations is the accuracy of such a report 
over a six month period. Whilst it would have been possible to obtain such exacerbation data 
from healthcare records it is well documented that people with COPD do not report all of 
their exacerbations to healthcare professionals.18, 110-112 Patient recall of COPD exacerbations 
has been shown to be highly reliable over a year: in the London COPD Cohort study there 
was no significant difference between the number of exacerbations recorded on diary cards 
and patient estimates of their exacerbation number over the same one year period (mean 2.4, 
SD 2.2 vs mean 2.3 SD 2.1), there was 93% agreement between patient recalled and diary-
recorded exacerbations.112 There was however, a difference between the number of treated 
exacerbations recorded on diary cards and the number of treated exacerbations remembered 
by the patient over the same one year period (mean 2.3 SD 2.1 vs 1.8 SD 1.8), there was 
88.6% agreement between patient recalled and diary-recorded treated exacerbations.112 The 
patient representatives helping with TWICS were adamant that it was fairly straight forward 
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to recall the number of exacerbations over a six month period. A small validation exercise 
was conducted at two of the largest sites (Aberdeen and Aintree) during TWICS to confirm 
that participant recall was indeed valid. The validation was done by requesting a 
care/encounter summary from the GP and comparing this against participant report. In 
Aberdeen, 43 records (20% sample) were checked; and in 37 there was complete agreement 
between participant and GP report. In Aintree, 24 records were been checked and in 16 there 
was complete agreement between patient and GP report.  Therefore in a 4% sample of 
participants there was 80% agreement. This rate of agreement was slightly lower than that 
reported by Quint et al112 however, current GP records may not be as reliable a source of 
exacerbation data as in the past, given that patients have rescue packs at home and can access 
help for their exacerbations through many non-GP sources, e.g. pharmacies, emergency and 
walk-in centres, Accident and Emergency departments etc.  
 
A limitation of TWICS was that more participants ceased taking their study drugs (26%) than 
anticipated (6%), although this was somewhat offset by 10% over-recruitment (n=154). There 
was no evidence of bias in ceasing study medication with the proportion and the reasons 
given for ceasing study medication being equally distributed between those allocated to low-
dose theophylline and those allocated to placebo. The original sample size for TWICS 
(n=1424) accounted for 6% of participants ceasing taking their study medication based on the 
four high quality studies reported in a Cochrane Review of theophylline in COPD, in which 
three of 51 (6%) participants ‘dropped out’.83 In reality 413 of the 1578 participants either 
never started/initiated medication (post randomisation exclusions n=11, non-initiation n=8) or 
ceased taking the study medication (non-persistence, n=393), this 26% rate of ceasing study 
medication is greater than anticipated but in keeping with ASSET trial of low-dose 
theophylline that reported a 34% rate for ceasing study medication.44 The higher than 
anticipated rate of ceasing study medication in TWICS was most likely the consequence of 
the relatively high rates of co-morbidities in participants giving rise to symptoms that were 
attributed to the study medication and a heightened awareness of adverse reactions listed in 
the PIL and the package insert accompanying the study medication. This is consistent with 
46% of participants reporting adverse reactions typical of high-dose theophylline (but equally 
distributed between the two study arms) and why 20% of those ceasing study medication 
gave gastrointestinal symptoms as the reason for ceasing study medication although there was 
no significant difference in the incidence of such symptoms in those ceasing low-dose 
theophylline and those ceasing placebo. Some participants were asked to discontinue study 
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medication because they had stopped taking an ICS. During the trial there was an emergent 
change in prescribing practice away from ICS containing preparations to LABA/LAMA 
inhalers, however this had minimal impact on the trial (certainly <20 participants), most 
probably because the participants in this study were at high risk of exacerbation and for 
whom there is still a role for ICS. Although 413 participants ceased study medication during 
TWICS, a review of the medication returns indicated that 66 of these participants had >70% 
adherence whilst taking the study medication when averaged over the 12 month treatment 
period, e.g ceased study medication at 11 months; these individuals were included in the per-
protocol analysis. Although per protocol analyses, are biased by their very nature  the per-
protocol analysis for this study included 1142 years of participant data (85% of the 1338 
years indicated by the power calculation) it is not surprising that the results of the per-
protocol analysis were almost identical to that of the intention to treat analysis. Although 
adherence with the study medication was quantified through pill counting it was not practical 
to assess adherence to the inhaled corticosteroid as this would have entailed use of non-
routine care methodologies such as diaries cards, metered inhalers etc. The rationale for the 
use of low-dose theophylline is as an adjunct to ICS therapy, that we were unable to verify 
adherence to ICS therapy is a limitation of this study.  
 
Generalisability 
This study has good external validity as it was of a pragmatic design that reflected normal 
clinical practice across both primary and secondary care in the UK. Participants remained on 
their existing COPD medications, they were managed in the normal way by their usual 
healthcare teams and the trial recruited from 121 sites (88 primary care, 33 secondary care) 
that spanned the UK, many of the secondary care sites were District General Hospitals. We 
consider it to be highly likely that TWICS participants are typical of normal clinical practice 
across both primary and secondary care in the UK and that the findings are generalizable to 
clinical practice in the UK. 
 
The TWICS study recruited participants highly likely to exacerbate in the one year treatment 
period as evidenced by two or more treated exacerbations in the previous year. In contrast to 
many COPD trials we did not exclude potential participants with mild COPD, as evidenced 
by FEV1>80% predicted, 9% of TWICS participants had mild COPD based on spirometry 
criteria but fulfilled the frequent exacerbator phenotype,21 enhancing the generalisability of 
the trial. Recruitment to TWICS was limited to frequent exacerbators because in clinic 
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practice these are the patients who are usually commenced on this ‘third line’ therapy,24 
moreover a trial of participants less likely to exacerbate e.g. one exacerbation in previous 
year, would have been much larger (n ~3000) and somewhat more costly. Although we did 
not test whether the addition of low-dose theophylline to ICS had an effect on people who 
were less frequent exacerbators there is no scientific or clinical reason why low-dose 
theophylline should have a differential effect on frequent/infrequent exacerbators and it 
would seem reasonable to extend the findings of the current study to people with COPD at 
low risk of exacerbating.  
 
Whilst the results of this trial are generalizable to the UK and probably other high income 
countries, the findings may not be applicable to low/medium income countries, with differing 
pharmacogenetic profiles, where theophylline remains a frequently used therapy in COPD 
most probably because it is inexpensive compared to inhaled therapies.113-116 The randomised 
double blind placebo controlled trial of Zhou et al raises the possibility that in China at least, 
there is a therapeutic response to low-dose theophylline in the absence of ICS.117 In this trial 
the addition of low-dose theophylline to usual COPD treatment in 110 people with COPD 
(theophylline n=57, placebo n=53) for a year significantly reduced the frequency of 
exacerbations when compared with the placebo group (0.79 SD 1.16 vs 1.70 SD 2.61, 
p=0.047). The participants in this trial differed considerably from those taking part in 
TWICS: only 30% were taking regular medication prior to the trial and this was restricted to 
inhaled salbutamol; use of ICS, LABA and LAMA were excluded; the target plasma 
theophylline concentration (5-10mg/l) was also somewhat higher than the target range (1-
5mg/l) identified for optimum synergistic interaction between corticosteroids and low-dose 
theophylline. The use of low-dose theophylline in conjunction with corticosteroids in China 
is being addressed by the ongoing theophylline and steroids in COPD study (TASCS) that is 
recruiting 2400 people with COPD in China.118 They are being randomly allocated to low-
dose prednisolone (5mg once a day) or low-dose theophylline (100mg twice a day) with low 
dose prednisolone (5mg once a day) for 48 weeks. The primary outcome is exacerbation rate 
over the 48 week treatment period. The trial is due to be completed by June 2018. It will be 
interesting to compare the results of TASCS with TWICS, although it should be noted that 
the routine use of oral corticosteroids as a maintenance treatment for COPD, even though 
they are cheaper than ICS, would never be contemplated in developed countries for clinical 
and ethical reasons. 
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Public and Patient Involvement 
Public and patient involvement in this study was limited but effective, nevertheless lessons 
were learnt that have been implemented in a subsequent NIHR-HTA funded study, e.g. a 
person with COPD is a joint grant holder.  
 
A patient with COPD was a voting member of the TWICS TSC, recruitment and retention of 
a patient representative was hindered by ill health.  The first patient approached declined 
because of ill health. The patient representative nominated by Chest Heart and Stroke 
Scotland as part of their Voices Scotland initiative had to resign because of ill health and a 
third patient representative was identified and he has made an active contribution to the 
TWICS study. Supporting the TSC patient representative was actively undertaken by several 
members of the local study team. In our subsequent NIHR-HTA funded trial we have a 
patient representative who is supported by CHSS’s Voices Scotland lead who is not only a 
voting member of the TSC but also co-ordinator and representative of a panel of 15 COPD 
patients (as they like to be called).  
 
A representative of the British Lung Foundation and a person with COPD made important 
contributions to study design procedures (what was acceptable - spirometry, and what was 
not acceptable - daily diary cards), perhaps the most important suggestions were to deliver 
trial medication to home addresses, and to facilitate follow-up for ill participants by way of 
home visits, telephone, and postal questionnaires. Public and patient involvement resulted in 
many changes to the design and content of the ‘short’ PIL (a one page summary PIL), and the 
‘long’ PIL (a more detailed PIL) and the importance of these changes is evidenced by the in 
success recruitment and there were no changes to the PIL throughout the study. Public and 
patient involvement was particularly insightful during TSC deliberations concerning the 
validity of patient recall of COPD exacerbations. 
 
The support of the BLF and CHSS has been invaluable throughout the study, identifying 
volunteers for public and patient involvement and publicising the study. 
 
Conclusions 
Main conclusions 
This is the first adequately powered multi-centre pragmatic double blind randomised placebo 
controlled trial to assess the effectiveness of adding low-dose theophylline to a drug regimen 
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containing inhaled corticosteroids in people with COPD at high risk of exacerbation, the 
analyses demonstrated that low-dose theophylline has no overall clinical or health economic 
benefit. 
 
Implications for practice 
The trial has shown that low-dose theophylline has no overall clinical impact when added to 
inhaled corticosteroids in COPD. We anticipate that the results of the trial will be 
incorporated in an ongoing systematic review of theophylline in COPD.119  Given that 
TWICS is one of the largest trials of theophylline to date, we anticipate that it will have a 
major influence on the meta-analyses and conclusions. National and International COPD 
Guidelines should take the results of TWICS into account when making recommendations on 
the treatment of COPD and the prevention of exacerbations of COPD. In the meantime 
clinical commissioners can now be encouraged to make informed decisions regarding the use 
theophylline in COPD. 
 
Recommendations for research 
The findings from one of the planned secondary analyses was that low-dose theophylline 
reduces the rate of admission to hospital because of severe COPD exacerbation. Whilst it is 
possible that this may be a chance finding, it is consistent with a recent report that roflumilast 
is most beneficial in people with prior COPD hospitalization for exacerbation and greater 
exacerbation frequency. A further study investigating the effect of low-dose theophylline in 
people with COPD who frequently exacerbate and are admitted to hospital is justifiable given 
their disproportionate impact on NHS resources.  
132 
ACKNOWLEDGEMENTS 
 
Contributions of authors 
Graham Devereux (Co-Chief Investigator) contributed to the conception and design of the 
trial, conduct of the trial, recruitment and follow-up of participants, the interpretation of 
results and writing/editing the report. 
Seonaidh Cotton contributed to the design of the trial, was responsible for the day-to-day 
management of the trial, and contributed to the interpretation of results and writing/editing 
the report. 
Shona Fielding contributed to the design of the trial, was responsible for statistical analysis, 
and contributed to the interpretation of results and writing/editing the report. 
Nicola McMeekin was responsible for the health economic analysis and contributed to the 
interpretation of results and writing/editing the report. 
Peter Barnes contributed to the conception and design of the trial, the interpretation of 
results and writing/editing the report. 
Andy Briggs contributed to the conception and design of the trial, oversaw the health 
economic analysis and contributed to the interpretation of results and writing/editing the 
report. 
Graham Burns contributed to the conception and design of the trial, the interpretation of 
results and writing/editing the report. 
Rekha Chaudhuri contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
Henry Chrystyn contributed to the conception and design of the trial, the interpretation of 
results and writing/editing the report. 
Lisa Davies contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
Anthony De Soyza contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
Simon Gompertz contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
133 
John Haughney contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
Karen Innes was responsible for aspects of the day-to-day management of the trial, and 
contributed to the interpretation of results and writing/editing the report. 
Joanna Kaniewska was responsible for aspects of the day-to-day management of the trial, 
and contributed to the interpretation of results and writing/editing the report. 
Amanda Lee contributed to the conception and design of the trial, oversaw the statistical 
analysis and contributed to the interpretation of results and writing/editing the report. 
Alyn Morice contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
John Norrie contributed to the conception and the design of the trial, the conduct of the trial, 
the interpretation of results and writing/editing the report. 
Anita Sullivan contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
Andrew Wilson contributed to the conception and design of the trial, conduct of the trial, 
recruitment and follow-up of participants, the interpretation of results and writing/editing the 
report. 
David Price (Co-Chief Investigator) contributed to the conception and design of the trial, the 
conduct of the trial, the interpretation of the results and writing/editing the report.   
 
Data sharing statement 
All data requests should be submitted to the corresponding author for consideration.  Access 
to available anonymised data may be granted following review.  
 
We would like to thank all the participants who took part in the study.  We are grateful to all 
the staff at recruitment sites that facilitated identification, recruitment and follow-up of study 
participants (listed below).  We are also grateful to other GP practices and organisations that 
acted as Participant Identification Centres for the study and practices that provided outcome 
data for study participants who were unable to attend for follow-up.  We could not have 
completed the study without the ongoing support of local and primary care research 
networks. 
134 
 NRS Primary Care Network (formerly Scottish Primary Care Research Network): 
Amanda Cardy, Samantha Holden, Tracy Ibbotson, Yvonne McIlvenna, Marie 
Pitkethly, Janice Reid, Kim Stringer 
 
 North of England Commissioning Support (NECS): Jeanette Dixon, Jill Ducker, 
Shona Haining, Gillian Johnson, Rachel Nixon, Norah Phipps, Cheryl Rigg 
 
 NIHR Clinical Research Network South West Peninsula: Cate Atkins, Helen Clough, 
Tania Crabb, Patricia Hollway, Sara McNamara, Lisa Treeby, Lorraine Underwood 
 
 NIHR CRN Eastern: Lynne Baker, Brenda DeBoys, Kim Fell, Fenglin Guo, Emily 
Ikelle, Helen Jung, Heather Leishman, Rachel Lister, Lynn Mather, Cristina Page, 
Barbara Stewart 
 
 NIHR CRN Wessex Primary Care: Christine Brown 
 
 NIHR CRN Yorkshire & Humber: Carla Bratten  
 
 NIHR CRN North Thames: Mandy Austin, Carole Bartlett, Carol Keel, Helen 
McIver, Lucy Peppiatt 
 
We thank Nadia Lewis-Burke for invaluable assistance in data checking.  We are grateful to 
Georgia Mannion-Krase, Andrea Fraser and Lana Mitchell for their secretarial and data co-
ordination support.  We are grateful to Kirsty McCormack for her help and advice in 
developing the grant proposal.  We thank Gladys McPherson, Mark Forrest and the 
Programming Team in CHaRT for developing and maintaining the study website.  We also 
thank Juliette Snow, Ruth Speedie and Rachel West for their help with contracting, and to 
Louise Cotterell and Glenys Milton for their help in managing the budget. 
 
We are grateful for the guidance and support of the Trial Steering Committee (Chairperson - 
Bill McNee; Independent members - Matt Sydes, Mike Thomas, Alister Laird, Marion 
Middler) and the Data Monitoring Committee (Chairperson - Hilary Pinnock; Independent 
members - Chris Weir, Michael Steiner).  We are also grateful to Bev Wears (British Lung 
135 
Foundation) and Jacqueline Waters for helpful comments on early drafts of the trial 
documentation. 
 
We acknowledge Napp Pharmaceuticals Limited for providing the trial drug (Uniphyllin 
200mg MR tablets) free of charge for use in the study. 
 
The Health Services Research Unit (HSRU) and the Health Economics Research Unit 
(HERU) are core funded by the Chief Scientist Office of the Scottish Government Health and 
Social Care Directorate.   
 
 
Disclaimer 
The project was funded by the NIHR Health Technology Assessment Programme (Project 
number: 11/58/15) and will be published in full in Health Technology Assessment, Vol. [x], 
No. [x]. See the HTA Programme website for further project information.   
 
The views and opinions expressed therein are those of the authors and do not necessarily reflect 
those of the Department of Health, or the funders that provide institutional support for the 
authors of this report.   
 
 
Staff at recruitment sites 
Secondary care sites 
Aberdeen Royal Infirmary Ratna Alluri, Faye Annison, David Christie, Michael Christie, 
Patricia Cooper, Lisa Davidson, Graham Devereux (PI), 
Margaret Fernie, Vicki Fraser, Amber Johnson, Alison McKay, 
Celia Meneses, Joy Miller, Beth Robb, Catriona (Tina) Stewart 
Aintree University Hospital 
NHS Foundation Trust 
Lisa Davies (PI), Nicola Blain, Victoria Hankin, Ben Huson 
Vlies, Nadia Lewis-Burke, Laura O-Neil, Rachel Powell, Jamie 
Rylance, Rebecca Tagney, Diane Wood, Dan Wootton 
Belfast City Hospital Peter Gray, Kathryn McDowell, Lorcan McGarvey (PI), Jolene 
Milligan, Brian Wells 
136 
Queen Elizabeth Hospital 
Birmingham 
Karen Boardman, Joanne Dasgin, Simon Gompertz (PI), Carole 
Green, Diane Griffiths, Melanie Gunn, Catherine Jones, Salma 
Kadiri, Heena Khiroya, Emma Low, Rahul Mahida, Mitesh 
Patel, Sarah Raybould, Julie Richards, Gurpreet Sangha, 
Elizabeth Sapey, Lydia Sexton, James Stockley, Anita Sullivan 
(PI), David Thickett, Rebecca Tongue,  the NIHR Wellcome 
Trust Clinical Research Facility, Birmingham 
Blackpool Victoria Hospital Charlotte Armer, Adeel Ashraf, Oliver Brennan, Melanie 
Caswell, Julie Chapman, Stacey Donaldson, Mohamed Etumi, 
Julie Frudd, Gemma Hatton, Aoife Lillis, Alison Mackle, Karen 
Pollard, Andrew Potter, Judith Saba, Tarek Saba (PI), Gurkaran 
Samra, Philomena Shooter, Suzannah Torres 
Bradford Royal Infirmary  Abid Aziz, Fahtima Begum, Stephen Cox, Umair Hamid, 
Rizwana Kausser, Leslie Masters, Sujie Mogane, Nabeela 
Nazir-Ahmed, Karen Regan, Dinesh Saralaya (PI), Kimberley 
Walker, Laura Walker, Helen Wilson 
Queen’s Hospital, Burton 
Hospitals NHS Foundation 
Trust 
Ann Adams, Mosan Ashraf, Gillian Bell, Julie Birch, Elizabeth 
Kemp, Clare Mewies, Uttam Nanda (PI), Mandy Oakley, Alison 
Tilley, Louise Wilcox, Clare Williams 
Calderdale Royal Hospital, 
Huddersfield Royal Infirmary, 
Calderdale & Huddersfield 
NHS Foundation Trust 
Annika Graham, Andrew Hardy, James Harris, Alan Hart-
Thomas, Lisa Horner, Adam Mawer, Rehan Naseer (PI), Sabiha 
Ravat, Simone Ryan, Kuljinder Sandhu, Christine Turner, Tracy 
Wood 
University Hospital of North 
Durham 
Sarah Clark, Peter Cook (PI), Andrea Kay, Richard Nendick, 
Neil Munro, Kathryn Potts, Lynsey Stephenson, Anne 
Sebakungu, Julie Temple 
Lister Hospital, (East and 
North Herts) 
Hannah Beadle, Kelly Chan, Katie Chong, Angela Cook, Carina 
Cruz, Sura Dabbagh, Pippa de Sousa, Sunita Gohil, Jodie 
Graham, Alison McMillan, Victoria Oliver, Mahul Patel, Louise 
Peacock, Anita Rana, Natalie Rahim, Emma Shinn, Thida Win 
(PI) 
Victoria Hospital, Kirkcaldy Julie Aitken, Sarah Aitken, Laura Beveridge, Keith Boath, 
Rebecca Cain, Devesh Dhasmana (PI), Sabha Khan, Maria 
Simpson, Athan Tachtatzis 
137 
Freeman Hospital, Newcastle Nicholas Aitken, Angela Bailey, Marion Brooks, Jamie Brown, 
Gareth Davies, Jade Davison, Margaret Day, Anthony De Soyza 
(PI), Hazel Douglas, Maureen Foreman, Ben Hood, Rebecca 
Johnson, Gerry Jones, Karen Martin, Donna McEvoy, Yoko 
Okada, Jack Oliver, Leeanne Ratcliffe, Sarah Robertson, 
Therese Small, Graham Soulsby, Julie Stephenson, Hesther 
Wilson, Sarah Woolcock 
Glasgow Hospitals (Gartnavel, 
Glasgow Royal, Southern 
General, Victoria Infirmary, 
Western Infirmary) 
Jacqueline Anderson, Lindsey Bailey, Anne Benson, Joan 
Blevings, Christine Bucknall, Rekha Chaudhuri (PI), Brian 
Choo-Kang, Patricia Clark, Douglas Cowan, Elizabeth Douglas, 
Tracyanne Grandison, Sharon Grant, Helen Hamilton, John 
Haughney, June Innes, Jane Lafferty, Nicola Lee, Audrey Lush, 
Margaret McFadden, Kirsty McLeish, Alison Martin, Lyndsey 
Meenaghan, Karen Montgomery, Helen Mulholland, Diane 
Murray, Dominic Rimmer, Colin Rodden, Deborah Stubbings, 
Joyce Thompson, Nicola Thomson 
Castle Hill Hospital, Hull Kayleigh Arnell, William Beswick, Margaret Crookes, Michael 
Crooks, Laura Douglas, Helen Fowles, Simon Hart, Rhian 
Horne, Joseph Howard, Victoria Lowthorpe, Alyn Morice (PI), 
Jackie Mower, Zainab Rai, Susannah Thackray-Nocera, Rachel 
Thompson, Adam Wolstencroft, Sara Wynn 
Raigmore Hospital, Inverness Fiona Barrett, Jim Finlayson, Laura O’Keeffe, Debbie 
McDonald, Mary McKenzie, Lorna Murray (PI), Gordon 
Rushworth, Donna Patience 
University Hospital Wishaw Angela Brown, Craig Chalmers, Steven Marshall, Louise 
McGee, Donna Orr, Manish Patel, Fiona Ross, Andrew Smith 
(PI) 
Royal Lancaster Infirmary Mark Wilkinson (PI), Laura Booth, Jayne Craig, Jade Drew, 
Tim Gatheral, Rebecca Jeffery, Jane Ritchie, Vickie Rose, 
Andrew Taylor 
Leighton Hospital, Crewe Kelly Amor, Duncan Bailey, Christopher Brockelsby, Duncan 
Fullerton (PI), Nikki Gautam, Gareth Jones, Taya Jones, Syed 
Kazmi, Diana Lees, Emma Margerun, Julie Meir, Richard 
Miller, Andy Ritchings, Sarah Tinsley 
138 
Musgrove Park Hospital James Allen, Korinna Andrews, Simon Barnes, Oliver 
Bintcliffe, Eliza Foster, Sarah Foster, Yvonne Moul, Justin 
Pepperell (PI), Dawn Redwood, Joy Rowe, Dinesh Shrikrishna, 
Tania Wainwright 
Norfolk and Norwich 
University Hospital 
Chris Atkins, Mark Baxter, Claire Brockwell, Melissa Crofts, 
Samantha Fulcher, Gail Heally, Carla Holloway, Divya Jacob, 
Sanjana Kamath, Jalpa Kotecha, Sue Robinson, Clare Self, 
Andrew Wilson (PI) 
University Hospital of North 
Tees 
Nicola Bateman, June Battram, Helen Carey, Julia Fuller, 
Richard Harrison (PI), Claire Irish, Graham Miller (PI), Lynda 
Poole, Ben Prudon, Angela Scott-Johnson, Gillian Wallace, Bill 
Wetherill 
City Hospital, Nottingham Tim Harrison (PI), Wendy Gerrard-Tarpey, Sheila Hodgson, 
Matthew Martin, Catherine Reynolds 
Derriford Hospital, Plymouth Julie Alderton, David Derry, Sharon Freeman, Jacinta Hardman, 
Maggie Kalita, Jennie Kingdon, Mike Marner, Tracy Mynes, 
Joanne Porter, Judy Sercombe, Caroline Snelgrove, Elizabeth 
Swanson, Trudy Turner, Neil Ward (PI), Jacqueline Westcott, 
Gloria Wong, Parag Yajnik 
South Tyneside District 
Hospital  
Amy Burns, Barrie Duncan, Nadia Elkaram, Liz Fuller (PI), 
Ben Hood, Paula Madgwick, Claire McBrearty, Sinead 
McHugh, Rachel Miller, Judith Moore, Asif Shah, Mark 
Shipley, Ruth Tindle, Michael Walton 
Torbay Hospital Gabrielle de Selincourt, Lee Dobson (PI), Lesley Evans, Bianca 
Hulance, Sally Maddison, Pauline Mercer, Sarah Mills, Andrew 
Mullinger, Hannah Shiels, Melanie Stone, Natalie Taylor, 
Christine Tsang, Amanda Vian, Sarah Wright 
New Cross Hospital, 
Wolverhampton 
Richard Carter, Kay Cash, Lee Dowson (PI), Ahmed Fahim, 
Clare Hammond, Kelly Kauldhar, Baljinder Kaur, Jonathan 
Mann, Sarah Milgate, Angela Morgan, Jaynesh Patel, Elizabeth 
Radford, Gurminder Sahota, Lucy Stelfox, Trevor Thompson, 
Helen Ward 
Worcestershire Royal Hospital Sarah Deacon, Alison Durie, Monica Gauntlett, Kim 
MacDonald, Terry Martin, Hugh Morrow, Stephen O'Hickey 
(PI), Heather Perry, Zee Shaan Parvez, Ann White 
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Yeovil District Hospital Joanna Allison, Sarah Board, Clare Buckley, Sarah Debruijn, 
Dave Donaldson, Tracey Duckett, Adam Edwards, Alison 
Lewis, Tressy Pitt-Kerby, Rejendra Sinha (PI), Thikra Al 
Wattar (PI), Jodhi Wilson, Diane Wood 
York Hospital, York Teaching 
Hospital NHS Foundation 
Trust 
Andrew Atherton, Judith Bell, Claire Brookes, Poppy Cottrell, 
Cheryl Donne, Mark Elliot, Christopher Emms, Richard Evans, 
Caroline Everett, Mark R Fearnley, Monica Haritakis, Yvonne 
McGill, Heidi Redfearn, Davina Smith, Mandy Ward, 
Jacqueline Westmoreland, John White (PI), John Wightman, 
Paul Wood, Lorraine Wright 
East of England primary care 
Alconbury & Brampton 
Surgeries 
Melanie Fowler, Alyssa Lawford, Duncan Outram (PI), 
Caroline Ward 
Alexandra & Crestview 
Surgeries 
James Atkins (PI), Christina Easter, Barbara Stewart 
Andaman Surgery Jane Atkins, Mark Butt (PI), Sarah Butt, Hitesh Kumar, Sue 
Lock, Laverne Rose 
Attleborough Surgeries Sabrina Khalaque (PI), Ruth Mallinson, Lucy McLean, Paul 
Roebuck 
Beccles Medical Centre Kathleen Archer, Charlotte Hawkins (PI), Monica Kettlewell, 
Julia McLean, Sarah McLennan, Vasilica Munteanu, Charlene 
Wakefield 
Bridge Road Surgery Martin Aylward (PI), Carolyn Harper, Eleanor Schofield, 
Nicola Shea, Sue Vigus 
Bridge Street Medical Centre 
(Cambridge) 
Corinne Bakker (PI), Louise Norman 
Bridge Street Surgery (Downham 
Market) 
Clare Hambling (PI), Barbara Stewart, Megan Winterbone 
Campingland Surgery Mark Holmes (PI), Tracey Sharp, Maxine Smith, Liz Wing 
Castle Partnership Penny Atkinson, Richard Gilbert (PI), Jo Walsh 
Coltishall Medical Practice Alison Melton, Angela Norton, Rajesh Selvam, Michele Taylor, 
Neil Taylor (PI) 
Comberton and Eversden 
Surgeries 
Will Bailey, Janice Mills, Ian Parker (PI) 
Cutlers Hill Surgery Claire Craik (PI), Sarah Caplin, Daniel Treen 
Davenport House Jenny Hughes, Anthea Doran, Chas Thenuwara (PI) 
De Parys Medical Centre Carolyn Boyd, John Goudling (PI), Linda Lomax 
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East Norfolk Medical Practice Liam Steven (PI), Lisa Matcalfe, Maxine Burton 
Elizabeth Courtauld Surgery Ali Alsawaf (PI), Sue Cole, Daniela Kreis-Alsayed, Phillipa 
Oval, David Sneddon, Jeanette Williams 
Gorleston Medical Centre Ann Abbott, Dawn Barnham, Lorraine Farrier, Sunder Gopaul 
(PI) 
Greyfriars Medical Centre Patrick Frew (PI), Katrina Kelly, Krystal Lewis-McDonald, 
Tara Maher, Stephanie Timberlake 
Harvey Group Practice Carolyn Downs, Matt Parfitt (PI) 
Holt Medical Practice Peter Franklin (PI), Annie Hughff 
Hoveton & Wroxham Medical 
Centre 
Carsten Dernedde (PI), Caroline Mansfield, Chris Wright 
Linton Health Centre Hayley Haworth, Laurence Kemp (PI), Claire Wade, Donna 
Watson, Fiona Wharton 
Long Stratton Medical 
Partnership 
Caroline Dear, Carol Gubby, Helen Mingaye, Mini Nelson (PI) 
Ludham & Stalham Green 
Surgeries 
Jessica Bane, Elizabeth Christie (PI), Tracey Edwards, Emma 
Lambon, Jennifer Liu 
Mount Farm Surgery Claire Giles (PI), Brian Ainsworth, Julie Friend, Peter Knights 
Mundesley Medical Centre Daryl Freeman (PI), Holly Fulcher, Carol Manson, India Mills, 
Jessica Payne 
Nuffield Road Medical Centre Tom Alderson (PI), Janette Bone, Jacqueline Day, Helen Jung, 
Sally Kaemer 
Orchard Surgery, Dereham Dawn Boyce, Stacey Hawkins, Jillian Pewtress, Vanaja Santosh 
(PI), Barbara Stewart 
Peninsula Practice Lindsey Crockett (PI), Linda Deabill, Ruth Osborne 
Portmill Surgery Jehad Aldegather (PI),  Lynne Shoebottom 
Rosedale Surgery Amanda Ayers, Jodie Button, Maarten Derks (PI) 
Roundwell Medical Centre Chaminda Dooldeniya (PI), Tess Cantan, Denise Steward, Kirsti 
Withington 
Salisbury House Surgery Yasar Khan (PI), Mehar Singh (PI), Carol Bunting, Helen Ingle, 
Sally Szuca, Paul Vogwell (PI) 
Sheringham Medical Practice Pauline Craske, Susan Lees, Ian Smith (PI), Julie Sterry, Nikita 
Williamson 
Spinney Surgery Gill Avery, Reyny Rahman (PI), Debra Wheatley 
St Stephens Gate Medical 
Practice 
Frances Scouller (PI), Matthew Butler, Loraine Leggett 
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St Johns Surgery (Terrington) Susan Atcheson (PI), Barbara Bruce, Jane Coston, Charlotte 
Walford 
Staithe Surgery Diana Hood (PI), Kate Bywater, Sylvia Jackson, Sue Perrott, 
Sally Ross-Benham 
The Over Surgery Lesley Bowring, Judith Davis (PI), Andrew Kennedy 
Trinity & Bowthorpe Medical 
Practice 
Gillian Denman, Xanthe Dunthorne, Helene Simper (PI) 
Vida Healthcare Ademola Adesanoya (PI), Felicity Bowerman, Audrey Brown, 
Janeen Henshaw, Lata Motwani, Amanda Pearson 
Wells Health Centre Gordon McAnsh (PI), Lisa Palmer, Jan Wright 
Wellside Surgery Jacqueline Martindale, Ian Williams (PI), Anita Willis 
Woodhall Farm Medical 
Centre 
David Adams, Winnie Chiu, Khalid Mirza (PI), Lucy Peppiatt 
Woolpit Health Centre Jenny Johnson, Karen Norcott, Ruth Osborne, William Smith, 
Richard West (PI) 
Wymondham Medical Centre Louanne Gault, Karen Hamer, Shelina Rajan, Stephen Thurston 
(PI) 
York Street Medical Practice Alistair Brown (PI), Helen Radlett, Stuart Thorpe 
North of England Primary Care 
Beacon View Medical Centre Vinod Kumar (PI), Alison McElvoy 
Beaumont Park Medical 
Group 
Jill Ducker, Angela McMenzie (PI) 
Belford Medical Practice Maureen Birdsall, Sebastian Moss (PI) 
Bellingham Practice Jill Ducker, Andrew Sewart (PI) 
Benfield Park Medical Centre Valerie Walker, Sian Williams (PI) 
Burn Brae Medical Group Anthea Adamson, Louise Chicken, Eleanor Gallagher, Nick 
Hargreaves (PI), Alison McClintock 
Castlegate & Derwent Surgery Jeanette Dixon, Mary Philipsz (PI), Barbara Robinson, Jackie 
Smith 
Corbridge Medical Group Janet Drinkwater, Jill Ducker, Sally Parkin (PI), Neil Stanley, 
Anna Townsend-Rose 
Elvaston Road Surgery Barbara Bailey, Stephen Hilton, Rachel Nixon 
Fell Cottage Surgery  Rachel Nixon, Cheryl Rigg, Katherine Woodcock (PI) 
Grove Medical Group Alison Carlyle, Guy Clement (PI), Jill Ducker, Ann Hately, 
Cheryl Rigg, Hannah Smith 
142 
Guidepost Medical Group Catherine Bromham (PI), Geraldine Richelle, Sue Rowlands, 
Geert Van Zon (PI) 
Haltwhistle Medical Group Sarah Davies (PI), Sarah Speed 
Haydon Bridge & Allendale 
Medical Practice 
Mary Douthwaite, Elaine Fiori, Emily Hadaway (PI), Mary 
Henderson 
Hetton Group Practice Julia Cook (PI), Jill Ducker, Judith Kirk, Rachel Nixon 
Humshaugh & Wark Medical 
Group 
Christine Counsell, Katherine Dixon, Louise Shearer, Hayley 
Wright (PI) 
Marine Avenue Surgery Ann Grieves, Justine Norman (PI) 
Maryport Health Services Ross Anderson (PI), Janice Cox, Jeanette Dixon, Janet Rasburn 
Priory Medical Group Andrew Duggan (PI), Jill Ducker, Tracey Pearson, Christine 
White 
Prudhoe Medical Group Michelle Orton, Margaret Ross, Helen Thornton (PI) 
Seaton Park Medical Group Aileen Rose, Emily Watson (PI) 
Sele Medical Practice Jill Ducker, Ben Frankel (PI), Julie Smith 
Temple Sowerby Medical 
Practice 
Jeanette Dixon, Helen Jervis (PI) 
The Village Surgery Jill Ducker, Simon Hartland, Linda Thompson (PI) 
Waterloo Medical Group Marie Imlach (PI), Elaine Sansom 
West Farm Surgery Christine Davidson, Kate Grisaffi (PI), Sally Morrison 
South West England primary care 
Barton Surgery Elizabeth Alborough (PI), Paula Brison, Ruth Christophers 
Bovey Tracey & Chudleigh 
Practice 
Carol Gubby, Rachael Minty, Daniel Thomas, Ben Ward (PI) 
Brunel Medical Practice Pamela Grills, Rayindra Naidoo, Lisa Van Kuyk, Richard Veale 
(PI) 
Claremont Medical Practice Kevin Douglas (PI), Beth Hawkes, Sonya McGill, Lucinda 
Ralph 
Coleridge Medical Centre Nigel De-Sousa (PI), Jane Stewart, Stacy Wilson 
Helston Medical Centre Gary Crocker, Linda Davies (PI), Linda Quinn 
Ide Lane Surgery Jackie Barrett, Jackie Crossman, Stephen Vercoe (PI), Rachel 
Winder 
Petroc Group Practice Philippa Haywood, Nicholas Jacobsen (PI), Alison Murton, 
Rebecca Nicholls, Martin Priest, Kirsty Rogers 
Richmond House Surgery Karen Bates (PI), Mary Guest, Sara McNamara, Kathy 
Polverino, Claire Southgate 
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Rolle Medical Partnership Merilyn Green, Barbara Welch, William Willcock (PI) 
Westlake Surgery Jo Jones, Calli Smith, Lindsay Smith (PI) 
Wessex primary care 
Friarsgate Practice Tara Clark, Stephen Fowler (PI), Claire Hallett, Elaine 
Spellerberg 
Park and St Francis Surgery Amy Glanville, Natasha Campbell, Samuel Glanville, Jo King, 
Mark Rickenbach (PI), Clare Sharland 
Swanage Medical Centre Claire Hombersley (PI), Natasha Ritchie, Sara Ward 
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APPENDIX 1: Rationale for the low-dose theophylline strategy 
 
Population theophylline pharmacokinetic studies, during the 1970s and 80s have demonstrated 
that disease status, weight and smoking decreases the half life of theophylline and increases its 
clearance.57-62 It has been shown that COPD patients who do not smoke have a reduced 
clearance compared to healthy volunteers.60 Based on these data and our publications63-66 an 
average population clearance value of theophylline in a non smoker is 40ml/hr/kg which is 
reduced to 32ml/hr/kg in a subject with COPD and by a further 20% if they have other related 
disease (eg severe congestive heart failure). This corresponds to the fast, normal and slow 
categories of plasma theophylline pharmacokinetic modelling, for COPD patients, provided in 
the table below. Smoking induces the theophylline clearance by approximately 60% which 
gradually returns to normal levels when they stop smoking. Other relevant population 
pharmacokinetic data, that is useful for loading doses, is a volume of distribution of 0.5L/kg.57-
66 
 
The use of actual weight or ideal body weight has been shown to have an effect on the clearance 
of theophylline in young adults that smoke. If a patient is obese they may be given a high dose 
when their actual weight is used. It is good practice to assume this occurs in all patients and 
thus use ideal body weight. Ideal body weight (IBW) can be calculated using the following 
equations.67 
 
IBWfemale =45 + 0.9(height in cms-152) Kg 
IBWmale = 50 + 0.9(height in cms-152) Kg 
 
The ideal body weight is used unless the actual weight is lower than the ideal body weight. 
For oral theophylline dosing the pharmacokinetic model is 
 
 
Where Css is the steady state theophylline concentration, F is the bioavailability of theophylline 
(F=1 for theophylline preparations), D is the dose, Cl is the clearance and  is the dosage 
interval (either 12 or 24 hours). Using this model and the population theophylline clearance 
values for COPD patients, in smokers and non smokers, described above then predicted Css 
are a follows.  



Cl
DF
Css

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Table 33 The results of pharmacokinetic modelling for theophylline doses 200mg bd and od 
for current smoking/not- current smoking subjects by weight and theophylline clearance. The 
plasma theophylline concentrations using the dosing schedule are shaded. (Prof Henry 
Chrystyn, personal communication) 
 
  Theophylline 200mg bd  Theophylline 200mg od 
  Steady state (Css) plasma theophylline concentration (mg/l) 
 Ideal body 
weight 
Subject theophylline clearance  Subject theophylline clearance 
 (kg) Slow Normal Fast  Slow Normal Fast 
Not current  40.1-50 17.4 13.0 10.4  8.7 6.5 5.2 
Smoker 50.1-60 13.9 10.4 8.3  6.9 5.2 4.2 
 60.1-70 11.6 8.7 6.9  5.8 4.3 3.5 
 70.1-80 9.9 7.4 6.0  5.0 3.7 3.0 
 80.1-90 8.7 6.5 5.2  4.3 3.3 2.6 
 90.1-100 7.7 5.8 4.6  3.9 2.9 2.3 
 100.1-110 6.9 5.2 4.2  3.5 2.6 2.1 
 110.1-120 6.3 4.7 3.8  3.2 2.4 1.9 
 >120 5.8 4.3 3.5  2.9 2.2 1.7 
         
Current 40.1-50 10.9 8.1 6.5  5.4 4.1 3.3 
Smoker 50.1-60 8.7 6.5 5.2  4.3 3.3 2.6 
 60.1-70 7.2 5.4 4.3  3.6 2.7 2.2 
 70.1-80 6.2 4.7 3.7  3.1 2.3 1.9 
 80.1-90 5.4 4.1 3.3  2.7 2.0 1.6 
 90.1-100 4.8 3.6 2.9  2.4 1.8 1.4 
 100.1-110 4.3 3.3 2.6  2.2 1.5 1.2 
 110.1-120 3.9 3.0 2.4  2.0 1.5 1.2 
 >120 3.6 2.7 2.2  1.8 1.4 1.1 
 
Confidence that low-dose theophylline can be achieved using the above dosing strategy is 
provided from a detailed analysis of a COPD study that measured theophylline concentrations 
for 3 different theophylline dosing regimens.63 In 33 COPD patients (mean weight (SD) weight 
of 64.6(14.3) Kg and age of 61.2(5.8) years) we found that the mean (SD) plasma theophylline 
concentration at steady state when they received a mean of 252 (87) mg bd was 6.3 (2.1). This 
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represents a clearance value of 51.6 ml/hr/kg. When their dose was increased to 430mg bd and 
then to 597(153) bd their mean (SD) steady state plasma theophylline concentrations were 
12.1(1.9) and 18.3(3.0) mg/L. This represents clearance values of 45.8ml/hr/kg and 
42.1ml/hrkg. This will include smokers and non smokers (numbers of each not recorded) and 
the latter clearance value is similar to the 40ml/hr/kg used in the population pharmacokinetics 
modelling for the ‘fast’ category. Our other publications (n=83 patients);64 (n=15)65 patients) 
on plasma theophylline highlight our confidence of using low-dose theophylline in TWICS.  
 
In the clinical situation whereby a clinician wishes to use intravenous aminophylline to treat a 
patient, participating in TWICS, with an acute exacerbation of COPD, the British National 
Formulary recommends a loading dose of intravenous aminophylline of 5mg/kg (typically 
250mg), this is usually omitted if the patient is already taking theophylline, this is then followed 
by an intravenous infusion of aminophylline of 0.5mg/kg.87 It is recommended that plasma 
theophylline be measured after 24 hours to direct the rate of further dosing. The 
pharmacokinetic model for a loading dose is 
 
 
Where Co is the concentration immediately after the slow intravenous bolus dose of 
aminophylline, F is the bioavailability (F=0.8 for aminophylline) and V is the volume of 
distribution. A loading dose of 5mg/kg would provide a Co of 
 
 
Since the predicted Css shown in the table above ranges from 2.2 to 8.7 mg/L then the 
maximum theophylline comsentration would be 16.7 mg/L.  Alternatively, a loading dose of 
250mg aminophylline could be given rather than a dose based on weight. A loading dose of 
250mg aminophylline in COPD patients weighing 40-100kg would provide a Co ranging from 
10 to 4 mg/L. There is a linear relationship between Css and weight. Similarly if the loading 
dose was 500mg aminophylline then the predicted Css would be double that for the 250mg 
dose. 
 
For an aminophylline infusion of 0.5mg/kg/hr.87 Based on a clearance of 40ml/hr/kg and the 
V
DF
Co


8mg/L
L/kg 0.5
5mg/kg0.8
Co



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following pharmacokinetic model 
. 
[Where Css is the steady state theophylline concentration, F is the bioavailability of 
theophylline (F=0.8 for aminophylline preparations), D is the dose, Cl is the clearance (using 
a clearance of 40ml/hr/Kg) and  is the dosage interval (1 hour for an intravenous infusion)] 
the predicted Css would be: 
 
. 
 
Note that the predicted Css is irrespective of weight (see above equation). The predicted Css 
in a COPD non smoker classified with a slow, normal and fast theophylline clearance given an 
infusion of 0.5 mg/hr/kg would be 10. 12.5 and 16.7 mg/L. In a smoker the respective predicted 
Css be 6.3, 7.8 and 10.4 mg/L.  
 
Importantly for the TWICS trial, it will be safe for participants to receive a 5mg/kg loading 
infusion of aminophylline followed by a 0.5mg/kg/hr infusion as the plasma concentration will 
not exceed the target 10-20mg/l range required for conventional theophylline dosing. 
 
 
  



Cl
DF
Css

10mg/L
1g0.04L/hr/k
5mg/hr/kg.00.8
Css




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APPENDIX 2: Validation of patient reported exacerbations 
Initially, we planned to validate the total number of COPD exacerbations for approximately 
20% of participants by examination of GP records.   
 
At the Trial Steering Committee meeting of 20 March 2017 the validation exercise 
comparing the number of exacerbations as recorded in GP records and reported by the 
participant was discussed. At that time, the focus of this validation had been in two of the 
largest sites: Aberdeen and Aintree.   The validation was done by requesting a care/encounter 
summary from the GP and comparing this against patient report.  In Aberdeen, 43 records 
had been checked; and in 37 there was complete agreement between patient report and GP 
report.  In Aintree, 24 records had been checked and in 16 there was complete agreement 
between patient report and GP report.   Therefore, 4% of participants had undergone 
validation, and there was approximately 80% concordance.  Concerns were raised that there 
is no ‘gold standard’ for the reporting of exacerbations, and that current GP records may not 
be as reliable a source of exacerbation data as in the past, given that patients have rescue 
packs at home and can access help for their exacerbations through many non-GP sources, e.g. 
pharmacies, emergency and walk-in centres, Accident and Emergency Departments etc. The 
published evidence is that patients are able to reliably report the number of exacerbations 
experienced in the previous year,112 furthermore the patient representatives for TWICS have 
been adamant that it is fairly straightforward to remember the number of exacerbations over 
this time-period. It was also noted that the primary outcome of this study is participant 
reported exacerbations and it is this outcome that drives demand for NHS services.   The 
Trial Steering Committee therefore recommended that we completed the validation exercise 
for the participants we had data on; but that the validation exercise did not need to be 
extended beyond these two sites or to include further participants.   
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APPENDIX 3: Breaches 
Site 
affected 
Description of breach Assessment 
Site 36 The site consented a patient into the study on 28 April 2014 before 
the site agreement had been signed by all parties. The study processes 
in place prevented the site from randomising the patient on the live 
randomisation system and also meant that a drug pack could not be 
dispensed.  
Non-serious 
Site 18 Participant had rescue medication, including erythromycin (one of 
the drugs that can increase serum theophylline) and in response to an 
exacerbation, the participant started to take the rescue medication 
without stopping her study medication. The patient came to no harm, 
and did not suffer any adverse effects.  
Non-serious 
Site 11 The CI raised concerns about the monitoring process following a 
routine study monitoring visit carried out by R&D monitors at the 
site. For two patients, the monitors recorded amber findings relating 
to the recording of co-morbities and concomitant medication the 
case-report form, and for one patient indicated that there was 
contraindicated medication. However, the data recorded in both case 
report forms was accurate and both patients were eligible. The breach 
related to the monitors incorrectly noting amber findings and making 
the research nurses modify the case report form by entering incorrect 
information. 
Non-serious 
Site 12 Participant was admitted to hospital. Prior to the admission the 
participant had been prescribed clarithromycin (one of the drugs that 
can increase serum theophylline). His study medication was stopped 
by the hospital pharmacist. The symptoms experienced by the 
participant (gastro oesophageal reflux) may have resulted from 
clarithromycin per se, and/or an interaction between clarithromycin 
and theophylline. Gastro oesophageal reflux is a side effect of both 
clarithromycin and theophylline. 
Non-serious 
163 
Site 
affected 
Description of breach Assessment 
Site 11 The third party distributor identified that they had despatched a 
shipment to a participant which contained drug pack numbers 40167 
(correctly) and 40166 (in error) on 5 November 2014. The participant 
was contacted on 29 January 2015 and indicated that he had started 
using kit number 40167 and that he had not opened kit number 
40166. He returned kit number 40166 to the research nurse later that 
day and it was destroyed. The participant was resupplied with an 
appropriate box of medication.  
Non-serious 
Site 27  At the point of randomisation (20 April 2014) the participant had 
been randomised as a smoker (rather than as an ex-smoker) and was 
allocated and received a dose of twice daily study medication (he 
should have received a once daily dose). On 5 November 2014, the 
patient was diagnosed with Atrial Fibrillation. No palpitations were 
noted. Atrial tachycardias are a known side effect of theophylline.  
The patient was unblinded in order to manage appropriately. The 
atrial fibrillation experienced by the patient may have been caused by 
the theophylline. The participant was seen on 6 January 2015 for a 
routine appointment, and his pulse was noted to be regular, ie 
spontaneously reverted to sinus rhythm. 
Serious 
Site 12 
 
Noted at 12 month follow-up the participant had been on Tildiem LA 
(300mg od) since recruitment into the study (26 February 2014). 
Tildiem LA is a form of diltiazem (diltiazem is one of the drugs listed 
into the trial protocol as known to interact with theophylline). 
Although this medication had been recorded on the baseline case 
report form, the patient was assessed as being eligible for the study.  
The patient was well throughout the study. No adverse events were 
noted. 
Non-serious 
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Site 
affected 
Description of breach Assessment 
Site 11 
 
During the 12 month follow-up appointment (19 May 2015), the 
participant mentioned that the community pharmacist had been 
supplying Uniphyllin 200mg (theophylline) in his dosette box. After 
taking the Uniphyllin included in the dosette box for 2-3 days, the 
participant realised that he may be taking theophylline as both the 
TWICS study medication and as prescribed medication. He therefore 
ceased taking the TWICS study medication.  The participant has 
noted no adverse effects as a result of this. 
Non-serious 
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Site 
affected 
Description of breach Assessment 
Site 78 Participant was randomised to twice daily study medication - dosing 
instruction “Take ONE tablet every morning and ONE tablet every 
evening” but took two tablets each morning and two each evening. 
After 10 days of taking the study medication, the participant noted he 
was experiencing nausea, tremors and disturbed sleep (which in part 
may have been anxiety related because of a forthcoming bypass 
operation); his dose was reduced by the study team to one tablet per 
day and his symptoms settled.  At the six month follow-up 
appointment, the participant noted that they were still taking “one 
tablet” but as they were feeling well, wished to start taking two 
tablets again. The study team agreed that he could increase his dose 
to two tablets per day (the recommended “low-dose” dose for a 
smoker of his height and weight.  He did this for three days and 
symptoms of nausea/sickness returned. The participant therefore 
reduced his dose to “one tablet” and the symptoms settled. In 
subsequent discussion with the participant it became clear that they 
had misinterpreted the initial instruction on medication use as two 
tablets twice day, and had been taking this dose rather than one tablet 
twice a day. For approximately 10 days between 3 December 2014 
and 17 December 2014, he had therefore been taking a dose in the 
normal therapeutic range (400mg twice daily) rather than a low-dose 
(200mg twice daily). For the period between 17 December 2014 and 
10 June 2015 he had been taking one tablet twice a day; this was the 
appropriate “low-dose” used within the study. For a further three 
days from 10 June 2015 the participant again misinterpreted the 
instruction on the medication bottle and took two tablets twice day (ie 
the normal therapeutic range rather than a low-dose).  
Non serious 
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Site 
affected 
Description of breach Assessment 
Site 12 Participant was prescribed Elleste Duet (which is an oestrogen; 
oestrogens may raise theophylline levels to within the normal 
therapeutic range rather than a low-dose) by her GP between being 
recruited into the study and her 6 month follow-up. At the six month 
follow-up (18 June 2015), she was advised to cease taking study 
medication. The interaction between Elleste Duet and theophylline is 
such that the serum levels of theophylline may be raised into the 
normal therapeutic range, and not to toxic levels. Thus any 
interaction does NOT raise safety concerns. 
Non serious 
Across 
sites 
Following review of emergency hospital admissions captured at 
follow-up, we identified a number of admissions which should have 
been captured as SAEs. None related to study medication. 
Non serious 
Site 12 The participant failed to attend for 12 month follow-up. Follow-up 
data was sought from his GP, and during this data collection exercise, 
it was noted that the participant had been prescribed Uniphyllin on 
repeat prescription since 8 May 2012. He had not disclosed this at 
recruitment or 6 month follow-up, or during any telephone calls. The 
prescription he brought to the recruitment appointment did not 
include the Uniphyllin. No adverse events were noted during follow-
up (last contact with participant was at the 46 week call). 
Non serious 
Site 12 Late reporting of an SAE in this participant (strangulated small bowel 
secondary to hernia, not related to study medication), who had ceased 
study medication prior to the event.  
Non serious 
Site 125 Participant was randomised on 12 January 2016 (200mg od); on 26 
January it was noted that he was already taking Aminophylline 
(225mg bd). Patient had taken study medication as well as routine 
Aminophylline for 8 days. The patient did not experience any adverse 
reactions. The GP has confirmed that the Aminophylline (225mg bd) 
plus study medication (if active; 200mg od) would not have taken the 
participant over the maximum daily dose 
Non serious 
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Site 
affected 
Description of breach Assessment 
Site 12 The trial office prepared a waybill for the dispatch of study 
medication with the house number transposed (and so the study 
medication was delivered to house number 35 rather than house 
number 53). The participant was resupplied, and the incorrect 
delivery was retrieved from house number 35.  
Non-serious 
Site 78 The third party distributor picked the wrong kit and this was 
dispatched to the participant. The wrong kit was retrieved from the 
participant and she was resupplied with the correct kit. 
Non-serious 
Site 14 Participant was recruited into the TWICS study whilst participating 
in another drug study (in breach of the TWICS eligibility criteria). 
There was no documentation in the medical notes in relation to the 
other study and the patient did not mention it at recruitment. The 
patient came to no harm. 
Non-serious 
Site 145 Participant randomised on 23 June 2016 to once daily study 
medication, and was allocated an appropriate labelled bottle. The 
participant took study medication twice daily for approximately 7 
days after commencing medication (this would have brought her into 
the normal therapeutic range for theophylline rather than a low-dose). 
The participant came to no harm (she noted some initial constipation 
which resolved). 
Non-serious 
Site 122 Participant was randomised to od study medication. The bottle was 
correctly labelled, but a dispensing label was added at the time the 
medication was dispensed which indicated a two a day dosing 
regimen. The error was noted and corrected. The participant took 
twice daily study medication for approximately 10 days (this would 
have brought him into the normal therapeutic range for theophylline 
rather than a low-dose) and came to no harm. 
Non-serious 
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Site 
affected 
Description of breach Assessment 
Site 159 In an attempt to prevent medication being prescribed that may 
interact with theophylline, the practice added theophylline to the 
repeat prescription as a study drug. The pharmacist dispensed liquid 
theophylline as part of the repeat prescription, and for a period of 7 
days, the participant took a dose of liquid theophylline three times per 
day and also took their study medication three times per day.  This 
would have brought the participant into the normal therapeutic range 
for theophylline rather than a low-dose. The participant came to no 
harm.  
Non serious 
Site 141 The third party distributor picked the wrong kit and this was 
dispatched to the participant. The wrong kit was retrieved from the 
participant and she was resupplied with the correct kit. 
Non-serious 
Site 115 Participant was recruited into the study in October 2015. During data 
checking in January 2017 it was noted that the participant was 
already taking Phyllocontin. The participant took trial medication for 
a full 12 months, and no adverse events were noted. Subsequent data 
checking identified five other participants who had been recruited 
whilst on a medication that may interact with theophylline: 
Site 32 – febuxostat; patient took study medication for 12 months, 
non-serious GI symptoms noted (abdominal pain, 2 x episodes of 
reflux) 
Site 80 – estradiol valerate; patient took study medication for 2 weeks 
and experienced non-serious side effects likely to be related to 
theophylline (nausea, headache, dizziness) 
Site 102 – roflumilast; participant took study medication for 12 
months, no adverse reactions noted during 12 month follow-up 
Site 131 – elleste duet; participant continues of study medication (due 
to complete 12 month follow-up); no adverse reactions noted  
Site 131 – estradiol; participant continues of study medication (due to 
complete 12 month follow-up); no adverse reactions noted  
Non-serious 
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APPENDIX 4: recruitment, by site 
  
Total number of  
participants recruited 
Secondary care sites (n=33) 1101 
Aberdeen Royal Infirmary 212 
Aintree University Hospital NHS Foundation Trust 127 
Belfast City Hospital 6 
Queen Elizabeth Hospital Birmingham 54 
Blackpool Victoria Hospital 57 
Bradford Royal Infirmary  9 
Queen’s Hospital, Burton Hospitals NHS Foundation Trust 4 
Calderdale Royal Hospital, Huddersfield Royal Infirmary, 
Calderdale & Huddersfield NHS Foundation Trust 
4 
University Hospital of North Durham 9 
Lister Hospital, East and North Hertfordshire NHS Trust 20 
Victoria Hospital, Kirkcaldy 29 
Freeman Hospital, Newcastle 45 
Glasgow Hospitals (Gartnavel, Glasgow Royal, Southern 
General, Victoria Infirmary, Western Infirmary)  
115 
Castle Hill Hospital, Hull 114 
Raigmore Hospital, Inverness 31 
University Hospital Wishaw 12 
Royal Lancaster Infirmary 19 
Leighton Hospital, Crewe 13 
Musgrove Park Hospital 6 
Norfolk and Norwich University Hospital 80 
University Hospital of North Tees 6 
City Hospital, Nottingham 11 
Derriford Hospital, Plymouth 4 
South Tyneside District Hospital  44 
Torbay Hospital 12 
New Cross Hospital, Wolverhampton 33 
Worcestershire Royal Hospital 11 
Yeovil District Hospital 8 
York Hospital, York Teaching Hospital NHS Foundation Trust 6 
East of England primary care (n=48) 242 
Alconbury and Brampton Surgeries 6 
Alexandra and Crestview Surgeries 5 
Andaman Surgery 7 
Attleborough Surgeries 7 
Beccles Medical Centre 7 
Bridge Road Surgery 4 
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Total number of  
participants recruited 
Bridge Street Medical Centre, Cambridge 2 
Bridge Street Surgery, Downham Market 8 
Campingland Surgery 2 
Castle Partnership 8 
Coltishall Medical Practice 4 
Comberton and Eversden Surgeries 3 
Cutlers Hill Surgery 2 
Davenport House 3 
De Parys Medical Centre 5 
East Norfolk Medical Practice 1 
Elizabeth Courtauld Surgery 1 
Gorleston Medical Centre 3 
Greyfriars Medical Centre 6 
Harvey Group Practice 6 
Holt Medical Practice 2 
Hoveton and Wroxham Medical Centre 6 
Linton Health Centre 5 
Long Stratton Medical Partnership 4 
Ludham & Stalham Green Surgeries 12 
Mount Farm Surgery 3 
Mundesley Medical Centre 14 
Nuffield Road Medical Centre 4 
Orchard Surgery, Dereham 3 
Peninsula Practice 6 
Portmill Surgery 4 
Rosedale Surgery 3 
Roundwell Medical Centre 5 
Salisbury House Surgery 3 
Sheringham Medical Practice 5 
Spinney Surgery 4 
St Stephens Gate Medical Practice 12 
St.Johns Surgery, Terrington 5 
Staithe Surgery 4 
The Over Surgery 1 
Trinity and Bowthorpe Medical Practice 2 
Vida Healthcare 11 
Wells Health Centre 3 
Wellside Surgery 3 
Woodhall Farm Medical Centre 3 
Woolpit Health Centre 19 
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Total number of  
participants recruited 
Wymondham Medical Practice 1 
York Street Medical Practice 5 
North of England primary care (n=26) 131 
Beacon View Medical Centre 8 
Beaumont Park Medical Group 4 
Belford Medical Practice 8 
Bellingham Practice  1 
Benfield Park Medical Centre 6 
Burn Brae Medical Group 1 
Castlegate & Derwent Surgery 29 
Corbridge Medical Group 6 
Elvaston Road Surgery 1 
Fell Cottage Surgery 2 
Grove Medical Group 1 
Guidepost Medical Group 7 
Haltwhistle Medical Group 2 
Haydon and Allendale Medical Practice 1 
Hetton Group Practice 4 
Humshaugh and Wark Medical Group 3 
Marine Avenue Surgery 2 
Maryport Health Services 9 
Priory Medical Group 2 
Prudhoe Medical Group 4 
Seaton Park Medical Group 2 
Sele Medical Group 6 
Temple Sowerby Medical Group 5 
The Village Surgery 4 
Waterloo Medical Group 11 
West Farm Surgery 2 
South West England primary care (n=11) 95 
Barton Surgery 6 
Bovey Tracey and Chudleigh Practice 9 
Brunel Medical Practice 20 
Claremont Medical Practice 4 
Coleridge Medical Centre 3 
Helston Medical Centre 2 
Ide Lane Surgery 2 
Petroc Group Practice 11 
Richmond House Surgery 5 
Rolle Medical Partnership 4 
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Total number of  
participants recruited 
Westlake Surgery 29 
Wessex primary care (n=3) 9 
Friarsgate Practice 1 
Park and St Francis Surgery 1 
Swanage Medical Centre 7 
Total recruitment 1578 
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APPENDIX 5: Supplementary tables 
Table 34: Baseline sociodemographic characteristics by location of recruitment 
 Primary care (n = 917) Secondary care (N=619) p-value 
Sex (N) 917   619   0.701 
  Male (n, %)  498 54.3  330 53.3  
  Female (n, %)  419 45.7  289 46.7  
Age (N, Mean, SD) 917 68.9 8.2 619 67.7 8.5 0.006 
Smoking status 917   619   <0.001 
  Current smoker (N, n, %)  322 35.1  164 26.5  
  Ex-smoker (N, n, %)  595 64.9  455 73.5  
Pack years (N, Mean, SD) 910 46.1 29.5 619 48.4 27.1 0.113 
BMI (N, Mean, SD) 917 27.4 6.1 619 27.0 6.1 0.284 
BMI group 917   619   0.463 
  Underweight (N, n, %)  41 4.5  29 4.7  
  Normal (N, n, %)  306 33.4  214 34.6  
  Overweight (N, n, %)  296 32.3  214 36.6  
  Obese (N, n, %)  274 29.9  162 26.2  
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Table 34 (continued): Baseline clinical characteristics by location of recruitment 
 Primary care Secondary care p-value 
Exacerbations in the last 12 months (N, mean, SD) 908 3.35 1.8 619 3.92 2.5 <0.001 
Exacerbations requiring hospitalisation in the last 12 months 
(N, mean, SD) 907 0.22 0.6 619 0.61 1.1 
  
<0.001 
GOLD 2011 category  901   615   0.006 
  C- ≥2 exacerbations in last year, mMRC 0-1 and CAT<10  
(N, n, %)  60 6.7  21 3.4 
 
  D ≥2 exacerbations in last year, mMRC ≥2and CAT≥10  
(N, n, %)  841 93.3  594 96.6 
 
FEV1 % predicted (N, mean, SD)  907 54.5 19.6 619 47.7 19.9 <0.001 
FEV1 % predicted category  907   619   <0.001 
  80+% [GOLD mild] (N, n, %)  100 11.0  40 6.5  
  50-79.9% [GOLD moderate] (N, n, %)  399 44.0  207 33.4  
  30-49.9% [GOLD severe] (N, n, %)  320 35.3  255 41.2  
  0-29.9% [GOLD very severe] (N, n, %)  88 9.7  117 18.9  
FVC % predicted (N, mean, SD)  904 86.4 23.3 619 83.7 22.1 0.022 
FEV1/FVC ratio (N, mean, SD) 904 50.8 14.2 619 45.8 20.4 <0.001 
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Table 34 (continued): Baseline clinical characteristics by location of recruitment 
 Primary care Secondary care p-value 
Current treatment for COPD        
Inhaled Corticosteroid  917   619   0.001 
  ICS only (N, n, %)  26 2.8  5 0.8  
  ICS LABA (N, n, %)  176 19.2  84 13.6  
  ICS LAMA (N, n, %)  12 1.3  10 1.6  
  ICS LABA/LAMA (N, n, %)  703 76.7  520 84.0  
Oral mucolytic use (N, n, %) 905 162 17.9 619 222 35.9 <0.001 
Long-term antibiotic use (N, n, %) 905 34 3.8 619 62 10.0 <0.001 
Co-morbidities        
  Asthma (N, n, %) 905 186 20.6 618 93 15.1 0.006 
  Bronchiectasis (N, n, %) 905 22 2.4 617 43 7.0 <0.001 
  Ischaemic Heart Disease (N, n, %) 903 107 11.9 618 97 15.7 0.031 
  Hypertension (N, n, %) 905 351 38.8 618 231 37.4 0.579 
  Diabetes Mellitus (N, n, %) 905 102 11.3 618 72 11.7 0.819 
  Osteoporosis (N, n, %) 905 99 10.9 318 96 15.5 0.008 
  Anxiety/depression treated in last 5 years (N, n, %) 905 231 25.5 618 195 31.6 0.010 
  Cerebrovascular event (N, n, %) 905 58 6.4 619 45 7.3 0.511 
BMI Body Mass Index, FEV1 Forced expiratory volume in 1 second; FVC Forced vital capacity; GOLD Global Initiative for Chronic Obstructive Lung 
Disease, ICS Inhaled corticosteroid; IQR interquartile range, LABA Long acting β2 agonist; LAMA Long-acting muscarinic antagonists, SD standard 
deviation 
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Table 34: Baseline patient reported symptoms and quality of life by location of recruitment  
 Primary care Secondary care p-value 
Degree of breathlessness (mMRC dyspnoea)  907   617   <0.001 
Not troubled by breathlessness except on strenuous exercise (N, n, %)  65 7.2  20 3.2  
Short of breath when hurrying or walking up a slight hill (N, n, %)  286 31.5  143 23.2  
Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own pace (N, n, 
%) 
 267 29.4  216 35.0  
Stops for breath after walking about 100 metres or after a few minutes on 
level ground (N, n, %) 
 234 25.8  186 30.2  
Too breathless to leave the house, or breathless when dressing or undressing 
(N, n, %) 
 55 6.1  52 8.4  
COPD assessment test (N, mean, SD) 905 21.6 7.6 615 23.9 7.6 <0.001 
COPD assessment test group 905   615   <0.001 
Low (score 0-9) (N, n, %)  60 6.6  21 3.4  
Medium (score 10-19) (N, n, %)  295 32.6  159 25.9  
High (score 20-29) (N, n, %)  391 43.2  285 46.3  
Very high (score 30-40) (N, n, %)  159 17.6  150 24.4  
EQ-5D-3L utility (N, mean, SD) 908 0.66 0.28 619 0.58 0.29 <0.001 
EQ-5D-3L VAS (N, mean, SD) 907 61.7 19.3 617 59.1 18.9 <0.001 
COPD Chronic Obstructive Pulmonary Disease, EQ-5D-3L EuroQoL 5 dimension 3 level, mMRC modified Medical Research Council, SD standard 
deviation, VAS visual analogue scale 
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Table 34: Baseline patient reported symptoms and quality of life by location of recruitment  
 Primary care Secondary care p-value 
Degree of breathlessness (mMRC dyspnoea)  907   617   <0.001 
Not troubled by breathlessness except on strenuous exercise (N, n, %)  65 7.2  20 3.2  
Short of breath when hurrying or walking up a slight hill (N, n, %)  286 31.5  143 23.2  
Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own pace (N, n, 
%) 
 267 29.4  216 35.0  
Stops for breath after walking about 100 metres or after a few minutes on 
level ground (N, n, %) 
 234 25.8  186 30.2  
Too breathless to leave the house, or breathless when dressing or 
undressing (N, n, %) 
 55 6.1  52 8.4  
COPD assessment test (N, mean, SD) 905 21.6 7.6 615 23.9 7.6 <0.001 
COPD assessment test group 905   615   <0.001 
Low (score 0-9) (N, n, %)  60 6.6  21 3.4  
Medium (score 10-19) (N, n, %)  295 32.6  159 25.9  
High (score 20-29) (N, n, %)  391 43.2  285 46.3  
Very high (score 30-40) (N, n, %)  159 17.6  150 24.4  
EQ-5D-3L utility (N, mean, SD) 908 0.66 0.28 619 0.58 0.29 <0.001 
EQ-5D-3L VAS (N, mean, SD) 907 61.7 19.3 617 59.1 18.9 <0.001 
COPD Chronic Obstructive Pulmonary Disease, EQ-5D-3L EuroQoL 5 dimension 3 level, mMRC modified Medical Research Council, SD 
standard deviation, VAS visual analogue scale 
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Table 35: Baseline sociodemographic characteristics comparing those with and without HARQ data. 
 
HARQ not 
completed  
(N = 1134) 
HARQ 
completed  
(N = 402) 
p-value 
Sex        
  Male (N, n, %) 1134 629 55.5 402 199 49.5 0.039a 
Age (N, Mean, SD) 1134 68.9 8.3 402 66.8 8.2 <0.001a 
Smoking status 1134   402   0.396a 
  Current smoker (n, %)  352 31.0  134 33.3  
  Ex-smoker (n, %)  782 69.0  268 66.7  
Pack years (N, Mean, SD) 1128 46.3 26.8 401 49.2 33.2 0.076b 
BMI (N, Mean, SD) 1134 27.2 6.01 402 27.4 6.4 0.689b 
a chi-squared test 
b independent samples t-test 
BMI Body Mass Index, SD Standard Deviation;  
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Table 36: Additional outcomes for ITT population for treatment of exacerbation 
 
Theophylline Placebo Model Estimate Lower CI Upper CI p-value 
Exacerbations treated with antibiotics only        
Total number included in analysis 772 764 
 
    
Number with at least one exacerbation 230 227 
 
    
Total number of exacerbations 338 368 
 
    
Mean number of exacerbations 0.44 0.48 unadjusted IRR 0.94 0.78 1.13 0.484 
SD (number of exacerbations) 0.82 0.97 adjusted IRRa 0.94 0.78 1.14 0.541 
Exacerbations treated with steroids only        
Total number included in analysis 772 764 
 
    
Number with at least one exacerbation 77 88 
 
    
Total number of exacerbations 117 124 
 
    
Mean number of exacerbations 0.15 0.16 unadjusted IRR 0.93 0.66 1.32 0.697 
SD (number of exacerbations) 0.60 0.58 adjusted IRRa 0.88 0.62 1.25 0.476 
Exacerbations treated with antibiotics and steroids        
Total number included in analysis 772 764 
 
    
Number with at least one exacerbation 487 479 
 
    
Total number of exacerbations 1171 1106 
 
    
Mean number of exacerbations 1.52 1.45 unadjusted IRR 1.05 0.93 1.17 0.446 
SD (number of exacerbations) 1.72 1.65 adjusted IRRa 1.02 0.92 1.14 0.725 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics.  
CI confidence interval, IRR incident rate ratio, HR hazard ratio, SD standard deviation 
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Table 37: Subgroup analysis for primary outcome (intention to treat analysis) 
Category 
 
Theophylline Placebo IRRa Lower 
CI 
Upper 
CI 
Interaction 
p-value 
All participants N 772 764 
    
 Mean 2.24 2.23 
    
 SD 1.99 1.97 0.99 0.91 1.08 
 
Gender        
Male N 418 410 
    
 Mean 2.23 2.18 1.01 0.87 1.17 
 
 SD 2.04 1.92 
    
Female N 354 354 
    
 Mean 2.25 2.28 0.97 0.83 1.14 0.609 
 SD 1.93 2.03 
    
Age group        
<60 years N 115 131 
    
 Mean 2.33 2.46 0.91 0.70 1.19 
 
 SD 2.01 1.81 
    
60-69 years N 313 284     
 Mean 2.27 2.13 1.07 0.89 1.28 0.198 
 SD 2.06 1.81     
70+ years N 344 349 
    
 Mean 2.18 2.23 0.96 0.82 1.13 0.637 
 SD 1.92 2.01 
    
Smoking Status        
current N 241 245 
    
 Mean 2.40 2.47 0.96 0.80 1.16 
 
 SD 2.01 2.07 
    
ex-smoker N 531 519 
    
 Mean 2.16 2.11 1.01 0.89 1.16 0.561 
 SD 1.97 1.92 
    
BMI category        
underweight N 37 33     
 Mean 2.51 2.45 0.93 0.57 1.52 0.894 
 SD 2.34 1.72     
normal N 277 243 
    
 Mean 2.29 2.41 0.95 0.79 1.15 
 
 SD 1.91 1.72 
    
overweight/obese N 458 488 
    
 Mean 2.18 2.13 1.02 0.88 1.17 0.478 
 SD 2.01 1.96 
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Table 37 (continued): Subgroup analysis for primary outcome (intention to treat analysis) 
Category 
 
Theophylline Placebo IRR Lower 
CI 
Upper 
CI 
Interaction 
p-value 
COPD treatment at baseline 
ICS/LAMA/LABA N 610 613 
    
 Mean 2.33 2.36 0.98 0.87 1.10 
 
 SD 2.05 1.87 
    
ICS/LABA or ICS/LAMA N 148 134 
    
 Mean 1.89 1.78 1.00 0.76 1.32 0.832 
 SD 1.70 1.87 
    
ICS only N 14 17 
    
 Mean 1.86 1.06 1.63 0.65 4.09 0.155 
 SD 1.92 1.43 
    
Number exacerbations in 12 months prior to baseline 
2 N 286 308 
    
 Mean 1.61 1.53 1.05 0.86 1.28 
 
 SD 1.66 1.85 
    
3-4 N 317 298 
    
 Mean 2.31 2.25 1.02 0.86 1.21 0.785 
 SD 1.93 1.85 
    
5+ N 169 158 
    
 Mean 3.16 3.55 0.89 0.73 1.09 0.139 
 SD 2.21 2.38 
    
GOLD Stage        
I-II N 370 376 
    
 Mean 1.93 2.03 0.97 0.82 1.14 
 
 SD 1.89 1.99 
    
III N 286 289 
    
 Mean 2.38 2.40 1.02 0.85 1.21 0.605 
 SD 2.03 1.99 
    
IV N 113 92 
    
 Mean 2.90 2.58 0.99 0.75 1.32 0.849 
 SD 2.03 2.04 
    
Oral corticosteroids at baseline 
no N 418 410 
    
 Mean 2.23 2.18 0.99 0.88 1.10 
 
 SD 2.04 1.92 
    
yes N 354 354 
    
 Mean 2.25 2.28 1.20 0.65 2.20 0.420 
 SD 1.93 2.03 
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Table 37 (continued): Subgroup analysis for primary outcome (intention to treat analysis) 
Category  Theophylline Placebo IRR Lower 
CI 
Upper 
CI 
Interaction 
p-value 
ICS dose at baseline        
>=1600µg/day N 549 547     
 Mean 2.38 2.31 0.98 0.87 1.12 0.642 
 SD 1.98 2.03     
<1600µg/day N 221 215     
 Mean 1.91 2.01 1.03 0.83 1.27  
 SD 1.98 1.80     
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the 
mean, gender (male/female), smoking in pack years, FEV1 % predicted, number of COPD exacerbations in 
the previous year, baseline COPD treatment, treatment with long term antibiotics. 
CI Confidence interval, SD Standard deviation, BMI Body mass index, GOLD Global Initiative for 
Chronic Obstructive Lung Disease, ICS Inhaled corticosteroid, IRR incidence rate ratio, LABA Long 
acting β2 agonist, LAMA Long acting muscarinic antagonist,  µg microgram 
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Table 38: Sensitivity analysis for the ITT population excluding the 33 participants who died during 12 month follow-up- exacerbations and hospital 
admissions 
 
Theophylline Placebo 
 
Estimate Lower CI Upper CI p-value 
Total exacerbations        
Total number included in analysis 753 750 
 
    
Person years follow-up 738.6 735.1 
 
    
Number with at least one exacerbation 619 596 
 
    
Total number of exacerbations 1690 1678 
 
    
Mean number of exacerbations 2.24 2.24 unadjusted IRR 1.00 0.91 1.09 0.934 
SD (number of exacerbations) 1.99 1.98 adjusted IRRa 0.99 0.91 1.07 0.729 
Exacerbations requiring hospital treatment        
Total number included in analysis 753 750 
 
    
Person years follow-up 738.6 735.1 
 
    
Number with at least one exacerbation 99 118 
 
    
Total number of exacerbations 126 172 
 
    
Mean number of exacerbations 0.17 0.23 unadjusted IRR 0.73 0.55 0.97 0.032 
SD (number of exacerbations) 0.49 0.66 adjusted IRRa 0.73 0.55 0.97 0.031 
Non-COPD hospital admissions        
Total number included in analysis 744 741 
 
    
N with at least one 77 87 
 
    
Total number of admissions 111 111 
 
    
Mean admission rate 0.15 0.15 unadjusted IRR 0.99 0.71 1.38 0.949 
SD admission rate 0.54 0.45 adjusted IRRa 1.03 0.74 1.43 0.875 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics.  
CI confidence interval, COPD Chronic Obstructive Pulmonary Disease, IRR incident rate ratio, SD standard deviation   
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Table 39: Sensitivity analysis for the ITT population excluding the 33 participants who died during 12 month follow-up: lung function and patient 
reported outcomes 
Outcome Time 
point 
 
Theophylline Placebo  Overall mean 
difference 
Lower CI Upper CI p-value 
% Predicted FEV1 Baseline Total N 750 743 
 
    
  
Mean 51.4 52.4 
 
    
  
SD 20.0 19.8 
 
    
 
6 months Total N 548 535 
 
    
  
Mean 52.4 53.2 
 
    
  
SD 20.4 20.9 
 
    
 
12 months Total N 533 488 
 
    
  
Mean 51.5 52.2 Unadjusted  -0.59 -2.54 1.36 0.551 
  
SD 20.4 21.6 Adjusteda  -0.58 -2.46 1.29 0.543 
% Predicted FVC Baseline Total N 748 742 
 
    
  
Mean 84.5 86.5 
 
    
  
SD 22.2 23.5 
 
    
 
6 months Total N 543 531 
 
    
  
Mean 84.0 84.6 
 
    
  
SD 22.74 24.8 
 
    
 
12 months Total N 525 485 
 
    
  
Mean 83.1 82.5 Unadjusted  -0.45 -2.59 1.69 0.678 
  
SD 23.8 25.1 Adjusteda  -0.37 -2.43 1.69 0.723 
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Table 39 (continued): Sensitivity analysis for the ITT population excluding the 33 participants who died during 12 month follow-up: lung function 
and patient reported outcomes 
Outcome Time 
point 
 
Theophylline Placebo 
 
Overall mean 
difference 
Lower CI Upper CI p-value 
CAT score Baseline Total N 745 742 
 
    
  
Mean 22.7 22.3 
 
    
  
SD 7.6 7.9 
 
    
 
6 months Total N 668 653 
 
    
  
Mean 21.2 21.1 
 
    
  
SD 8.1 8.3 
 
    
 
12 months Total N 633 615 
 
    
  
Mean 21.4 21.4 Unadjusted 0.16 -0.56 0.89 0.661 
  
SD 8.2 8.6 Adjusteda 0.02 -0.65 0.69 0.950 
HARQ Baseline Total N 193 197 
 
    
  
Mean 25.2 25.8 
 
    
  
SD 16.1 14.9 
 
    
 
6 months Total N 189 187 
 
    
  
Mean 21.9 22.8 
 
    
  
SD 15.13 15.7 
 
    
 
12 months Total N 184 172 
 
    
  
Mean 24.1 24.2 Unadjusted -0.62 -3.15 1.91 0.631 
  
SD 15.70 15.94 Adjusteda -0.89 -3.27 1.50 0.468 
a adjusted for: centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, gender (male/female), smoking in pack years, 
FEV1 % predicted, number of COPD exacerbations in the previous year, baseline COPD treatment, treatment with long term antibiotics.  
CAT COPD Assessment Test, CI confidence interval, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, HARQ Hull Airways Reflux 
Questionnaire, SD standard deviation  
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APPENDIX 6: Line-listings of serious adverse events 
 
Table 40: Events recorded as Suspected Unexpected Serious Adverse Reactions (SUSARs) 
Case 
ID 
Country 
Gender 
Age 
Event Outcome Date of onset 
Time to 
onset‡ 
Assessment of 
relatedness to 
study drug 
Daily dose Route 
Formulation 
Dates of 
treatment  
Comments 
System organ classification: Cardiac disorders 
ID 070 UK 
Female 
72 
2:1 AV block   Recovered 
with 
sequelae 
April 2015 Possible 200mg theophylline 
once daily 
4 March 2015 to  
12 April 2015 
PI disputed diagnosis of AV 
block made by cardiology team.  
CI noted normal ECG after 
discontinuing study drug prior 
to development of AV block, 
also noted that theophylline  
increased heart rate rather than 
to slow it and therefore unlikely 
to be related to study drug. 
ID 143 UK 
Female 
59 
STEMI, PCI to 
LCx and OM, 
Cor Pulmonale, 
Mild to 
moderate LVSD 
on 
ventriculogram 
 
Recovered 30 March 
2016 
Possible 200mg theophylline 
once daily 
21 March 2016 to 
27 March 2016 
PI suggested that there was 
possible association with study 
drug.  CI noted that the 
participant had ceased study 
medication 3 days prior to the 
cardiac event and therefore 
highly unlikely to be related to 
study drug. 
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Table 41: Events recorded as possible Serious Adverse Reactions (SARs) 
Case 
ID† 
Country 
Gender 
Age 
Serious Adverse 
Event 
Outcome Date of onset 
Time to onset‡ 
Assessment of 
relatedness to 
study drug 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
System organ classification: Cardiac disorders 
007 UK 
Male 
66 
Atypical atrial 
flutter/atrial 
tachycardia 
Recovered 25 August 2014 Possible  200mg theophylline 
twice daily 
 
6 August 2014 to 
12 August 2014;  
19 August 2014 to 
25 August 
 
018 UK 
Male 
79 
Syncopal episode 
resulting in 
fracture to right 
fourth metacarpal 
Recovered 8 November 
2014 
Possible 200mg theophylline 
once daily 
 
30 March 2014 to 
31 March 2015 
 
029 UK 
Male 
81 
Atrial fibrillation Not 
recovered 
31 October 
2014 
Possible 200mg theophylline 
twice daily 
 
30 April 2014 to 26 
January 2015 
 
072 UK 
Male 
82 
Non-sustained 
ventricular 
tachycardia 
Recovered 
with 
sequelae 
14 August 2015 
 
Possible 200mg theophylline 
once daily  
 
25 August 2014 to 
14 August 2015 
 
 
186 UK 
Male 
76 
Palpitations Not 
recovered 
11 August 2016 Possible 200mg placebo 
once daily  
 
4 August 2016 – 11 
August 2016 
 
 
189 UK 
Female 
73 
Palpitations and 
tachycardia 
Not 
recovered 
16 August 2016 Possible 200mg theophylline 
once daily 
 
16 February 2016 – 
5 September 2016 
 
 
213 UK 
Female 
54 
Palpitations 
 
Unknown 12 October 
2016 
Probable 200mg placebo 
once daily  
27 May 2016 –  
17 October 2016 
 
233 UK 
Male  
73 
Sinus tachycardia Recovered 18 November 
2016 
Possible 200mg placebo 
once daily  
25 November 2015 
ongoing at time of 
event 
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Table 41 (continued): Events recorded as possible Serious Adverse Reactions (SARs) 
Case 
ID† 
Country 
Gender 
Age 
Serious Adverse 
Event 
Outcome Date of onset 
Time to onset‡ 
Assessment of 
relatedness to 
study drug 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
System organ classification: Gastrointestinal disorders 
103 UK 
Female 
71 
Dyspeptic pain Recovered 22 October 
2015 
Possible 200mg placebo 
once daily 
 
12 October 2015 to 
27 October 2015 
 
System organ classification: Investigations 
268 UK 
Male 
76 
Weight loss, 
lethargy 
Unknown 19 April 2017 Possible 200mg placebo 
once daily  
9 June 2016 
ongoing at time of 
event 
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Table 42:  Events recorded as Serious Adverse Events (SAEs)a 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
System organ classification: Infections and infestations 
012 UK 
Male 
74 
Infected Elbow Recovering 30 September 
2014 
200mg placebo once 
daily 
 
12 September 2014 
ongoing  
 
055 UK 
Female 
54 
Right leg cellulitis Recovered 10 June 2015 200mg theophylline once 
daily 
 
9 December 2014 
to 11 December 
2014 
 
060b UK 
Female 
82 
Urinary tract infection Unknown 9 July 2015 200mg placebo once 
daily 
 
Never commenced 
study medication 
(study medication 
not dispensed) 
Did not start/initiate study 
medication 
071 UK 
Female 
76 
Sepsis Recovered 
with sequelae 
19 August 2015 200mg placebo once 
daily  
1 July 2015 
ongoing at time of 
event 
 
081 UK  
Male 
70 
Left arm cellulitis Recovered 16 September 
2015 
200mg placebo once 
daily 
 
3 April 2015 to  
16 September 2015 
 
110 UK  
Female 
75 
Cellulitis lower leg  
secondary to cat bite 
Unknown 13 December 
2015 
200mg theophylline once 
daily 
 
2 December 2015  
ongoing at time of 
event 
 
120  UK 
Female 
77 
Cellulitis, delirium Recovered 13 December 
2015 
200mg theophylline once 
daily 
 
13 February 2015 
ongoing at time of 
event 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
127 UK 
Female 
82 
Urinary tract infection 
 
Recovered 29 December 
2015 
200mg theophylline once 
daily 
 
27 February 2015 
to  
29 December 2015 
 
128 UK 
Female 
71 
Sepsis Unknown 08 February 
2016 
200mg placebo once 
daily 
 
26 January 2016 
ongoing at time of 
event 
 
134 UK 
Male 
79 
Urinary tract infection 
and reduced mobility 
Recovered 26 November 
2015 
200mg theophylline 
twice daily 
 
16 September 2015 
to 25 January 2016 
 
174 UK 
Female 
64 
Infection, ?source Recovered 28 May 2016 200mg theophylline once 
daily 
 
23 June 2015  
ongoing at time of 
event 
 
181 UK, 
Female  
76 
Atrial flutter secondary 
to sepsis from lower limb 
cellulitis 
Recovering 04 August 2016 200mg theophylline once 
daily  
19 May 2016 
ongoing at time of 
event 
Recorded as infection as this 
was the primary driver of 
atrial flutter 
201 UK 
Male  
57 
Exacerbation of COPD, 
leading to type 2 
respiratory failure, 
bilateral leg swelling and 
also developed C. diff 
while in hospital 
Unknown 13 June 2016 
 
200mg placebo once 
daily  
19 April 2016 to  
13 July 2017 
Recorded as infection 
because of clostridium 
difficile infection. The 
exacerbation of COPD 
captured as primary 
outcome 
203 UK 
Female 
78 
Gram negative 
bacteraemia 
Recovered 20 August 2016 200mg placebo once 
daily  
15 July 2016 to  
5 September 2016 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
217 UK 
Male  
69 
Cellulitis Recovered 12 February 
2015 
200mg theophylline once 
daily  
7 July 2014 to 
24 November 2014 
 
220 UK 
Female 
77 
Infective gastroenteritis Recovered 04 May 2016 200mg theophylline once 
daily  
Never commenced 
study medication 
Did not start/initiate study 
medication 
221 UK 
Female 
77 
Cellulitis Recovered 10 July 2016 200mg theophylline once 
daily  
Never commenced 
study medication 
Did not start/initiate study 
medication 
222 UK 
Female 
77 
Confusion, possible 
secondary to cellulitis 
Recovered 2 October 2016 200mg theophylline once 
daily  
Never commenced 
study medication 
Did not start/initiate study 
medication 
Recorded as infection as this 
was the primary driver of 
confusion 
225 UK 
Male  
78 
Sepsis Recovered 13 November 
2016 
200mg placebo once 
daily  
14 June 2016 
ongoing at time of 
event 
 
239 UK 
Male 
74 
Fall/?sepsis Unknown 28 December 
2016 
200mg theophylline once 
daily  
2 August 2016 
ongoing at time of 
event 
Recorded as infection as this 
was the primary driver of 
falls 
244 UK 
Male 
66 
Ankle joint infection Recovering 07 January 2017 
 
200mg placebo once 
daily  
22 January 2016 
ongoing at time of 
event 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
247 UK 
Female 
65 
Urinary tract infection Recovered 10 October 
2016 
200mg placebo once 
daily  
3 August 2016 
ongoing at time of 
event 
 
249 UK 
Male 
77 
Urinary tract infection Recovered 19 January 2017 200mg theophylline once 
daily  
9 February 2016 
ongoing at time of 
event 
 
251 UK 
Female 
71 
Periumbilical abscess Recovered 6 October 2016 200mg theophylline once 
daily  
27 November 2015 
ongoing at time of 
event 
 
253 UK 
Female 
60 
Urinary tract infection 
and possible viral 
gastroenteritis 
Recovered 10 December 
2016 
200mg theophylline once 
daily  
21 March 2016 to 
29 March 2016 
 
281 
 
UK 
Male 
71 
Gastroenteritis Recovered  6 February 2017 200mg theophylline once 
daily  
9 June 2016 to 
20 July 2016 
 
System organ classification: Neoplasm benign, malignant and unspecified 
010 UK 
Female 
74 
Moderately differentiated 
squamous cell carcinoma 
of supraglottic 
submucosal T3 N2c M0 
Recovered Unknown – 
reported 29 
September 2014 
200mg theophylline once 
daily 
 
14 April 2014 to 28 
February 2015 
 
011 UK 
Male 
68 
Lung cancer Not recovered Unknown 
Reported 30 
September 2014 
200mg placebo once 
daily 
 
19 May 2014 to 30 
September 2014 
 
193 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
017 UK 
Female 
71 
Left lower lobe lesion 
with pleural effusion 
Unknown 29 October 
2014 
200mg theophylline once 
daily 
 
19 May 2014 to 13 
November 2014 
 
019 UK 
Male 
68 
Metastatic lung cancer 
stage T2a N3 M1b 
Fatal 
 
18 November 
2014 
200mg theophylline once 
daily 
 
7 July 2014 to 27 
August 2014 
 
021 UK 
Female 
85 
Metastatic bladder cancer Fatal 7 October 2014 200mg placebo once 
daily 
 
2 April 2014 to 2 
June 2014 
 
022 UK 
Male 
70 
Perforated caecal tumour Fatal 24 November 
2014 
200mg theophylline once 
daily 
 
24 July 2014 to 
November 2014 
 
039 UK 
Female 
70 
Intermediate grade 
neuroendocrine 
tumour/atypical 
carcinoid 
Recovering 16 January 2015 200mg placebo once 
daily 
 
7 March 2015 to 3 
June 2015 
 
040 UK 
Female  
77 
Large pelvic mass/ 
Sigmoid carcinoma 
Not recovered 12 April 2014 200mg theophylline once 
daily 
 
21 May 2014 to 25 
April 2015 
 
059 UK 
Female 
79 
Lung malignancy Unknown 6 June 2015 200mg theophylline once 
daily 
 
17 July 2014 to July 
2015 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
068 UK 
Male  
83 
Lung cancer Fatal 12 August 2015 
 
200mg theophylline once 
daily  
18 August 2014 to  
27 May 2015 
 
078 UK 
Female 
66 
Metastatic colonic 
malignancy 
Fatal 16 July 2015 200mg placebo once 
daily 
 
16 December 2014 
to 19 January 2015 
 
109 UK 
Male 
63 
 
Left breast cancer Recovering 4 November 
2015 
200mg theophylline 
twice daily  
24 June 2015 
ongoing at time of 
event 
 
112 UK 
Male 
61 
Laryngeal cancer Fatal 11 September 
2015 
200mg placebo once 
daily 
 
Never commenced 
study medication 
 
Did not start/initiate study 
medication 
117 UK 
Female  
64 
Right hilar mass Not recovered 15 December 
2015 
  
200mg theophylline once 
daily 
 
5 August 2015 to 
25 August 2015 
 
123 UK 
Male  
80 
Metastatic disease in the 
liver with no obvious 
primary 
Unknown 11 December 
2015 
200mg placebo once 
daily 
 
21 July 2015 to  
31 August 2015 
 
132 UK 
Female 
67 
Central tumour, 
mediastinal 
lymphadenopathy, 
cerebral metastases 
Not recovered 12 February 
2016 
200mg theophylline once 
daily 
 
4 February 2016 to  
19 February 2016 
 
195 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
141 UK 
Male 
67 
Metastatic cancer Unknown 17 March 2016 200mg placebo once 
daily 
 
14 April 2015  to  
13 April 2016 
 
147 UK 
Female 
72 
Lung cancer Not recovered 1 April 2016 200mg theophylline once 
daily 
 
15 October 2015 
ongoing at time of 
event 
 
148 UK 
Female 
72 
Haemoptysis secondary 
to lung cancer 
Recovering 1 April 2016 200mg theophylline once 
daily 
 
15 October 2015 
ongoing at time of 
event 
 
160 UK 
Female 
76 
Pancreatic malignancy 
with biliary obstruction 
Fatal 3 May 2016 
 
200mg theophylline once 
daily 
 
17 March 2016 to  
17 May 2016 
 
202 UK 
Male 
61 
T2 N2b squamous cell 
carcinoma of his right 
pyriform fossa 
Unknown 8 March 2016 200mg placebo once 
daily  
28 August 2015 
ongoing at time of 
event 
 
219 UK 
Female 
68 
Lung neoplasm Not recovered Unknown 200mg theophylline once 
daily  
19 July 2016 to 
3 January 2017 
 
228 UK 
Female 
59 
Investigation following 
CT scan showing nodule 
- Primary lung tumour 
Unknown 15 November 
2016 
200mg placebo once 
daily  
1 June 2016 
ongoing at time of 
event 
 
231 UK 
Male 
70 
Lung cancer Not recovered 04 November 
2016 
200mg placebo twice 
daily  
3 December 2015 
ongoing at time of 
event 
 
196 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
238 UK 
Male 
70 
Grade 2 prostate cancer Unknown 22 December 
2016 
200mg placebo once 
daily  
28 July 2016 
ongoing at time of 
event 
 
241 UK 
Female 
58 
Mastectomy for breast 
cancer 
Recovering 19 December 
2016 
200mg theophylline once 
daily  
18 February 2016 
ongoing at time of 
event 
 
254 UK 
Female 
67 
Right breast cancer Unknown 02 March 2017 200mg theophylline once 
daily  
27 May 2016 
ongoing at time of 
event 
 
 
260 UK 
Female 
81 
Uterine cancer Recovering 27 February 
2017 
200mg theophylline once 
daily  
3 March 2016 
ongoing at time of 
event 
 
263 UK 
Female 
64 
Chronic lymphocytic 
leukaemia 
Not recovered 5 April 2017 200mg placebo once 
daily  
25 August 2016 
ongoing at time of 
event 
 
286 UK 
Male 
70 
Hepatic flexure cancer 
(Dukes B) 
Recovering 20 July 2017 200mg theophylline once 
daily  
4 August 2016 
ongoing at time of 
event 
 
289 UK 
Female 
82 
Death, I (a) Metastatic 
Cholangiocarcinoma, II 
COPD. 
Fatal| 8 November 
2017 
200mg placebo once 
daily  
Never commenced 
study medication  
Did not start/initiate study 
medication 
System organ classification: Blood and lymphatic system disorders 
197 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
173 UK 
Male 
71 
Iron deficiency anaemia Recovered 18 February 
2016 
200mg placebo once 
daily 
 
29 June 2015 
ongoing at time of 
event  
 
 
 
184 UK 
Female 
72 
Abdominal haematoma Recovering 03 May 2016 200mg placebo once 
daily  
07 August 2015 
ongoing at time of 
event 
 
 
System organ classification: Immune system disorders 
None        
System organ classification: Endocrine disorders 
None        
System organ classification: Metabolism and nutrition disorders 
245 UK 
Male 
79 
Dysphagia Unknown 27 January 2017 200mg theophylline once 
daily  
14 July 2016 to 
31 January 2017 
 
246 UK 
Male 
79 
Refeeding syndrome Unknown 28 January 2017 200mg theophylline once 
daily  
14 July 2016 to 
31 January 2017 
 
System organ classification: Psychiatric disorders 
073 UK 
Male 
57 
Overdose of 
amitriptyline and alcohol 
Recovering 01 September 
2015 
200mg placebo once 
daily  
04 August 2015 to  
02 September 2015 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
098 UK 
Male 
58 
Overdose of 
amitriptyline and alcohol 
Not recovered 8 November 
2015 
200mg placebo once 
daily 
 
04 August 2015 to  
02 September 2015 
  
 
146 UK 
Male 
59 
Admission to psychiatric 
ward with a depressive 
episode 
 
Recovered 24 July 2015 200mg placebo twice 
daily  
8 April 2015 to  
30 June 2015 
 
 
183 UK 
Male 
73 
Asphyxiation as a result 
of suicide 
Fatal 13 July 2016 200mg theophylline once 
daily  
9 September 2015 
to 13 July 2016 
 
System organ classification: Nervous system disorders 
014 UK 
Male 
76 
Transient ischaemic 
attack, atrial fibrillation 
Recovered 
with sequelae 
1 September 
2014 
200mg theophylline 
twice daily 
 
3 June 2014 to 9 
January 2015 
 
025 UK 
Male 
76 
Stroke Recovering 11 November 
2014 
200mg theophylline 
twice daily 
 
3 June 2014 to 
November 2014, 
restarted briefly at 
start of January 
2015 
 
027 UK 
Male 
66 
Seizure secondary to 
intracerebral 
haemorrhage 
Recovered 13 January 2015 200mg theophylline once 
daily 
 
31 March 2014 to 
26 March 2015 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
033 UK 
Female 
44 
Headache 
 
Recovered 19 February 
2015 
200mg theophylline once 
daily 
 
7 January 2015 
ongoing at time of 
event 
 
043 UK 
Male 
65 
Subdural 
bleed/haematoma as 
result of fall prior to trial 
inclusion 
Unknown 1 April 2015 200mg theophylline once 
daily 
 
23 April 2015 
ongoing at time of 
event 
 
050 UK 
Female 
78 
Suspected cerebral 
infarct 
Recovering 23 May 2015 200mg placebo once 
daily 
 
30 April 2015 to 21 
May 2015 
 
064 UK 
Male 
78 
Subdural haemorrhage Fatal 20 June 2015 200mg theophylline once 
daily 
 
23 April 2015 to 23 
July 2015 
 
077 
 
UK 
Male  
73 
Spinal canal stenosis Recovered 10 September 
2015 
200mg theophylline once 
daily 
 
21 April 2015 to 
9 September 2015 
 
080 UK  
Female 
82 
Partial anterior 
circulation infarct 
Recovered 7 September 
2015 
200mg theophylline once 
daily 
 
27 February 2015 
to 7 September 
2015 
 
085 UK 
Male 
73 
Chest pain / spinal 
stenosis 
Recovered  20 July 2015 200mg theophylline once 
daily 
 
13 October 2014 to  
12 October 2015 
 
200 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
099 UK 
Male 
78 
 
Lewy body dementia 
 
 
Recovered 6 November 
2015 
 
200mg placebo once 
daily 
 
1 December 2014 
ongoing at time of 
event 
 
107 UK 
Female 
82 
Right total anterior 
circulation stroke 
syndrome or Todd’s 
Palsy 
Recovered 21 October 
2015 
200mg theophylline once 
daily 
 
27 February 2015 
ongoing at time of 
event 
 
114 UK 
Male 
76 
Bilateral thalamic infract Not recovered 31 December 
2015 
 
200mg theophylline once 
daily 
 
15 September 2015 
ongoing at time of 
event 
 
 
 
118 UK 
Male 
81 
CVA Recovering 31 December 
2015 
 
200mg placebo once 
daily 
 
30 January 2015 
then stopped trial 
drugs as soon as 
admitted. 
 
131 UK 
Female 
58 
?TIA 
 
Recovering 18 January 2016 200mg placebo once 
daily 
 
24 March 2015 to  
18 August 2015 
 
 
140 UK 
Female 
72 
Dizziness and vomiting Recovered 
with sequelae 
22 March 2016 200mg theophylline once 
daily 
 
01 April 2015 
ongoing at time of 
event 
 
 
201 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
151 UK 
Male 
62 
Confusion with 
worsening headache 
Recovered 16 December 
2015 
200mg placebo once 
daily 
 
10 April 2015 to  
15 April 2016 
 
172 UK 
Male 
72 
Ischaemic stroke, 
community acquired 
pneumonia 
Recovering  1 July 2016 
 
  
200mg theophylline once 
daily 
 
2 February 2016 
ongoing at time of 
event 
 
176 UK 
Female 
79 
Subarachnoid 
haemorrhage 
Unknown 6 June 2016 200mg placebo once 
daily 
 
15 September 2015 
to 06 June 2016 
 
 
269 UK 
Male  
68 
Frontal lobe dementia Fatal Unknown 200mg placebo once 
daily  
12 April 2016 to 
18 October 2016 
 
System organ classification: Eye disorders 
None        
System organ classification: Ear and labyrinth disorders 
None        
System Organ Classification: Cardiac disorders 
004 UK 
Female 
84 
Pulmonary oedema Recovered 24 June 2014 200mg placebo once 
daily 
9 April 2014 to 20 
June 2014 
 
013 UK 
Male 
72 
Death: Cause of death 
myocardial infarction, 
infective exacerbation of 
COPD, atrial fibrillation 
Fatal 1 October 2014 200mg placebo once 
daily 
30 May 2014 to 13 
August 2014 
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Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
026 UK 
Male 
90 
Orthostatic hypotension Recovered 
with sequelae 
28 December 
2014 
200mg theophylline once 
daily 
7 May 2014 to 6 
June 2014 
 
031 UK 
Male 
75 
Out of hospital cardiac 
arrest; end stage COPD; 
mitral valve prolapse 
Fatal 8 January 2015 200mg theophylline once 
daily 
21 June 2014 to 4 
September 2014 
 
032 UK 
Male 
57 
Chest pain Recovered 1 December 
2014 
200mg placebo once 
daily 
31 March 2014 to 2 
April 2015 
 
036 UK 
Male 
71 
Antero-lateral N-STEMI 
(myocardial infarction) 
Recovered 26 February 
2015 
200mg placebo once 
daily 
13 March 2014 to 
26 February 2015 
 
042 UK 
Male 
75 
Cardiac arrest at home; 
Carcinoma of the right 
upper lobe and COPD 
Fatal 28 April 2015 200mg placebo once 
daily 
18 August 2014 to 
April 2015 
 
052 UK 
Female 
76 
Angina Recovered 
with sequelae 
11 July 2014 200mg theophylline once 
daily 
3 April 2014 to 2 
April 2015 
 
053 UK 
Female 
76 
Angina Recovered 
with sequelae 
31 July 2014 200mg theophylline once 
daily 
3 April 2014 to 2 
April 2015 
 
203 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
056 UK 
Male 
65 
Atrial Fibrillation/flutter Recovered 
with sequelae 
16 June 2014 200mg placebo once 
daily 
1 June 2015 to 16 
June 2015 
Initially reported as possibly 
related to the study 
medication; at follow-up to 
the SAE reported as having 
no relationship to study 
medication. 
062 UK 
Female 
78 
Carotid vascular disease Recovered 
with sequelae 
4 June 2015 200mg placebo once 
daily 
 
29 April 2015 to 12 
May 2015 
 
063 UK 
Female 
78 
Angina  Recovered 
with sequelae 
5 June 2015 200mg placebo once 
daily 
29 April 2015 to 12 
May 2015 
 
079 UK 
Female 
82 
Missed STEMI vs 
Broken heart syndrome 
Recovered 16 August 2015 200mg theophylline once 
daily 
27 February 2015 
to 16 August 2015 
 
082 UK 
Female 
70 
Fast atrial fibrillation  Recovering 2 October 2015 200mg placebo once 
daily 
25 November 2014 
to 28 July 2015 
 
086 UK 
Male 
59 
 
Unstable angina 
 
Recovered 09 September 
2015 
200mg placebo once 
daily 
08 April 2015 to  
30 June 2015 
 
097 UK 
Female 
74 
Left ventricular failure Recovered 1 November 
2015 
200mg placebo once 
daily 
6 January 2015 
ongoing at time of 
event  
 
204 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
102 UK  
Male 
82 
Collapse not otherwise 
specified 
Unknown 25 November 
2015 
200mg placebo once 
daily 
21 May 2015 
ongoing at time of 
event 
 
119 UK 
Female 
77 
Exacerbation of COPD; 
pulmonary congestion 
Recovered  4 December 
2015 
 
200mg theophylline once 
daily 
13 February 2015 
ongoing at time of 
event 
 
122 UK 
Female 
77 
Left ventricular failure, 
secondary to acute MI, 
secondary sepsis, 
secondary to pneumonia 
Fatal 17 January 2016 200mg theophylline once 
daily 
14 February 2015 
to 18 January 2016 
Recorded as cardiac 
because of pulmonary 
congestion, the exacerbation 
of COPD was captured as 
primary outcome 
126 UK 
Female 
82 
Congestive cardiac 
failure 
Recovered 16 December 
2015 
200mg theophylline once 
daily 
27 February 2015 
to 16 December 
2015 
 
133 UK 
Male 
69 
Cardiac arrest  Fatal 26 January 2016 200mg placebo once 
daily 
21 October 2015 to 
26 January 2016 
 
 
149 UK 
Female 
62 
Heart failure 
 
Recovered 1 February 2016 200mg placebo once 
daily 
14 April 2015 
ongoing at time of 
event 
 
164 UK 
Male  
79 
Cardiac arrest 
 
Fatal 12 May 2016 200mg theophylline once 
daily 
31 October 2015 to  
19 December 2015 
 
205 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
178 UK 
Male 
78 
Heart failure, AKI Fatal 21 July 2016 
 
200mg theophylline once 
daily 
01 June 2016 to 21 
July 2016 
 
 
 
179 UK 
Male  
68 
Cardiac arrest Fatal  9 July 2016 200mg theophylline once 
daily 
27 November 2015 
to 08 July 2016 
 
185 UK 
Male 
76 
?Heart attack Not recovered 
 
12 August 2016 200mg placebo once 
daily 
3 June 2016 to 
23 September 2016 
 
192 UK 
Female  
64 
Narrow complex 
tachycardia, exacerbation 
of COPD 
Recovering  29 June 2016
  
200mg theophylline once 
daily 
26 August 2015 
ongoing at time of 
event 
 
195 UK 
Male 
86 
Chest pain – likely 
angina 
Recovered 11 February 
2015 
 
200mg placebo once 
daily 
5 September 2014 
to 11 September 
2014 
 
196 UK 
Male  
86 
Unstable angina Recovered 09 June 2015 200mg placebo once 
daily  
5 September 2014 
to 11 September 
2014 
 
205 UK 
Male 
55 
Acute Coronary 
Syndrome 
Unknown 14 September 
2016 
200mg placebo twice 
daily  
5 February 2016 
ongoing at time of 
event 
 
206 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
223 UK 
Male 
73 
Acute myocardial 
infarction 
Unknown 24 October 
2016 
200mg placebo once 
daily  
7 June 2016 
ongoing at time of 
event 
 
 
240 UK 
Female  
78 
Heart failure, moderate 
to severe AS 
Unknown 29 November 
2016 
200mg placebo once 
daily  
15 July 2016 to 
5 September 2016 
 
242 UK 
Male 
73 
NSTEMI Recovered 
with sequelae 
15 October 
2016 
200mg theophylline once 
daily  
1 February 2016 to 
9 January 2017 
 
243 UK 
Male 
63 
Congestive heart failure 
 
Recovering 21 December 
2016 
200mg placebo twice 
daily  
26 July 2016 
ongoing at time of 
event 
 
250 UK 
Female 
69 
ST elevation Myocardial 
Infarction 
Recovered 23 February 
2016 
200mg placebo once 
daily  
27 February 2015 
to 30 July 2015 
 
258 UK 
Male  
88 
Non ST elevation 
myocardial infarction 
Recovered 9 October 2016 200mg placebo once 
daily  
13 November 2015 
ongoing at time of 
event 
 
265 UK 
Male 
64 
End stage congestive 
cardiac failure 
Fatal 12 April 2017 200mg placebo twice 
daily  
26 July 2016 to 30 
April 2017 
 
207 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
276 UK 
Male 
68 
Acute Pulmonary 
Oedema 
Fatal 1 June 2017 200mg theophylline once 
daily  
14 July 2016 to 1 
June 2017  
 
282 UK 
Female 
65 
Atrial Fibrillation and 
Heart Failure 
Recovered 10 June 2016 200mg placebo once 
daily  
11 May 2016 
ongoing at time of 
event 
 
284 UK 
Female 
69 
Postural hypotension Recovered 31 May 2017 200mg placebo once 
daily  
11 August 2016 
ongoing at time of 
event 
 
System Organ Classification: Vascular disorder 
001 UK 
Male 
57 
Old cerebellar 
gliosis/stroke 
Recovered 25 April 2014 200mg placebo once 
daily 
 
31 March 2014 
ongoing at time of 
event 
 
066 UK 
Male 
62 
COPD with lower 
respiratory tract infection 
and DVT 
Recovered 20 June 2015 200mg placebo once 
daily  
18 September 2014 
to October 2014 (18 
doses in total) 
Recorded as vascular 
because exacerbation of 
COPD captured as primary 
outcome 
105 UK 
Male 
75 
Ruptured abdominal 
aortic aneurysm 
Fatal 29 November 
2015 
200mg theophylline 
twice daily  
14 October 2015 to 
29 November 2015 
 
168 UK 
Female 
76 
Right leg DVT Recovering 14 June 2016 
 
200mg theophylline once 
daily 
 
2 December 2015 
ongoing at time of 
event 
 
208 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
182 UK 
Female 
72 
Collapse Unknown 5 August 2016 200mg placebo once 
daily  
26 January 2016 
ongoing at time of 
event 
 
224 UK 
Male 
78 
Intracerebral 
haemorrhage 
Recovered 6 November 
2016 
200mg placebo once 
daily  
14 June 2016 
ongoing at time of 
event 
 
252 UK 
Male 
69 
Right ICA occlusion Recovering 26 December 
2016 
200mg placebo once 
daily  
1 March 2016 to 17 
February 2017 
 
255 UK 
Male 
74 
Bilateral subdural 
haematomas 
Recovered 
with sequelae 
28 December 
2015 
200mg theophylline once 
daily  
21 April 2015 to 
17 September 2015 
 
256 UK 
Male 
74 
DVT/PE Recovered 
with sequelae 
28 December 
2015 
200mg theophylline once 
daily  
21 April 2015 to 
17 September 2015 
 
267 UK 
Female 
73 
Uncontrolled 
hypertension 
Recovered  13 April 2017 200mg theophylline once 
daily  
13 April 2016 
ongoing at time of 
event 
 
270 UK 
Male 
68 
Collapse ?cause 
 
Recovered 
 
17 June 2016 200mg placebo once 
daily  
12 April 2016 to 
18 October 2016 
 
285 UK 
Male 
77 
Ruptured abdominal 
aortic aneurysm 
Fatal 7 August 2017 200mg theophylline once 
daily  
17 August 2016 to 
9 October 2016 
 
209 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
System Organ Classification: Respiratory, thoracic and mediastinal disorders 
002 UK 
Male 
70 
Death – Pneumonia, 
diabetic hypoglycaemia 
Fatal 12 May 2014 200mg theophylline once 
daily 
 
24 April 2014 to 11 
May 2014 
 
003 UK 
Female 
74 
pulmonary embolism Recovered 24 June 2014 200mg placebo once 
daily 
 
16 June 2014 
ongoing at time of 
event 
 
015 UK 
Female 
65 
Death: exacerbation of 
COPD 
Fatal 30 October 
2014 
200mg placebo once 
daily 
 
24 June 2014 to 30 
October 2014 
 
023 UK 
Female 
69 
Chest infection/chest 
pain/Left upper rib 
fracture 
Recovered 17 October 
2014 
200mg placebo once 
daily 
 
25 July 2014 to 29 
July 2014 
 
024 UK 
Female 
68 
Death: type 2 respiratory 
failure, COPD, MS 
Fatal 20 December 
2014 
200mg theophylline once 
daily 
 
22 May 2014 to 27 
August 2014 
 
034 UK 
Male 
74 
Death: severe COPD Fatal 16 February 
2015 
200mg placebo once 
daily 
 
16 June 2014 to 
February 2015 
 
035 UK 
Male 
46 
Hyperventilation Recovered 11 November 
2014 
200mg placebo twice 
daily 
 
10 September 2014 
ongoing at time of 
event 
 
210 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
044 UK 
Male 
73 
Death: Exacerbation of 
COPD 
Fatal 11 April 2015 200mg theophylline once 
daily 
 
18 February 2015 
to 7 April 2015 
 
046 UK 
Male  
90 
Symptomatic pleural 
effusions, hospital 
acquired pneumonia 
Recovered 
with sequelae 
11 May 2015 200mg theophylline once 
daily 
 
7 May 2014 to 18 
May 2015 
 
047 UK 
Male 
47 
Shortness of breath; most 
likely exacerbation of 
COPD 
Recovered 6 December 
2015 
200mg placebo twice 
daily 
 
10 September 2014 
ongoing at time of 
event 
 
057 UK 
Female 
73 
Death: End stage COPD Fatal 15 June 2015 200mg placebo once 
daily 
 
3 March 2015 to  
31 March 2015 
 
058 UK 
Female 
74 
Pleuritic chest pain Recovered 15 March 2015 200mg theophylline once 
daily 
 
10 July 2014 to 11 
August 2014 
 
061 UK 
Male 
72 
Pleuritic chest pain Recovered 20 July 2015 200mg theophylline once 
daily 
 
10 July 2015 
ongoing at time of 
event  
 
067 UK  
Male  
62 
Community acquired 
pneumonia, vomited, 
aspirated and cardiac 
arrest 
Fatal 17 July 2015 200mg placebo once 
daily  
18 September 2014 
to October 2014 (18 
doses in total) 
 
211 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
069 UK 
Female 
67 
Pleuritic chest pain 
 
Recovered 24 February 
2015 
200mg theophylline once 
daily  
27 August 2014 to  
09 November 2014 
 
083 UK 
Male 
71 
Increased breathlessness Recovered 1 April 2015 
 
200mg theophylline once 
daily 
 
23 September 2014 
to 12 October 2015 
 
088 UK 
Male 
79 
Cor Pulmonale 
secondary to COPD 
Fatal 4 October 2015 200mg placebo once 
daily 
 
21 April 2015 to  
7 September 2015 
 
089 UK 
Male 
83 
Infective exacerbation of 
COPD, pleural effusion 
Unknown 11 July 2015 200mg theophylline once 
daily 
 
18 August 2014 to 
27 May 2015 
 
093 UK 
Male 
78 
Shortness of breath Recovering 09 October 
2015 
200mg placebo once 
daily 
 
1 December 2014 
ongoing at time of 
event 
 
116 UK 
Female 
71 
Pulmonary embolism Recovering 19 December 
2015 
 
200mg placebo once 
daily 
 
07 August 2015 
ongoing at time of 
event 
 
124 UK 
Male 
73 
1a Acute kidney injury, 
1b septicaemia, 1c lower 
respiratory tract 
infection; 2 COPD, AF, 
Acromegaly  
 
Fatal 9 April 2015 200mg placebo once 
daily 
 
1 May 2014  2015 
to 08 April 2015 
Recorded as respiratory 
because prime driver was 
lower respiratory tract 
infection, acute kidney injury 
and septicaemia secondary. 
212 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
125 UK  
Male 
80 
Pneumonia Fatal 31 December 
2015 
200mg placebo once 
daily 
 
24 November 2015 
to 30 December 
2015 
 
154 UK 
Female  
72  
Pleuritic chest pain 
 
Recovered 12 January 2016 
 
200mg theophylline once 
daily 
 
14 November 2015 
to 20 December 
2015 
 
155 UK  
Male  
55 
Renal failure, secondary 
to chest infection 
Fatal 12 April 2016 200mg placebo twice 
daily 
 
20 October 2015 to 
April 2016 
Recorded as respiratory 
because prime driver was 
lower respiratory tract 
infection, renal failure 
secondary 
165 UK  
Male 
71 
Haemoptysis 
 
Recovered 11 May 2016 
  
200mg placebo once 
daily 
 
29 June 2015 
ongoing at time of 
event 
 
166 UK 
Male 
76 
Bronchiectasis Recovered 7 March 2016 200mg placebo once 
daily 
 
10 December 2015 
ongoing at time of 
event 
 
170 UK 
Male 
72 
Pneumothorax 
 
Recovered  01 May 2016 200mg placebo once 
daily 
 
8 July 2015 
ongoing at time of 
event  
 
 
 
213 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
175 UK  
Female 
64 
Respiratory failure and 
CO narcosis following 
exacerbation of COPD 
and chest infection 
Recovering 12 May 2016 200mg theophylline once 
daily 
 
14 March 2016 to  
12 May 2016 
 
 
177 UK 
Female 
71 
Pulmonary embolism Recovering 18 July 2016 200mg theophylline once 
daily 
 
28 November 2015 
ongoing at time of 
event 
 
197 UK 
Male 
70 
Pneumonia, pulmonary 
embolism, cavitating 
lesion on CT chest 
Recovered 
with sequelea 
22 August 2016 
 
200mg placebo once 
daily  
4 May 2016 to 23 
August 2016 
 
208 UK 
Male 
63 
Right pneumothorax 
 
Recovered 27 June 2014 200mg theophylline once 
daily  
24 April 2014 to 
23 June 2014 
 
209 UK 
Male 
63 
Right pneumothorax Recovered 31 August 2014 200mg theophylline once 
daily  
24 April 2014 to 
23 June 2014 
 
212 UK 
Female 
64 
Pleurisy or 
musculoskeletal pain 
Recovered 10 February 
2016 
200mg theophylline once 
daily  
09 April 2015 
ongoing at time of 
event 
 
226 UK 
Female  
59 
Bronchiectasis Unknown 15 November 
2016 
200mg placebo once 
daily  
1 June 2016 
ongoing at time of 
event 
 
214 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
230 UK 
Female 
55 
Hypoxia Recovering 28 November 
2016 
200mg placebo once 
daily  
20 January 2016 
ongoing at time of 
event 
 
234 UK 
Male 
62 
COPD 
 
Fatal Unknown 200mg theophylline once 
daily  
19 January 2016 
ongoing at time of 
event 
 
248 UK 
Male 
79 
Aspiration pneumonia Fatal 02 February 
2017 
200mg theophylline once 
daily  
14 July 2016 to 
31 January 2017 
 
257 UK 
Male 
88 
Chest infection Fatal 20 February 
2017 
200mg theophylline once 
daily  
6 March 2016  to 
25 February 2017 
 
264 UK 
Male 
68 
1) bilateral 
bronchopneumonia  
2) pulmonary oedema 
secondary to heart failure 
and acute kidney injury  
3) progressive frontal 
lobe dementia and COPD 
Fatal 22 November 
2016 
 
200mg placebo once 
daily  
12 April 2016 to 
18 October 2016 
 
 
266 UK 
Female 
71 
Pleuritic chest pain Recovered 
 
12 July 2015 200mg placebo once 
daily  
15 September 2014 
to 2 February 2015 
 
288 UK 
Female 
78 
Death, pneumonia, 
severe COPD, frailty 
Fatal 9 December 
2015 
200mg theophylline once 
daily  
20 April 2015 to 
17 November 2015 
 
215 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
System organ classification: Gastrointestinal disorders 
009 UK 
Male 
55 
Adhesional Bowel 
Obstruction 
Recovered 11 September 
2014 
200mg theophylline once 
daily 
 
24 May 2014 to 11 
September 2014 
 
016 UK 
Male 
76 
Blockage in oesophagus Recovered 1 November 
2014 
200mg theophylline once 
daily 
 
2 October 2014 
ongoing at time of 
event 
 
020 UK 
Male 
72 
Inflammation of 
oesophagus 
Recovered 16 September 
2014 
200mg placebo once 
daily 
 
8 July 2014 to 24 
June 2015 
 
030 UK 
Female 
82 
Viral gastroenteritis Recovered 15 January 2015 200mg placebo once 
daily 
 
1 April 2014 to 
January 2015 
 
 
037 UK 
Female  
43 
Abdominal pain and liver 
steatosis 
Unknown 11 March 2015 200mg theophylline once 
daily 
 
13 January 2015 
ongoing at time of 
event 
 
038 UK 
Female 
79 
Vomiting, fever, severe 
abdominal pain 
Recovering 21 March 2015 200mg placebo once 
daily 
 
4 February 2015 to 
8 August 2015 
 
048 UK 
Male 
78 
Diverticulitis Recovered 8 September 
2014 
200mg placebo once 
daily 
 
6 March 2014 to 15 
October 2014 
 
216 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
049 UK 
Male 
78 
Diverticulitis Recovered 8 December 
2014 
200mg placebo once 
daily 
 
6 March 2014 to 15 
October 2014 
 
051 UK 
Female 
72 
Severe constipation Recovered 7 June 2015 200mg theophylline once 
daily 
 
2 May 2014 to 5 
May 2014 
 
054 UK 
Female 
54 
Gastritis Recovered 25 April 2015 200mg theophylline once 
daily 
 
9 December 2014 
to 11 December 
2014 
 
065 UK 
Female 
58 
Diverticulitis Recovered 26 July 2015 200mg placebo once 
daily 
 
3 July 2015 
ongoing at time of 
event 
 
074 UK 
Male 
66 
Appendicitis Recovered 28 August 2015 200mg theophylline once 
daily 
 
29 July 2015 to  
27 August 2015 
 
087 UK 
Male 
71 
Laparoscopic 
appendectomy 
 
Recovered 09 November 
2014 
200mg theophylline once 
daily 
 
05 September 2014 
ongoing at time of 
event 
 
090 UK 
Female 
82 
Abdominal pain 
 
Recovered 5 October 2014 200mg theophylline once 
daily 
 
14 May 2014 to  
17 May 2014 
 
 
100 UK 
Female 
59 
Strangulated small bowel 
secondary to hernia 
Recovered 1 November 
2014 
 
200mg placebo once 
daily 
 
4 August 2014 to  
1 September 2014 
 
217 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
101 UK 
Female 
60 
Oesophagitis and 
oesophageal stricture 
Recovered 6 July 2015 200mg placebo once 
daily 
 
4 August 2014 to  
1 September 2014 
 
111 UK 
Male 
71 
Haematemesis Recovered 22 November 
2014 
 
200mg placebo once 
daily 
 
20 March 2014 
ongoing at time of 
event 
 
121 UK 
Male 
58 
Perforated duodenal 
ulcer 
Recovered 25 September 
2015 
200mg theophylline once 
daily 
 
03 February 2015 
to 15 January 2016 
 
129 UK 
Male 
49 
Laparotomy and 
adhesiolysis following 
severe abdominal pain. 
Recovering 15 February 
2016 
200mg theophylline 
twice daily 
 
23 April 2015 
ongoing at time of 
event 
 
 
136 UK 
Male 
70 
Rectal bleed. ? Infective/ 
ischaemic colitis 
Recovering 6 March 2016 
 
200mg theophylline once 
daily 
 
12 August 2015 to  
31 December 2015 
 
150 UK 
Male 
71 
Diverticular disease Recovered 6 April 2016 200mg theophylline once 
daily 
 
22 March 2016 
ongoing at time of 
event 
 
158 UK 
Female 
72 
Nausea and vomiting, 
acute abdominal pain 
Recovering 3 May 2016 
 
200mg theophylline once 
daily 
 
26 November 2015 
ongoing at time of 
event 
 
218 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
163 UK 
Male 
56 
Anal abscess/fistula Not recovered 10 January 2016 200mg theophylline 
twice daily 
 
04 July 2015 
ongoing at time of 
event 
 
171 UK 
Male 
71 
Diverticulitis Unknown 27 June 2016 200mg theophylline once 
daily 
 
21 March 2016 to  
29 June 2016 
 
193 UK 
Male 
59 
Bowel obstruction Recovered 05 August 2016 
 
200mg theophylline once 
daily  
29 July 2016 
ongoing at time of 
event 
 
198 UK 
Female 
59 
Gastroenteritis Recovered 01 May 2016 200mg theophylline once 
daily  
21 March 2016 to 
29 March 2016 
 
210 UK 
Female 
71 
Acute pancreatitis Recovering 6 October 2016 200mg theophylline once 
daily  
27 November 2015 
ongoing at time of 
event 
 
 
 
235 UK 
Male 
68 
(COPD) and acute upper 
gastro intestinal 
haemorrhage due to 
duodenal ulcer 
Fatal Unknown 200mg theophylline 
twice daily  
28 June 2016 to 19 
December 2016 
Recorded as gastrointestinal 
because exacerbation of 
COPD captured as primary 
outcome 
262 UK 
Male 
80 
Constipation Recovered 
with sequelae 
05 March 2017 200mg placebo once 
daily  
11 May 2016 
ongoing at time of 
event 
 
219 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
275 UK 
Female 
88 
Constipation Recovered 06 December 
2016 
200mg placebo once 
daily  
1 June 2016 
ongoing at time of 
event 
 
277 UK 
Male 
76 
Constipation Recovered 28 December 
2016 
200mg theophylline once 
daily  
3 June 2016 to 
22 June 2016 
 
 
279 UK 
Female 
73 
Diverticulitis ‘flare up’ Recovered 02 March 2017 200mg theophylline once 
daily  
18 July 2016 to 
2 August 2016 
 
 
 
287 UK 
Male 
77 
Constipation Unknown 8 May 2017   200mg theophylline once 
daily  
17 August 2016 to 
9 October 2016 
 
System organ classification: Hepatobiliary disorders 
008 UK 
Male 
66 
Acute hepatitis Recovered 25 August 2014 200mg placebo twice 
daily 
 
23 August 2014 to 
25 August 2014 
 
130 UK  
Female 
67 
Obstructive jaundiced 
and evidence of 
intraductal calculi 
Recovered 11 January 2016 200mg placebo once 
daily 
 
24 February 2015 
ongoing at time of 
event 
 
138 UK 
Female  
68 
Vomiting Recovered 22 November 
2015 
200mg theophylline once 
daily 
 
20 March 2015 to  
11 March 2016 
 
220 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
152 UK 
Female 
72 
Cholangitis and 
laparoscopic 
cholecystectomy 
Recovered 21 December 
2015 
200mg theophylline once 
daily 
 
14 November 2015 
to 20 December 
2015 
 
236 UK 
Male 
76 
Groin pain (possible 
biliary sepsis) 
Recovered 12 August 2016 200mg placebo once 
daily  
7 June 2016 
ongoing at time of 
event 
 
273 UK 
Male 
87 
Gallstones Recovered 
with sequelae 
1 November 
2016 
200mg placebo once 
daily  
24 August 2016 
ongoing at time of 
event 
 
System organ classification: Skin and subcutaneous tissue disorders 
135 UK 
Male  
80 
Skin rash Recovered 29 December 
2015 
200mg theophylline once 
daily 
 
February 2015 to  
14 February 2015 
 
 
 
 
System Organ Classification: musculoskeletal and connective tissue disorders 
006 UK 
Male 
61 
Suspected fractured ribs Recovering 31 May 2014 200mg placebo once 
daily 
 
4 March 2014 to 10 
May 2014 
 
084 UK 
Female 
55 
Chest pain Recovered 3 July 2015 200mg placebo once 
daily 
 
24 April 2015 
ongoing at time of 
event 
 
221 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
092 UK 
Female 
58 
Atypical chest pain 
 
Recovered  27 August 2015 
 
200mg placebo once 
daily 
 
11 May 2015 
ongoing at time of 
event 
 
139 UK 
Female 
69 
Chest tightness Recovered 11 January 2016 200mg theophylline once 
daily 
 
23 September 2015 
ongoing at time of 
event 
 
144 UK 
Male 
82 
Acute stiff neck Recovering 25 February 
2016 
200mg placebo twice 
daily 
 
21 May 2015 to  
25 February 2016 
 
145 UK 
Male  
82 
GP referral due to 
swallowing problems and 
neck pain ongoing at 
time of event for 2-3 
weeks 
Recovered 
with sequelae 
21 March 2016 200mg placebo twice 
daily 
 
21 May 2015 to  
25 February 2016 
 
156 UK 
Female  
72 
Left rib fracture 
(osteoporotic, not 
traumatic) 
Recovering 25 April 2016 200mg placebo once 
daily 
 
7 August 2015 
ongoing at time of 
event 
 
159 UK 
Male 
71 
Musculoskeletal chest 
pain 
Recovering 10 May 2016 200mg theophylline once 
daily 
 
17 November 2015 
to 17 May 2016 
 
161 UK 
Male 
56 
Hyperaesthesia of insulin 
injection site 
Recovered 11 December 
2015 
200mg placebo once 
daily 
 
25 June 2015 
ongoing at time of 
event 
 
222 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
162 UK 
Male 
56 
Right ankle pain, 
?cellulitis 
Recovering 
 
3 May 2016 200mg placebo once 
daily 
 
25 June 2015 
ongoing at time of 
event 
 
187 UK 
Male 
61  
Musculoskeletal chest 
pain 
Recovered 3 May 2014 200mg theophylline once 
daily  
24 April 2014 to 23 
June 2014 
 
188 UK 
Male 
71 
Chest pain Recovered 16 August 2016 200mg placebo once 
daily  
17 November 2015 
ongoing at time of 
event 
 
199 UK 
Female 
59 
Musculoskeletal pain Recovered 03 July 2016 200mg theophylline once 
daily  
21 March 2016 to 
29 March 2016 
 
211 UK 
Female 
76 
Back pain following fall Recovered 14 May 2015 200mg placebo once 
daily  
5 June 2014 to 9 
June 2014 
 
 
259 UK 
Female 
72 
Primary diagnosis gout 
of her Left big toe, with a 
secondary diagnosis of 
infection 
Unknown 1 March 2017 200mg theophylline once 
daily  
18 April 2016 
ongoing at time of 
event 
 
261 UK 
Female 
76 
Abdominal pain Recovered 01 February 
2017 
200mg placebo once 
daily  
26 August 2016 
ongoing at time of 
event 
Considered to be of 
musculoskeletal origin 
System organ classification: Renal and urinary disorders 
223 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
076 UK 
Male 
60 
Kidney stones Recovering 2 September 
2015 
200mg placebo once 
daily 
 
6 January 2015 
ongoing at time of 
event 
 
104 UK 
Male 
83 
Urinary retention 
 
Recovering 18 November 
2015 
200mg placebo once 
daily 
 
28 May 2015 
ongoing at time of 
event 
 
106 UK 
Female 
82 
Acute kidney injury 
 
Recovered 30 November 
2015 
 
200mg theophylline once 
daily 
 
27 February 2015 
ongoing at time of 
event 
 
157 UK 
Male 
63 
Right renal colic 
 
Recovered 29 Feb 2016 200mg placebo twice 
daily 
 
04 November 2015 
to 05 January 2016 
 
200 UK 
Female 
59 
UTI with stage 1 AKI Recovered 16 August 2016 200mg theophylline once 
daily  
21 March 2016 to 
29 March 2016 
 
207 UK 
Female 
75 
Multi-resistant E.coli 
UTI 
 
Recovered 25 November 
2014 
200mg theophylline once 
daily  
28 August 2014 to 
1 September 2014 
 
229 UK 
Female  
73 
Deranged renal function, 
lower respiratory tract 
infection, 
Recovered 20 November 
2016 
200mg theophylline once 
daily  
11 April 2016 to 
20 April 2016 
 
237 UK 
Male 
76 
Haematuria 
 
Recovering 2 December 
2016 
200mg placebo once 
daily  
7 June 2016 to 12 
August 2016 
 
224 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
280 UK 
Male 
83 
Shortness of breath due 
to fluid overload 
secondary to renal 
disease 
 
Recovered 30 March 2016 200mg theophylline once 
daily  
2 March 2016 to 12 
April 2016 
 
283 UK 
Female 
78 
Proximal ureteric stone 
causing obstruction of 
left kidney. 
 
Recovered 5 December 
2016 
200mg theophylline once 
daily  
26 July 2016 
ongoing at time of 
event 
 
System Organ Classification: Pregnancy, puerperium and perinatal conditions  
None        
System Organ Classification: Reproductive system and breast disorders  
None        
System Organ Classification: Congenital, familial and genetic disorders  
None        
System Organ Classification: General disorders and administration site conditions  
None        
System organ classification: Investigations 
113 UK 
Female  
55 
Asymptomatic raised 
calcium levels 
Recovered 4 December 
2015 
200mg placebo once 
daily 
 
23 June 2015 
ongoing at time of 
event 
 
System Organ Classification: Injury, poisoning and procedural complications 
225 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
005 UK 
Female 
68 
Left tibial plateau 
fracture 
Recovering 1 July 2014 200mg theophylline once 
daily 
 
8 May 2014 
ongoing at time of 
event 
 
028 UK 
Female 
67 
Fractured pubic ramus 
and right acetabulum 
Recovered 12 November 
2014 
200mg theophylline once 
daily 
 
22 August 2014 to 
9 November 2014 
 
041 UK 
Male 
55 
Death: Head Injury Fatal 19 April 2015 200mg theophylline once 
daily 
 
13 March 2015 to 
19 April 2015 
 
075 UK 
Male 
90 
Fall (mechanical) 
 
Recovered 12 March 2015 
 
200mg placebo once 
daily 
 
4 September 2014 
to September 2015 
 
091 UK 
Female 
58 
Rectus sheath 
haematoma 
Recovered 23 September 
2015 
200mg placebo once 
daily 
 
11 May 2015 
ongoing at time of 
event 
Secondary to trauma 
094 UK 
Male 
85 
Fractured neck of femur Recovered 14 August 2015 200mg placebo once 
daily 
 
23 March 2015 
ongoing at time of 
event 
 
095 UK 
Female 
82 
Fracture left wrist Recovered 28 April 2015 200mg placebo once 
daily 
 
30 October 2014 to  
5 November 2014 
 
096 UK 
Female 
65 
Fractured distal radius 
and ulna 
Recovered 04 September 
2015 
200mg placebo once 
daily 
 
15 June 2015 
ongoing at time of 
event 
 
226 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
108 UK 
Male 
49 
Laceration to left hand Unknown 29 September 
2015 
200mg theophylline 
twice daily  
23 April 2015 
ongoing at time of 
event 
 
115 UK 
Female 
76 
Fall Recovered 26 December 
2015 
200mg placebo once 
daily 
12 December 2015 
to 31 December 
2015 
 
137 UK 
Male  
60 
Lower back pain since 
fall on floor during the 
night for 2 hours duration 
Recovered 7 March 2016 200mg theophylline once 
daily 
 
7 April 2015 
ongoing at time of 
event 
 
153 UK 
Female 
72 
Post-op wound infection Recovered 9 January 2016 200mg theophylline once 
daily 
 
13 November 2015 
to 20 December 
2015 
 
169 UK 
Male 
80 
Raised INR 4.2 and HB 
97; ?GI bleed 
Recovering 01 July 2016 200mg theophylline once 
daily 
 
21 October 2015 
ongoing at time of 
event 
Inappropriately high dose of 
warfarin 
180 UK 
Male 
83 
Head injury Recovered 06 July 2016 200mg placebo once 
daily 
 
10 February 2016 
ongoing at time of 
event 
 
190 UK 
Male 
69 
Fractured rib Not recovered 19 August 2016 
  
200mg placebo once 
daily  
21 March 2016 
ongoing at time of 
event 
 
204 UK 
Female 
81 
Right distal fibula and 
medial malleolus 
Unknown 03 September 
2016 
 
200mg theophylline once 
daily  
19 July 2016 to 19 
December 2016 
 
227 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
206 UK 
Male  
74 
Fell downstairs and 
fractured clavicle, 
shoulder and broke ribs 
Recovering 1 August 2016 200mg placebo once 
daily  
24 August 2015 to 
11 February 2016 
 
214 UK 
Male 
63 
Fall 
 
Recovered 15 January 2015 
 
200mg placebo once 
daily  
4 March 2014 
ongoing at time of 
event 
 
 
216 UK 
Male 
69 
Persistent vomiting Recovered 17 January 2015 200mg theophylline once 
daily  
7 July 2014 to 
24 November 2014 
Thought to be related to 
chemotherapy 
218 UK 
Male  
69 
Confusion (steroid 
induced psychosis) 
Recovered 04 April 2015 200mg theophylline once 
daily  
7 July 2014 to 
24 November 2014 
 
271 UK 
Female 
76 
Closed fracture neck of 
femur 
Unknown 14 May 2017 200mg placebo once 
daily  
27 May 2016 
ongoing at time of 
event 
 
272 UK 
Male 
58 
Fall like syncopal attack Recovered 26 March 2015 200mg theophylline once 
daily  
12 March 2015 to 
18 April 2015 
 
274 UK 
Male 
84 
Fall Fatal  14 October 
2016 
200mg placebo once 
daily  
23 May 2016 to 
6 October 2016 
 
228 
Case ID  Country 
Gender 
Age 
Serious Adverse Event Outcome Date of onset 
Time to onset‡ 
Daily dose Route 
Formulation 
Dates of treatment  Comments 
278 UK 
Female 
61 
Fractured neck of femur Recovered 8 May 2017 
 
200mg placebo once 
daily  
17 May 2016 
ongoing at time of 
event 
 
System organ classification: Surgical and medical procedures 
045 UK 
Male 
69 
Optical urethrotomy Recovered 27 March 2015 200mg theophylline 
twice daily  
30 July 2014 to 29 
July 2015 
 
System organ classification:  Social circumstances 
None        
a Seven other events were recorded by sites as SAEs.  These are not reported in the tables above (or in table 16 in the main body of the report) for the following reasons:  Two 
were retracted because they were not considered to be serious (IDs 167, 191); One was retracted and resubmitted as a follow-up (ID 194); Four captured primary (COPD 
exacerbation) or secondary (pneumonia) outcome data and are reported as such in chapter 4 (IDs 142, 215, 227 and 232) 
b Event not included in Table 16 as this person did not start their study medication 
 
 
